BOS	O	O
we	O	O
also	O	O
describe	O	O
a	O	O
new	O	O
,	O	O
noninvasive	O	O
method	O	O
to	O	O
assess	O	O
magnesium-induced	O	O
neuromuscular	I-ADR	I-ADR
block	I-ADR	I-ADR
when	O	O
curariform	O	O
muscle	O	O
relaxant	O	O
was	O	O
given	O	O
simultaneously	O	O
.	O	O
EOS	O	O
BOS	O	O
hepatobiliary	I-ADR	I-ADR
disorders	I-ADR	I-ADR
associated	O	O
with	O	O
orally	O	O
administered	O	O
terbinafine	O	O
have	O	O
rarely	O	O
been	O	O
reported	O	O
.	O	O
EOS	O	O
BOS	O	O
terbinafine-induced	O	O
cholestatic	I-ADR	I-ADR
liver	I-ADR	I-ADR
disease	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
prolonged	O	O
terbinafine-induced	O	O
cholestatic	I-ADR	I-ADR
liver	I-ADR	I-ADR
disease	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
a	O	O
patient	O	O
with	O	O
a	O	O
large	O	O
hydatid	O	O
cyst	O	O
of	O	O
the	O	O
left	O	O
lobe	O	I-ADR
of	O	O
the	O	O
liver	O	O
developed	O	O
metabolic	I-ADR	I-ADR
acidosis	I-ADR	I-ADR
following	O	O
rather	O	O
liberal	O	O
use	O	O
of	O	O
cetrimide-chlorhexidine	O	O
solution	O	O
as	O	O
a	O	O
scolicidal	O	O
agent	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
patient	O	O
with	O	O
a	O	O
large	O	O
hydatid	O	O
cyst	O	O
of	O	O
the	O	O
left	O	O
lobe	O	I-ADR
of	O	O
the	O	O
liver	O	O
developed	O	O
metabolic	I-ADR	I-ADR
acidosis	I-ADR	I-ADR
following	O	O
rather	O	O
liberal	O	O
use	O	O
of	O	O
cetrimide-chlorhexidine	O	O
solution	O	O
as	O	O
a	O	O
scolicidal	O	O
agent	O	O
.	O	O
EOS	O	O
BOS	O	O
metabolic	I-ADR	I-ADR
acidosis	I-ADR	I-ADR
induced	O	O
by	O	O
cetrimide-chlorhexidine	O	O
solution	O	O
in	O	O
hydatid	O	O
cyst	O	O
surgery	O	O
.	O	O
EOS	O	O
BOS	O	O
metabolic	I-ADR	I-ADR
acidosis	I-ADR	I-ADR
induced	O	O
by	O	O
cetrimide-chlorhexidine	O	O
solution	O	O
in	O	O
hydatid	O	O
cyst	O	O
surgery	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
poisoning	I-ADR	O
with	O	O
3,4-	O	O
methylenedioxymet-amphetamine	O	O
ecstasy	O	O
that	O	O
presented	O	O
with	O	O
all	O	O
the	O	O
features	O	O
suggestive	O	O
of	O	O
a	O	O
fatal	O	I-ADR
outcome	O	O
,	O	O
including	O	O
a	O	O
creatinine	O	I-ADR
phosphokinase	O	I-ADR
level	O	I-ADR
markedly	O	O
higher	O	O
than	O	O
any	O	O
previously	O	O
reported	O	O
.	O	O
EOS	O	O
BOS	O	O
however	O	O
,	O	O
dermatologists	O	O
should	O	O
be	O	O
cautious	O	O
about	O	O
a	O	O
photosensitivity	I-ADR	I-ADR
reaction	O	I-ADR
induced	O	O
by	O	O
mequitazine	O	O
or	O	O
other	O	O
phenothiazine-derivative	O	O
drugs	O	O
.	O	O
EOS	O	O
BOS	O	O
in	O	O
addition	O	O
,	O	O
an	O	O
immediate	O	O
erythematous	I-ADR	I-ADR
macule	I-ADR	I-ADR
was	O	O
observed	O	O
on	O	O
the	O	O
photopatch	O	O
test	O	O
site	O	O
of	O	O
mequitazine	O	O
directly	O	O
after	O	O
uv	O	O
exposure	O	O
which	O	O
was	O	O
similar	O	O
to	O	O
the	O	O
immediate	I-ADR	O
erythema	I-ADR	I-ADR
noted	O	O
in	O	O
chlorpromazine	O	O
photoallergy	O	O
.	O	O
EOS	O	O
BOS	O	O
in	O	O
case	O	O
no	O	O
.	O	O
2	O	O
,	O	O
the	O	O
pathogenic	O	O
mechanism	O	O
seemed	O	O
to	O	O
be	O	O
persistent	O	O
light	O	I-ADR
reaction	O	I-ADR
preceded	O	O
by	O	O
systemic	O	O
photoallergy	O	O
,	O	O
as	O	O
he	O	O
had	O	O
taken	O	O
mequitazine	O	O
for	O	O
6	O	O
months	O	O
,	O	O
and	O	O
there	O	O
were	O	O
strong	O	O
positive	O	O
photopatch	O	O
test	O	O
results	O	O
with	O	O
immediate	O	O
erythema	I-ADR	I-ADR
reaction	O	O
,	O	O
cross-reaction	I-ADR	O
to	I-ADR	O
promethazine	I-ADR	O
,	O	O
decreased	I-ADR	O
med	I-ADR	O
to	I-ADR	O
both	I-ADR	O
uva	I-ADR	O
and	I-ADR	O
uvb	I-ADR	O
,	O	O
and	O	O
persistence	I-ADR	O
of	I-ADR	O
the	I-ADR	O
photosensitivity	I-ADR	I-ADR
over	O	O
a	O	O
3	O	O
-	O	O
year	O	O
follow-up	O	O
period	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
mequitazine	O	O
.	O	O
EOS	O	O
BOS	O	O
in	O	O
case	O	O
no	O	O
.	O	O
2	O	O
,	O	O
the	O	O
pathogenic	O	O
mechanism	O	O
seemed	O	O
to	O	O
be	O	O
persistent	O	O
light	O	I-ADR
reaction	O	I-ADR
preceded	O	O
by	O	O
systemic	O	O
photoallergy	O	O
,	O	O
as	O	O
he	O	O
had	O	O
taken	O	O
mequitazine	O	O
for	O	O
6	O	O
months	O	O
,	O	O
and	O	O
there	O	O
were	O	O
strong	O	O
positive	O	O
photopatch	O	O
test	O	O
results	O	O
with	O	O
immediate	O	O
erythema	I-ADR	I-ADR
reaction	O	O
,	O	O
cross-reaction	I-ADR	O
to	I-ADR	O
promethazine	I-ADR	O
,	O	O
decreased	I-ADR	O
med	I-ADR	O
to	I-ADR	O
both	I-ADR	O
uva	I-ADR	O
and	I-ADR	O
uvb	I-ADR	O
,	O	O
and	O	O
persistence	I-ADR	O
of	I-ADR	O
the	I-ADR	O
photosensitivity	I-ADR	I-ADR
over	O	O
a	O	O
3	O	O
-	O	O
year	O	O
follow-up	O	O
period	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
mequitazine	O	O
.	O	O
EOS	O	O
BOS	O	O
mequitazine	O	O
seemed	O	O
to	O	O
play	O	O
a	O	O
part	O	O
similar	O	O
to	O	O
chlorpromazine	O	O
,	O	O
and	O	O
absence	O	O
of	O	O
mequitazine-induced	O	O
photosensitivity	I-ADR	I-ADR
may	O	O
be	O	O
due	O	O
to	O	O
a	O	O
relatively	O	O
low	O	O
dosage	O	O
of	O	O
the	O	O
drug	O	O
.	O	O
EOS	O	O
BOS	O	O
two	O	O
cases	O	O
of	O	O
mequitazine-induced	O	O
photosensitivity	I-ADR	I-ADR
reactions	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
experienced	O	O
2	O	O
cases	O	O
of	O	O
mequitazine-induced	O	O
photosensitivity	I-ADR	I-ADR
reaction	I-ADR	I-ADR
in	O	O
patients	O	O
who	O	O
took	O	O
mequitazine	O	O
for	O	O
their	O	O
dermatologic	O	O
problems	O	O
.	O	O
EOS	O	O
BOS	O	O
keratitis	I-ADR	I-ADR
in	O	O
methamphetamine	O	O
abusers	O	O
.	O	O
EOS	O	O
BOS	O	O
methamphetamine's	O	O
extensive	O	O
physiologic	O	O
effects	O	O
,	O	O
inconsistent	O	O
street	O	O
purity	O	O
,	O	O
and	O	O
multiple	O	O
routes	O	O
of	O	O
administration	O	O
offer	O	O
many	O	O
possibilities	O	O
for	O	O
injury	I-ADR	I-ADR
to	I-ADR	O
the	I-ADR	O
cornea	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
potential	O	O
causes	O	O
of	O	O
methamphetamine-related	O	O
keratitis	I-ADR	I-ADR
can	O	O
be	O	O
divided	O	O
into	O	O
four	O	O
categories	O	O
resulting	O	O
from	O	O
(	O	O
a	O	O
)	O	O
direct	O	O
pharmacologic	O	O
and	O	O
physical	O	O
effects	O	O
of	O	O
methamphetamine	O	O
;	O	O
(	O	O
b	O	O
)	O	O
the	O	O
toxic	O	O
effects	O	O
of	O	O
diluting	O	O
or	O	O
"	O	O
cutting	O	O
"	O	O
agents	O	O
such	O	O
as	O	O
lidocaine	O	O
and	O	O
quinine	O	O
;	O	O
(	O	O
c	O	O
)	O	O
effects	O	O
related	O	O
to	O	O
the	O	O
route	O	O
of	O	O
drug	O	O
administration	O	O
(	O	O
intravenous	O	O
,	O	O
inhalation	O	O
,	O	O
smoking	O	O
);	O	O
and	O	O
(	O	O
d	O	O
)	O	O
manufacture-related	O	O
effects	O	O
of	O	O
exposure	O	O
to	O	O
unintentional	O	O
caustic	O	O
contaminants	O	O
in	O	O
the	O	O
final	O	O
product	O	O
.	O	O
EOS	O	O
BOS	O	O
potential	O	O
causes	O	O
of	O	O
methamphetamine-related	O	O
keratitis	I-ADR	I-ADR
can	O	O
be	O	O
divided	O	O
into	O	O
four	O	O
categories	O	O
resulting	O	O
from	O	O
(	O	O
a	O	O
)	O	O
direct	O	O
pharmacologic	O	O
and	O	O
physical	O	O
effects	O	O
of	O	O
methamphetamine	O	O
;	O	O
(	O	O
b	O	O
)	O	O
the	O	O
toxic	I-ADR	O
effects	I-ADR	O
of	O	O
diluting	O	O
or	O	O
"	O	O
cutting	O	O
"	O	O
agents	O	O
such	O	O
as	O	O
lidocaine	O	O
and	O	O
quinine	O	O
;	O	O
(	O	O
c	O	O
)	O	O
effects	O	O
related	O	O
to	O	O
the	O	O
route	O	O
of	O	O
drug	O	O
administration	O	O
(	O	O
intravenous	O	O
,	O	O
inhalation	O	O
,	O	O
smoking	O	O
);	O	O
and	O	O
(	O	O
d	O	O
)	O	O
manufacture-related	O	O
effects	O	O
of	O	O
exposure	O	O
to	O	O
unintentional	O	O
caustic	O	O
contaminants	O	O
in	O	O
the	O	O
final	O	O
product	O	O
.	O	O
EOS	O	O
BOS	O	O
potential	O	O
causes	O	O
of	O	O
methamphetamine-related	O	O
keratitis	I-ADR	I-ADR
can	O	O
be	O	O
divided	O	O
into	O	O
four	O	O
categories	O	O
resulting	O	O
from	O	O
(	O	O
a	O	O
)	O	O
direct	O	O
pharmacologic	O	O
and	O	O
physical	O	O
effects	O	O
of	O	O
methamphetamine	O	O
;	O	O
(	O	O
b	O	O
)	O	O
the	O	O
toxic	I-ADR	O
effects	I-ADR	O
of	O	O
diluting	O	O
or	O	O
"	O	O
cutting	O	O
"	O	O
agents	O	O
such	O	O
as	O	O
lidocaine	O	O
and	O	O
quinine	O	O
;	O	O
(	O	O
c	O	O
)	O	O
effects	O	O
related	O	O
to	O	O
the	O	O
route	O	O
of	O	O
drug	O	O
administration	O	O
(	O	O
intravenous	O	O
,	O	O
inhalation	O	O
,	O	O
smoking	O	O
);	O	O
and	O	O
(	O	O
d	O	O
)	O	O
manufacture-related	O	O
effects	O	O
of	O	O
exposure	O	O
to	O	O
unintentional	O	O
caustic	O	O
contaminants	O	O
in	O	O
the	O	O
final	O	O
product	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
increasing	O	O
prevalence	O	O
of	O	O
methamphetamine	O	O
abuse	O	O
and	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
associated	O	O
ulcers	I-ADR	I-ADR
should	O	O
alert	O	O
ophthalmologists	O	O
to	O	O
the	O	O
problem	O	O
of	O	O
methamphetamine-related	O	O
keratitis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
four	O	O
cases	O	O
of	O	O
severe	I-ADR	I-ADR
corneal	I-ADR	I-ADR
ulceration	I-ADR	I-ADR
in	O	O
methamphetamine	O	O
abusers	O	O
.	O	O
EOS	O	O
BOS	O	O
background	O	O
:	O	O
methotrexate	O	O
(	O	O
mtx	O	O
)	O	O
may	O	O
induce	O	O
liver	I-ADR	I-ADR
damage	I-ADR	I-ADR
,	O	O
which	O	O
in	O	O
some	O	O
psoriatics	O	O
will	O	O
lead	O	O
to	O	O
fibrosis	I-ADR	I-ADR
or	O	O
cirrhosis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
background	O	O
:	O	O
methotrexate	O	O
(	O	O
mtx	O	O
)	O	O
may	O	O
induce	O	O
liver	I-ADR	I-ADR
damage	I-ADR	I-ADR
,	O	O
which	O	O
in	O	O
some	O	O
psoriatics	O	O
will	O	O
lead	O	O
to	O	O
fibrosis	I-ADR	I-ADR
or	O	O
cirrhosis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
this	O	O
study	O	O
confirmed	O	O
that	O	O
in	O	O
most	O	O
patients	O	O
mtx-induced	O	O
liver	I-ADR	I-ADR
cirrhosis	I-ADR	I-ADR
is	O	O
not	O	O
aggressive	O	O
.	O	O
EOS	O	O
BOS	O	O
however	O	O
,	O	O
continued	O	O
low-dose	O	O
mtx	O	O
led	O	O
,	O	O
in	O	O
spite	O	O
of	O	O
normal	O	O
liver	O	O
tests	O	O
,	O	O
8	O	O
years	O	O
after	O	O
the	O	O
last	O	O
biopsy	O	O
to	O	O
liver	I-ADR	O
failure	I-ADR	I-ADR
and	O	O
death	I-ADR	I-ADR
in	O	O
1	O	O
of	O	O
our	O	O
patients	O	O
.	O	O
EOS	O	O
BOS	O	O
methotrexate-induced	O	O
liver	I-ADR	I-ADR
cirrhosis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
studies	O	O
performed	O	O
10	O	O
years	O	O
ago	O	O
on	O	O
25	O	O
patients	O	O
with	O	O
mtx-induced	O	O
liver	I-ADR	I-ADR
cirrhosis	I-ADR	I-ADR
indicated	O	O
that	O	O
this	O	O
type	O	O
of	O	O
cirrhosis	I-ADR	I-ADR
was	O	O
not	O	O
of	O	O
an	O	O
aggressive	O	O
nature	O	O
.	O	O
EOS	O	O
BOS	O	O
after	O	O
therapy	O	O
for	O	O
diabetic	O	O
coma	O	O
with	O	O
insulin	O	O
(	O	O
containing	O	O
the	O	O
preservative	O	O
cresol	O	O
)	O	O
and	O	O
electrolyte	O	O
solutions	O	O
was	O	O
started	O	O
,	O	O
the	O	O
patient	O	O
complained	O	O
of	O	O
increasing	I-ADR	I-ADR
myalgia	I-ADR	I-ADR
,	O	O
developed	O	O
a	O	O
high	I-ADR	I-ADR
fever	I-ADR	I-ADR
and	O	O
respiratory	I-ADR	I-ADR
and	I-ADR	O
metabolic	I-ADR	I-ADR
acidosis	I-ADR	I-ADR
and	O	O
lost	I-ADR	I-ADR
consciousness	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
after	O	O
therapy	O	O
for	O	O
diabetic	O	O
coma	O	O
with	O	O
insulin	O	O
(	O	O
containing	O	O
the	O	O
preservative	O	O
cresol	O	O
)	O	O
and	O	O
electrolyte	O	O
solutions	O	O
was	O	O
started	O	O
,	O	O
the	O	O
patient	O	O
complained	O	O
of	O	O
increasing	I-ADR	I-ADR
myalgia	I-ADR	I-ADR
,	O	O
developed	O	O
a	O	O
high	I-ADR	I-ADR
fever	I-ADR	I-ADR
and	O	O
respiratory	I-ADR	I-ADR
and	I-ADR	O
metabolic	I-ADR	I-ADR
acidosis	I-ADR	I-ADR
and	O	O
lost	I-ADR	I-ADR
consciousness	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
however	O	O
,	O	O
other	O	O
factors	O	O
or	O	O
drugs	O	O
(	O	O
e	O	O
.	O	O
g	O	O
.	O	O
cresol	O	O
)	O	O
are	O	O
thought	O	O
to	O	O
induce	O	O
mh	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
this	O	O
case	O	O
supports	O	O
the	O	O
assessment	O	O
that	O	O
mh	I-ADR	O
and	O	O
diabetes	O	O
are	O	O
associated	O	O
diseases	O	O
and	O	O
that	O	O
cresol	O	O
could	O	O
possibly	O	O
trigger	O	O
mh	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
the	O	O
use	O	O
of	O	O
beclomethasone	O	O
diproprionate	O	O
inhaler	O	O
complicated	O	O
by	O	O
the	O	O
development	O	O
of	O	O
an	O	O
eosinophilic	I-ADR	I-ADR
pneumonia	I-ADR	I-ADR
reaction	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
fatal	I-ADR	I-ADR
intravascular	I-ADR	I-ADR
autoimmune	I-ADR	I-ADR
hemolytic	I-ADR	I-ADR
anemia	I-ADR	I-ADR
after	O	O
fludarabine	O	O
treatment	O	O
for	O	O
chronic	O	O
lymphocytic	O	O
leukemia	O	O
.	O	O
EOS	O	O
BOS	O	O
physicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
risk	O	O
of	O	O
severe	O	O
aiha	I-ADR	O
in	O	O
cll	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
aiha	I-ADR	O
or	O	O
positivation	I-ADR	O
of	I-ADR	O
the	I-ADR	O
dat	I-ADR	O
during	O	O
previous	O	O
fludarabine	O	O
administration	O	O
,	O	O
or	O	O
in	O	O
case	O	O
of	O	O
secondary	O	O
fixation	O	O
of	O	O
complement	O	O
to	O	O
the	O	O
red	O	O
cell	O	O
membrane	O	O
occurring	O	O
during	O	O
fludarabine	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
occurrence	O	O
of	O	O
severe	O	O
aiha	I-ADR	O
in	O	O
cll	O	O
patients	O	O
treated	O	O
with	O	O
fludarabine	O	O
has	O	O
been	O	O
reported	O	O
by	O	O
several	O	O
authors	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
chronic	O	O
lymphocytic	O	O
leukemia	O	O
(	O	O
cll	O	O
)	O	O
who	O	O
developed	O	O
fatal	I-ADR	I-ADR
intravascular	I-ADR	I-ADR
autoimmune	I-ADR	I-ADR
hemolytic	I-ADR	I-ADR
anemia	I-ADR	I-ADR
(	O	O
aiha	I-ADR	I-ADR
)	O	O
after	O	O
fludarabine	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
when	O	O
the	O	O
patient	O	O
was	O	O
treated	O	O
again	O	O
with	O	O
fludarabine	O	O
nine	O	O
months	O	O
later	O	O
,	O	O
the	O	O
dat	I-ADR	O
became	I-ADR	O
positive	I-ADR	O
with	I-ADR	O
anti-igg	I-ADR	O
and	I-ADR	O
anti-c	I-ADR	O
3d	I-ADR	O
antiglobulins	I-ADR	I-ADR
after	O	O
the	O	O
second	O	O
course	O	O
of	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
she	O	O
had	O	O
just	O	O
finished	O	O
a	O	O
3	O	O
-	O	O
week	O	O
course	O	O
of	O	O
intravenous	O	O
tobramycin	O	O
for	O	O
bronchiectasis	O	O
and	O	O
had	O	O
an	O	O
elevated	O	O
serum	O	O
tobramycin	O	O
trough	O	O
level	O	O
1	O	O
week	O	O
before	O	O
the	O	O
onset	O	O
of	O	O
tetany	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
tetany	I-ADR	I-ADR
in	O	O
a	O	O
child	O	O
with	O	O
aids	O	O
receiving	O	O
intravenous	O	O
tobramycin	O	O
.	O	O
EOS	O	O
BOS	O	O
this	O	O
pattern	O	O
is	O	O
suggestive	O	O
of	O	O
renal	I-ADR	I-ADR
toxicity	I-ADR	I-ADR
due	O	O
to	O	O
tobramycin	O	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
in	O	O
our	O	O
reported	O	O
case	O	O
,	O	O
a	O	O
local	O	O
hyperproduction	I-ADR	O
of	I-ADR	O
tnf-alpha	I-ADR	O
from	O	O
macrophages	O	O
that	O	O
was	O	O
induced	O	O
by	O	O
the	O	O
injected	O	O
insulin	O	O
could	O	O
explain	O	O
the	O	O
dedifferentiation	I-ADR	O
of	I-ADR	O
the	I-ADR	O
adipocytes	I-ADR	I-ADR
of	O	O
the	O	O
subcutaneous	O	O
tissue	O	I-ADR
and	O	O
the	O	O
reversion	O	O
that	O	O
was	O	O
induced	O	O
by	O	O
the	O	O
local	O	O
injection	O	O
of	O	O
dexamethasone	O	O
.	O	O
EOS	O	O
BOS	O	O
insulin-induced	O	O
lipoatrophy	I-ADR	I-ADR
in	O	O
type	O	O
i	O	O
diabetes	O	O
.	O	O
EOS	O	O
BOS	O	O
objective	O	O
:	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O	O
that	O	O
tumor	O	O
necrosis	O	I-ADR
factor	O	O
(	O	O
tnf	O	O
)	O	O
-	O	O
alpha	O	O
may	O	O
mediate	O	O
the	O	O
loss	O	I-ADR
and	O	O
the	O	O
dedifferentiation	O	O
of	O	O
subcutaneous	O	O
fat	O	O
tissue	O	O
in	O	O
the	O	O
insulin-induced	O	O
lipoatrophies	I-ADR	O
of	O	O
a	O	O
diabetic	O	O
patient	O	O
who	O	O
presented	O	O
extensive	O	O
lesions	O	O
.	O	O
EOS	O	O
BOS	O	O
erosion	I-ADR	I-ADR
of	I-ADR	O
psoriatic	I-ADR	I-ADR
plaques	I-ADR	I-ADR
:	O	O
an	O	O
early	O	O
sign	O	O
of	O	O
methotrexate	O	O
toxicity	O	O
.	O	O
EOS	O	O
BOS	O	O
methotrexate	O	O
is	O	O
an	O	O
effective	O	O
but	O	O
potentially	I-ADR	O
toxic	I-ADR	O
treatment	O	O
for	O	O
psoriasis	O	O
.	O	O
EOS	O	O
BOS	O	O
painful	I-ADR	O
erosion	I-ADR	I-ADR
of	I-ADR	O
psoriatic	I-ADR	I-ADR
plaques	I-ADR	I-ADR
is	O	O
a	O	O
less	O	O
common	O	O
sign	O	O
of	O	O
methotrexate	O	O
toxicity	O	O
that	O	O
may	O	O
precede	O	O
evidence	O	O
of	O	O
bone	I-ADR	O
marrow	I-ADR	O
suppression	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
two	O	O
patients	O	O
in	O	O
whom	O	O
painful	I-ADR	O
erosions	I-ADR	I-ADR
of	I-ADR	O
their	I-ADR	I-ADR
psoriasis	I-ADR	I-ADR
developed	O	O
as	O	O
the	O	O
presenting	O	O
sign	O	O
of	O	O
methotrexate	O	O
toxicity	O	O
and	O	O
review	O	O
the	O	O
literature	O	O
,	O	O
emphasizing	O	O
the	O	O
risk	O	O
factors	O	O
associated	O	O
with	O	O
this	O	O
manifestation	O	O
.	O	O
EOS	O	O
BOS	O	O
well-known	O	O
signs	O	O
of	O	O
methotrexate	O	O
toxicity	O	I-ADR
include	O	O
bone	I-ADR	I-ADR
marrow	I-ADR	I-ADR
suppression	I-ADR	I-ADR
and	O	O
oral	I-ADR	O
and	I-ADR	O
gastrointestinal	I-ADR	I-ADR
ulceration	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
after	O	O
treatment	O	O
with	O	O
cimetidine	O	O
,	O	O
there	O	O
was	O	O
a	O	O
rapid	O	I-ADR
deterioration	O	I-ADR
with	O	O
decreased	I-ADR	I-ADR
oxygen	I-ADR	I-ADR
saturation	I-ADR	I-ADR
and	I-ADR	O
arterial	I-ADR	I-ADR
po2	I-ADR	I-ADR
values	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
caution	O	O
with	O	O
use	O	O
of	O	O
cimetidine	O	O
in	O	O
tolazoline	O	O
induced	O	O
upper	I-ADR	I-ADR
gastrointestinal	I-ADR	I-ADR
bleeding	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
caution	O	O
with	O	O
use	O	O
of	O	O
cimetidine	O	O
in	O	O
tolazoline	O	O
induced	O	O
upper	I-ADR	I-ADR
gastrointestinal	I-ADR	I-ADR
bleeding	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
however	O	O
,	O	O
given	O	O
the	O	O
clinically	O	O
significant	O	O
result	O	O
to	O	O
the	O	O
interaction	O	O
between	O	O
tolazoline	O	O
and	O	O
cimetidine	O	O
we	O	O
report	O	O
,	O	O
the	O	O
use	O	O
of	O	O
cimetidine	O	O
in	O	O
tolazoline	O	O
induced	O	O
upper	I-ADR	I-ADR
gastrointestinal	I-ADR	I-ADR
hemorrhage	I-ADR	I-ADR
should	O	O
deserve	O	O
more	O	O
attention	O	O
.	O	O
EOS	O	O
BOS	O	O
however	O	O
,	O	O
given	O	O
the	O	O
clinically	O	O
significant	O	O
result	O	O
to	O	O
the	O	O
interaction	O	O
between	O	O
tolazoline	O	O
and	O	O
cimetidine	O	O
we	O	O
report	O	O
,	O	O
the	O	O
use	O	O
of	O	O
cimetidine	O	O
in	O	O
tolazoline	O	O
induced	O	O
upper	I-ADR	I-ADR
gastrointestinal	I-ADR	I-ADR
hemorrhage	I-ADR	I-ADR
should	O	O
deserve	O	O
more	O	O
attention	O	O
.	O	O
EOS	O	O
BOS	O	O
hypoxemia	O	I-ADR
improved	O	O
during	O	O
continuous	O	O
tolazoline	O	O
infusion	O	O
,	O	O
but	O	O
gastrointestinal	I-ADR	I-ADR
bleeding	I-ADR	I-ADR
occurred	O	O
.	O	O
EOS	O	O
BOS	O	O
zolpidem	O	O
(	O	O
ambien	O	O
)	O	O
,	O	O
a	O	O
relatively	O	O
new	O	O
nonbenzodiazepine	O	O
sedative-hypnotic	O	O
,	O	O
was	O	O
involved	O	O
in	O	O
the	O	O
death	I-ADR	O
of	O	O
a	O	O
39	O	O
-	O	O
year-old	O	O
obese	O	O
male	O	O
who	O	O
was	O	O
being	O	O
treated	O	O
for	O	O
depression	O	O
and	O	O
insomnia	O	O
.	O	O
EOS	O	O
BOS	O	O
zolpidem	O	O
(	O	O
ambien	O	O
)	O	O
,	O	O
a	O	O
relatively	O	O
new	O	O
nonbenzodiazepine	O	O
sedative-hypnotic	O	O
,	O	O
was	O	O
involved	O	O
in	O	O
the	O	O
death	I-ADR	O
of	O	O
a	O	O
39	O	O
-	O	O
year-old	O	O
obese	O	O
male	O	O
who	O	O
was	O	O
being	O	O
treated	O	O
for	O	O
depression	O	O
and	O	O
insomnia	O	O
.	O	O
EOS	O	O
BOS	O	O
zolpidem	O	O
tissue	O	O
concentrations	O	O
in	O	O
a	O	O
multiple	O	O
drug	O	O
related	O	O
death	I-ADR	O
involving	O	O
ambien	O	O
.	O	O
EOS	O	O
BOS	O	O
zolpidem	O	O
tissue	O	O
concentrations	O	O
in	O	O
a	O	O
multiple	O	O
drug	O	O
related	O	O
death	I-ADR	O
involving	O	O
ambien	O	O
.	O	O
EOS	O	O
BOS	O	O
infants	O	O
are	O	O
particularly	O	O
susceptible	O	O
to	O	O
chronic	O	O
nitrate-induced	O	O
methemoglobinemia	I-ADR	I-ADR
because	O	O
of	O	O
their	O	O
low	O	O
stomach	O	O
acid	O	O
production	O	O
,	O	O
large	O	O
numbers	O	O
of	O	O
nitrite-reducing	O	O
bacteria	O	O
,	O	O
and	O	O
the	O	O
relatively	O	O
easy	O	O
oxidation	O	O
of	O	O
fetal	O	O
hemoglobin	O	O
.	O	O
EOS	O	O
BOS	O	O
after	O	O
induction	O	O
of	O	O
general	O	O
anesthesia	O	O
and	O	O
administration	O	O
of	O	O
a	O	O
standard	O	O
dose	O	O
of	O	O
intravenous	O	O
esmolol	O	O
hydrochloride	O	O
,	O	O
her	O	O
cardiac	O	I-ADR
rhythm	O	I-ADR
progressed	O	O
to	O	O
asystole	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
cardiac	I-ADR	I-ADR
arrest	I-ADR	I-ADR
after	O	O
esmolol	O	O
administration	O	O
:	O	O
a	O	O
review	O	O
of	O	O
acute	O	O
beta-blocker	O	O
toxicity	O	O
.	O	O
EOS	O	O
BOS	O	O
atenolol	O	O
induced	O	O
memory	I-ADR	I-ADR
impairment	I-ADR	I-ADR
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O
EOS	O	O
BOS	O	O
his	O	O
impaired	I-ADR	I-ADR
memory	I-ADR	I-ADR
was	O	O
found	O	O
to	O	O
be	O	O
due	O	O
to	O	O
the	O	O
atenolol	O	O
he	O	O
was	O	O
on	O	O
and	O	O
he	O	O
made	O	O
a	O	O
complete	O	O
recovery	O	O
on	O	O
withdrawing	O	O
the	O	O
beta-blocker	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
potential	O	O
role	O	O
for	O	O
renal	O	O
and	O	O
hepatic	O	I-ADR
impairment	O	I-ADR
in	O	O
the	O	O
observed	O	O
protracted	O	O
course	O	O
of	O	O
amiodarone-induced	O	O
thyrotoxicosis	I-ADR	I-ADR
is	O	O
suggested	O	O
.	O	O
EOS	O	O
BOS	O	O
failure	O	O
of	O	O
plasmapheresis	O	O
,	O	O
corticosteroids	O	O
and	O	O
thionamides	O	O
to	O	O
ameliorate	O	O
a	O	O
case	O	O
of	O	O
protracted	O	O
amiodarone-induced	O	O
thyroiditis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
amiodarone-induced	O	O
thyrotoxicosis	I-ADR	I-ADR
of	O	O
protracted	O	O
duration	O	O
,	O	O
unresponsive	O	O
to	O	O
conventional	O	O
thionamide	O	O
therapy	O	O
,	O	O
with	O	O
therapy	O	O
limited	O	O
by	O	O
severe	O	O
adverse	O	O
drug	O	O
reactions	O	O
.	O	O
EOS	O	O
BOS	O	O
psychotic	I-ADR	I-ADR
disorder	I-ADR	I-ADR
associated	O	O
with	O	O
isoniazid	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
evaluated	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
a	O	O
psychotic	I-ADR	I-ADR
disorder	I-ADR	I-ADR
after	O	O
4	O	O
months	O	O
of	O	O
isoniazid	O	O
prophylaxis	O	O
for	O	O
a	O	O
positive	O	O
tuberculosis	O	O
tine	O	O
test	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
case	O	O
report	O	O
is	O	O
presented	O	O
concerning	O	O
the	O	O
administration	O	O
of	O	O
ketanserin	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
pulmonary	I-ADR	I-ADR
vasoconstriction	I-ADR	I-ADR
and	O	O
right	I-ADR	I-ADR
ventricular	I-ADR	I-ADR
failure	I-ADR	I-ADR
following	O	O
the	O	O
infusion	O	O
of	O	O
protamine	O	O
in	O	O
a	O	O
patient	O	O
undergoing	O	O
coronary	O	O
artery	O	O
bypass	O	O
surgery	O	O
and	O	O
mitral	O	O
valve	O	O
replacement	O	O
.	O	O
EOS	O	O
BOS	O	O
ketanserin	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
protamine-induced	O	O
pulmonary	I-ADR	I-ADR
hypertension	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
the	O	O
reversal	O	O
of	O	O
heparin	O	O
by	O	O
protamine	O	O
may	O	O
cause	O	O
severe	I-ADR	I-ADR
hemodynamic	I-ADR	I-ADR
deterioration	I-ADR	I-ADR
,	O	O
characterized	O	O
by	O	O
systemic	I-ADR	I-ADR
hypotension	I-ADR	I-ADR
,	O	O
pulmonary	I-ADR	I-ADR
hypertension	I-ADR	I-ADR
,	O	O
and	O	O
bronchoconstriction	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
a	O	O
drug	O	O
addict	O	O
with	O	O
staphylococcal	O	O
endocarditis	O	O
treated	O	O
with	O	O
methicillin	O	O
,	O	O
who	O	O
developed	O	O
massive	I-ADR	I-ADR
proteinuria	I-ADR	I-ADR
and	O	O
acute	I-ADR	I-ADR
nephritic	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
is	O	O
described	O	O
.	O	O
EOS	O	O
BOS	O	O
focal	I-ADR	I-ADR
glomerulonephritis	I-ADR	I-ADR
and	O	O
interstitial	I-ADR	I-ADR
nephritis	I-ADR	I-ADR
in	O	O
methicillin-treated	O	O
,	O	O
heroin-related	O	O
infective	O	I-ADR
endocarditis	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
methods	O	O
/	O	O
results	O	O
:	O	O
this	O	O
paper	O	O
presents	O	O
a	O	O
new	O	O
case	O	O
of	O	O
rifabutin	O	O
uveitis	I-ADR	I-ADR
and	O	O
a	O	O
review	O	O
of	O	O
the	O	O
various	O	O
published	O	O
reports	O	O
to	O	O
date	O	O
.	O	O
EOS	O	O
BOS	O	O
over	O	O
the	O	O
past	O	O
3	O	O
years	O	O
there	O	O
have	O	O
been	O	O
several	O	O
reports	O	O
of	O	O
uveitis	I-ADR	I-ADR
associated	O	O
with	O	O
rifabutin	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
uveitis	I-ADR	I-ADR
associated	O	O
with	O	O
rifabutin	O	O
therapy	O	O
:	O	O
a	O	O
clinical	O	O
alert	O	O
.	O	O
EOS	O	O
BOS	O	O
case	O	O
description	O	O
:	O	O
a	O	O
59	O	O
-	O	O
year-old	O	O
man	O	O
with	O	O
known	O	O
neurocysticercosis	O	O
developed	O	O
a	O	O
large	I-ADR	O
cerebral	I-ADR	I-ADR
infarction	I-ADR	I-ADR
during	O	O
praziquantel	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
large	I-ADR	O
cerebral	I-ADR	I-ADR
infarction	I-ADR	I-ADR
during	O	O
praziquantel	O	O
therapy	O	O
in	O	O
neurocysticercosis	O	O
.	O	O
EOS	O	O
BOS	O	O
data	O	O
synthesis	O	O
:	O	O
genetic	O	O
deficiencies	O	O
in	O	O
dpd	O	O
,	O	O
the	O	O
rate-limiting	O	O
enzyme	O	O
responsible	O	O
for	O	O
5	O	O
-	O	O
fu	O	O
catabolism	O	O
,	O	O
may	O	O
occur	O	O
in	O	O
3	O	O
%	O	O
or	O	O
more	O	O
of	O	O
patients	O	O
with	O	O
cancer	O	O
putting	O	O
them	O	O
at	O	O
increased	O	O
risk	O	O
for	O	O
unusually	O	O
severe	O	I-ADR
adverse	O	O
reactions	O	I-ADR
(	O	O
e	O	O
.	O	O
g	O	O
.	O	O
,	O	O
diarrhea	I-ADR	I-ADR
,	O	O
stomatitis	I-ADR	I-ADR
,	O	O
mucositis	I-ADR	I-ADR
,	O	O
myelosuppression	I-ADR	I-ADR
,	O	O
neurotoxicity	I-ADR	I-ADR
)	O	O
to	O	O
standard	O	O
doses	O	O
of	O	O
5	O	O
-	O	O
fu	O	O
.	O	O
EOS	O	O
BOS	O	O
dihydropyrimidine	O	I-ADR
dehydrogenase	O	I-ADR
deficiency	O	I-ADR
:	O	O
a	O	O
pharmacogenetic	O	O
defect	O	O
causing	O	O
severe	I-ADR	O
adverse	I-ADR	O
reactions	I-ADR	O
to	O	O
5	O	O
-	O	O
fluorouracil-based	O	O
chemotherapy	O	O
.	O	O
EOS	O	O
BOS	O	O
purpose	O	O
/	O	O
objectives	O	O
:	O	O
to	O	O
describe	O	O
the	O	O
pharmacogenetic	O	O
syndrome	O	O
of	O	O
dihydropyrimidine	O	O
dehydrogenase	O	O
(	O	O
dpd	O	O
)	O	O
deficiency	O	O
,	O	O
which	O	O
predisposes	O	O
patients	O	O
with	O	O
cancer	O	O
to	O	O
potentially	O	O
lethal	I-ADR	O
adverse	I-ADR	O
reactions	I-ADR	O
following	O	O
5	O	O
-	O	O
fluorouracil	O	O
(	O	O
5	O	O
-	O	O
fu	O	O
)	O	O
-	O	O
based	O	O
chemotherapy	O	O
.	O	O
EOS	O	O
BOS	O	O
purpose	O	O
/	O	O
objectives	O	O
:	O	O
to	O	O
describe	O	O
the	O	O
pharmacogenetic	O	O
syndrome	O	O
of	O	O
dihydropyrimidine	O	O
dehydrogenase	O	O
(	O	O
dpd	O	O
)	O	O
deficiency	O	O
,	O	O
which	O	O
predisposes	O	O
patients	O	O
with	O	O
cancer	O	O
to	O	O
potentially	O	O
lethal	I-ADR	O
adverse	I-ADR	O
reactions	I-ADR	O
following	O	O
5	O	O
-	O	O
fluorouracil	O	O
(	O	O
5	O	O
-	O	O
fu	O	O
)	O	O
-	O	O
based	O	O
chemotherapy	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
principle	O	O
treatment	O	O
for	O	O
dpd-deficient	O	O
patients	O	O
with	O	O
severe	O	O
acute	O	O
5	O	O
-	O	O
fu	O	O
reactions	O	O
is	O	O
supportive	O	O
care	O	O
;	O	O
however	O	O
,	O	O
the	O	O
administration	O	O
of	O	O
thymidine	O	O
potentially	O	O
may	O	O
reverse	O	O
severe	O	O
5	O	O
-	O	O
fu-induced	O	O
neurologic	I-ADR	I-ADR
symptoms	I-ADR	I-ADR
such	O	O
as	O	O
encephalopathy	I-ADR	I-ADR
and	O	O
coma	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
a	O	O
49	O	O
-	O	O
year-old	O	O
man	O	O
with	O	O
crohn's	O	O
disease	O	O
treated	O	O
with	O	O
prednisone	O	O
and	O	O
mesalamine	O	O
(	O	O
5	O	O
-	O	O
asa	O	O
)	O	O
developed	O	O
worsening	O	I-ADR
respiratory	O	I-ADR
distress	O	I-ADR
and	O	O
fever	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
a	O	O
49	O	O
-	O	O
year-old	O	O
man	O	O
with	O	O
crohn's	O	O
disease	O	O
treated	O	O
with	O	O
prednisone	O	O
and	O	O
mesalamine	O	O
(	O	O
5	O	O
-	O	O
asa	O	O
)	O	O
developed	O	O
worsening	I-ADR	I-ADR
respiratory	I-ADR	I-ADR
distress	I-ADR	I-ADR
and	O	O
fever	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
a	O	O
49	O	O
-	O	O
year-old	O	O
man	O	O
with	O	O
crohn's	O	O
disease	O	O
treated	O	O
with	O	O
prednisone	O	O
and	O	O
mesalamine	O	O
(	O	O
5	O	O
-	O	O
asa	O	O
)	O	O
developed	O	O
worsening	I-ADR	I-ADR
respiratory	I-ADR	I-ADR
distress	I-ADR	I-ADR
and	O	O
fever	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
mesalamine-induced	O	O
hypersensitivity	I-ADR	I-ADR
pneumonitis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
mesalamine	O	O
may	O	O
cause	O	O
hypersensitivity	I-ADR	I-ADR
pneumonitis	I-ADR	I-ADR
in	O	O
patients	O	O
with	O	O
crohn's	O	O
disease	O	O
.	O	O
EOS	O	O
BOS	O	O
immunosuppression	O	I-ADR
elicited	O	O
by	O	O
the	O	O
extensive	O	O
administration	O	O
of	O	O
prednisolone	O	O
was	O	O
suspected	O	O
for	O	O
the	O	O
initiation	O	O
of	O	O
the	O	O
generalized	O	O
mite	I-ADR	O
infestation	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
background	O	O
:	O	O
colchicine	O	O
has	O	O
a	O	O
known	O	O
adverse	I-ADR	O
effect	I-ADR	O
on	I-ADR	O
wound	I-ADR	O
healing	I-ADR	O
through	O	O
its	O	O
inhibitory	O	O
effect	O	O
on	O	O
tubulin-dependent	O	O
cell	O	O
functions	O	O
and	O	O
through	O	O
collagenase	I-ADR	O
activation	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
conclusion	O	O
:	O	O
the	O	O
findings	O	O
in	O	O
these	O	O
two	O	O
patients	O	O
suggest	O	O
that	O	O
colchicine	O	O
may	O	O
delay	I-ADR	O
corneal	I-ADR	I-ADR
wound	I-ADR	I-ADR
healing	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
delay	I-ADR	O
of	I-ADR	O
corneal	I-ADR	I-ADR
wound	I-ADR	I-ADR
healing	I-ADR	O
in	O	O
patients	O	O
treated	O	O
with	O	O
colchicine	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
authors	O	O
report	O	O
on	O	O
two	O	O
patients	O	O
with	O	O
corneal	I-ADR	I-ADR
ulcers	I-ADR	I-ADR
refractory	I-ADR	O
to	I-ADR	O
conventional	I-ADR	O
treatment	I-ADR	O
while	O	O
the	O	O
patients	O	O
were	O	O
undergoing	O	O
oral	O	O
colchicine	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
authors	O	O
suggest	O	O
that	O	O
in	O	O
patients	O	O
with	O	O
corneal	I-ADR	I-ADR
ulcers	I-ADR	I-ADR
refractory	I-ADR	O
to	I-ADR	O
conventional	I-ADR	O
treatment	I-ADR	O
who	O	O
are	O	O
receiving	O	O
colchicine	O	O
,	O	O
cessation	O	O
of	O	O
colchicine	O	O
therapy	O	O
should	O	O
be	O	O
considered	O	O
.	O	O
EOS	O	O
BOS	O	O
fulminant	I-ADR	I-ADR
hepatic	I-ADR	I-ADR
failure	I-ADR	I-ADR
associated	O	O
with	O	O
bicalutamide	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
17	O	O
-	O	O
year-old	O	O
female	O	O
patient	O	O
who	O	O
had	O	O
been	O	O
taking	O	O
oral	O	O
minocycline	O	O
(	O	O
50	O	O
mg	O	O
twice	O	O
daily	O	O
)	O	O
for	O	O
3	O	O
weeks	O	O
for	O	O
acne	O	O
developed	O	O
an	O	O
eruption	I-ADR	I-ADR
that	O	O
progressed	O	O
to	O	O
an	O	O
exfoliative	I-ADR	I-ADR
dermatitis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
fever	I-ADR	I-ADR
,	O	O
lymphadenopathy	I-ADR	I-ADR
,	O	O
eosinophilia	I-ADR	I-ADR
,	O	O
lymphocytosis	I-ADR	I-ADR
,	O	O
hepatitis	I-ADR	I-ADR
,	O	O
and	O	O
dermatitis	I-ADR	I-ADR
:	O	O
a	O	O
severe	O	I-ADR
adverse	O	I-ADR
reaction	O	I-ADR
to	O	O
minocycline	O	O
.	O	O
EOS	O	O
BOS	O	O
this	O	O
severe	I-ADR	O
illness	I-ADR	I-ADR
was	O	O
likely	O	O
caused	O	O
by	O	O
minocycline	O	O
,	O	O
and	O	O
we	O	O
speculate	O	O
that	O	O
minocycline	O	O
may	O	O
have	O	O
acted	O	O
as	O	O
a	O	O
superantigen	O	O
,	O	O
causing	O	O
lymphocyte	I-ADR	I-ADR
over-activation	I-ADR	I-ADR
and	O	O
massive	I-ADR	I-ADR
cytokine	I-ADR	I-ADR
release	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
delayed	I-ADR	I-ADR
hypersensitivity	I-ADR	I-ADR
to	O	O
flurbiprofen	O	O
.	O	O
EOS	O	O
BOS	O	O
eye	I-ADR	I-ADR
movement	I-ADR	I-ADR
disorders	I-ADR	I-ADR
in	O	O
bone	O	O
marrow	O	O
transplant	O	O
patients	O	O
on	O	O
cyclosporin	O	O
and	O	O
ganciclovir	O	O
.	O	O
EOS	O	O
BOS	O	O
eye	I-ADR	I-ADR
movement	I-ADR	I-ADR
disorders	I-ADR	I-ADR
in	O	O
bone	O	O
marrow	O	O
transplant	O	O
patients	O	O
on	O	O
cyclosporin	O	O
and	O	O
ganciclovir	O	O
.	O	O
EOS	O	O
BOS	O	O
one	O	O
patient	O	O
had	O	O
mri	I-ADR	I-ADR
t2	I-ADR	I-ADR
abnormalities	I-ADR	I-ADR
compatible	O	O
with	O	O
cyclosporin	O	O
neurotoxicity	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
postulate	O	O
that	O	O
cyclosporin	O	O
,	O	O
possibly	O	O
together	O	O
with	O	O
ganciclovir	O	O
,	O	O
can	O	O
produce	O	O
transient	I-ADR	I-ADR
brain	I-ADR	I-ADR
stem	I-ADR	I-ADR
or	I-ADR	O
neuromuscular	I-ADR	I-ADR
dysfunction	I-ADR	I-ADR
with	O	O
eye	I-ADR	I-ADR
movement	I-ADR	I-ADR
abnormality	I-ADR	I-ADR
in	O	O
occasional	O	O
patients	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
postulate	O	O
that	O	O
cyclosporin	O	O
,	O	O
possibly	O	O
together	O	O
with	O	O
ganciclovir	O	O
,	O	O
can	O	O
produce	O	O
transient	I-ADR	I-ADR
brain	I-ADR	I-ADR
stem	I-ADR	I-ADR
or	I-ADR	O
neuromuscular	I-ADR	I-ADR
dysfunction	I-ADR	I-ADR
with	O	O
eye	I-ADR	I-ADR
movement	I-ADR	I-ADR
abnormality	I-ADR	I-ADR
in	O	O
occasional	O	O
patients	O	O
.	O	O
EOS	O	O
BOS	O	O
conclusion	O	O
:	O	O
while	O	O
thrombosis	I-ADR	I-ADR
has	O	O
been	O	O
reported	O	O
with	O	O
gnrh-a	O	O
therapy	O	O
in	O	O
men	O	O
with	O	O
prostate	O	O
cancer	O	O
,	O	O
its	O	O
association	O	O
with	O	O
treatment	O	O
in	O	O
this	O	O
benign	O	O
case	O	O
may	O	O
have	O	O
been	O	O
a	O	O
consequence	O	O
of	O	O
the	O	O
massive	O	I-ADR
tumor	O	I-ADR
size	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
possible	O	O
effects	O	O
of	O	O
tamoxifen	O	O
upon	O	O
the	O	O
uterus	O	O
are	O	O
discussed	O	O
in	O	O
this	O	O
article	O	O
,	O	O
in	O	O
view	O	O
of	O	O
reports	O	O
of	O	O
tamoxifen	O	O
associated	O	O
with	O	O
endometrial	I-ADR	I-ADR
carcinoma	I-ADR	I-ADR
and	O	O
endometriosis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
case	O	O
study	O	O
:	O	O
adverse	I-ADR	O
response	I-ADR	O
to	O	O
clonidine	O	O
.	O	O
EOS	O	O
BOS	O	O
four	O	O
cases	O	O
of	O	O
adverse	I-ADR	O
experiences	I-ADR	O
with	O	O
clonidine	O	O
are	O	O
described	O	O
.	O	O
EOS	O	O
BOS	O	O
in	O	O
one	O	O
instance	O	O
a	O	O
systemic	I-ADR	O
hypoglycemic	I-ADR	I-ADR
reaction	I-ADR	I-ADR
resulting	O	O
in	O	O
head	I-ADR	I-ADR
trauma	I-ADR	I-ADR
and	O	O
confusion	I-ADR	I-ADR
ended	O	O
in	O	O
an	O	O
emegency	O	O
hospital	O	O
admission	O	O
following	O	O
the	O	O
substitution	O	O
of	O	O
acetohexamide	O	O
for	O	O
acetazolamide	O	O
.	O	O
EOS	O	O
BOS	O	O
discontinuation	O	O
of	O	O
the	O	O
itraconazole	O	O
caused	O	O
resolution	O	O
of	O	O
the	O	O
drug	I-ADR	O
eruption	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
primary	I-ADR	I-ADR
cutaneous	I-ADR	I-ADR
coccidioidomycosis	I-ADR	I-ADR
and	O	O
subsequent	O	O
drug	I-ADR	O
eruption	I-ADR	I-ADR
to	O	O
itraconazole	O	O
in	O	O
a	O	O
dog	O	O
.	O	O
EOS	O	O
BOS	O	O
its	O	O
overall	O	O
toxicity	I-ADR	O
is	O	O
considerably	O	O
less	O	O
compared	O	O
to	O	O
standard	O	O
induction	O	O
chemotherapy	O	O
;	O	O
however	O	O
,	O	O
it	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
a	O	O
potentially	I-ADR	O
fatal	I-ADR	O
symptom	I-ADR	O
complex	O	O
referred	O	O
to	O	O
as	O	O
"	O	O
retinoic	O	O
acid	O	O
syndrome	O	O
.	O	O
"	O	O
this	O	O
report	O	O
describes	O	O
a	O	O
patient	O	O
with	O	O
apl	O	O
who	O	O
developed	O	O
the	O	O
syndrome	O	I-ADR
a	O	O
few	O	O
weeks	O	O
after	O	O
initiating	O	O
induction	O	O
therapy	O	O
with	O	O
atra	O	O
despite	O	O
being	O	O
treated	O	O
for	O	O
hyperleukocytosis	O	O
.	O	O
EOS	O	O
BOS	O	O
eleven	O	O
days	O	O
after	O	O
initiation	O	O
of	O	O
therapy	O	O
with	O	O
amiodarone	O	O
,	O	O
the	O	O
patient	O	O
experienced	O	O
syncope	I-ADR	I-ADR
and	O	O
was	O	O
noted	O	O
to	O	O
have	O	O
recurrent	O	O
episodes	O	O
of	O	O
polymorphous	I-ADR	I-ADR
ventricular	I-ADR	I-ADR
tachycardia	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
nonsustained	I-ADR	I-ADR
polymorphous	I-ADR	I-ADR
ventricular	I-ADR	I-ADR
tachycardia	I-ADR	I-ADR
during	O	O
amiodarone	O	O
therapy	O	O
for	O	O
atrial	O	O
fibrillation	O	O
complicating	O	O
cardiomyopathy	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
probable	O	O
proarrhythmic	I-ADR	O
action	O	O
of	O	O
amiodarone	O	O
,	O	O
although	O	O
rare	O	O
,	O	O
is	O	O
reviewed	O	O
along	O	O
with	O	O
a	O	O
discussion	O	O
of	O	O
the	O	O
novel	O	O
use	O	O
of	O	O
intravenous	O	O
magnesium	O	O
sulfate	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
acute	I-ADR	I-ADR
asthma	I-ADR	I-ADR
associated	O	O
with	O	O
sustained-release	O	O
verapamil	O	O
.	O	O
EOS	O	O
BOS	O	O
although	O	O
dyspnea	I-ADR	I-ADR
associated	O	O
with	O	O
verapamil	O	O
administration	O	O
has	O	O
been	O	O
reported	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
an	O	O
elderly	O	O
asymptomatic	O	O
asthmatic	O	O
patient	O	O
with	O	O
hypertension	O	O
who	O	O
developed	O	O
an	O	O
acute	I-ADR	I-ADR
asthma	I-ADR	I-ADR
attack	O	I-ADR
following	O	O
sustained-release	O	O
verapamil	O	O
administration	O	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
sustained-release	O	O
verapamil	O	O
is	O	O
thought	O	O
to	O	O
be	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
asthma	I-ADR	O
attack	I-ADR	O
in	O	O
this	O	O
patient	O	O
because	O	O
she	O	O
was	O	O
not	O	O
taking	O	O
any	O	O
other	O	O
preparations	O	O
;	O	O
the	O	O
symptoms	O	O
started	O	O
with	O	O
the	O	O
administration	O	O
of	O	O
sustained-release	O	O
verapamil	O	O
and	O	O
were	O	O
relieved	O	O
after	O	O
its	O	O
discontinuation	O	O
.	O	O
EOS	O	O
BOS	O	O
objective	O	O
:	O	O
to	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
asymptomatic	O	O
bronchial	O	O
asthma	O	O
and	O	O
hypertension	O	O
who	O	O
developed	O	O
an	O	O
acute	I-ADR	I-ADR
asthma	I-ADR	I-ADR
attack	O	I-ADR
after	O	O
receiving	O	O
sustained-release	O	O
verapamil	O	O
.	O	O
EOS	O	O
BOS	O	O
she	O	O
continued	O	O
taking	O	O
verapamil	O	O
for	O	O
6	O	O
months	O	O
,	O	O
then	O	O
,	O	O
on	O	O
her	O	O
own	O	O
,	O	O
stopped	O	O
all	O	O
medications	O	O
including	O	O
the	O	O
sustained-release	O	O
verapamil	O	O
,	O	O
and	O	O
her	O	O
asthma	I-ADR	I-ADR
symptoms	O	I-ADR
disappeared	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
infectious	O	O
mononucleosis	O	O
treated	O	O
with	O	O
cephalexin	O	O
who	O	O
later	O	O
showed	O	O
a	O	O
rash	I-ADR	I-ADR
is	O	O
presented	O	O
and	O	O
the	O	O
previous	O	O
literature	O	O
is	O	O
reviewed	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
rash	I-ADR	I-ADR
seen	O	O
in	O	O
this	O	O
patient	O	O
,	O	O
who	O	O
was	O	O
treated	O	O
with	O	O
cephalexin	O	O
,	O	O
may	O	O
be	O	O
similar	O	O
to	O	O
the	O	O
rash	I-ADR	I-ADR
seen	O	O
with	O	O
ampicillin	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
infectious	O	O
mononucleosis	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
rash	I-ADR	I-ADR
seen	O	O
in	O	O
this	O	O
patient	O	O
,	O	O
who	O	O
was	O	O
treated	O	O
with	O	O
cephalexin	O	O
,	O	O
may	O	O
be	O	O
similar	O	O
to	O	O
the	O	O
rash	I-ADR	I-ADR
seen	O	O
with	O	O
ampicillin	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
infectious	O	O
mononucleosis	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
possible	O	O
case	O	O
of	O	O
carbamazepine	O	O
induced	O	O
pancreatitis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
the	O	O
authors	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	O	I-ADR
pancreatitis	I-ADR	I-ADR
(	O	O
ap	O	O
)	O	O
occurring	O	O
in	O	O
a	O	O
patient	O	O
under	O	O
treatment	O	O
with	O	O
carbamazepine	O	O
(	O	O
cbz	O	O
)	O	O
for	O	O
post-traumatic	O	O
petit	O	O
mal	O	O
epilepsy	O	O
,	O	O
and	O	O
review	O	O
the	O	O
current	O	O
literature	O	O
of	O	O
drug-induced	O	O
ap	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
authors	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	O	I-ADR
pancreatitis	I-ADR	I-ADR
(	O	O
ap	O	O
)	O	O
occurring	O	O
in	O	O
a	O	O
patient	O	O
under	O	O
treatment	O	O
with	O	O
carbamazepine	O	O
(	O	O
cbz	O	O
)	O	O
for	O	O
post-traumatic	O	O
petit	O	O
mal	O	O
epilepsy	O	O
,	O	O
and	O	O
review	O	O
the	O	O
current	O	O
literature	O	O
of	O	O
drug-induced	O	O
ap	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
evidence	O	O
of	O	O
high	O	O
plasmatic	O	O
levels	O	O
of	O	O
cbz	O	O
and	O	O
the	O	O
absence	O	O
of	O	O
other	O	O
aetiologic	O	O
factors	O	O
lead	O	O
the	O	O
authors	O	O
to	O	O
conclude	O	O
that	O	O
the	O	O
overdose	O	O
of	O	O
cbz	O	O
could	O	O
have	O	O
represented	O	O
the	O	O
precipitating	O	O
of	O	O
the	O	O
episode	O	O
of	O	O
acute	I-ADR	I-ADR
pancreatitis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
although	O	O
risk	O	O
factors	O	O
for	O	O
mtx-induced	O	O
pulmonary	I-ADR	I-ADR
toxicity	I-ADR	I-ADR
are	O	O
poorly	O	O
understood	O	O
,	O	O
the	O	O
presence	O	O
in	O	O
3	O	O
out	O	O
of	O	O
5	O	O
of	O	O
our	O	O
patients	O	O
of	O	O
pre-existing	O	O
lung	O	O
disease	O	O
,	O	O
represented	O	O
by	O	O
diffuse	O	O
interstitial	O	I-ADR
changes	O	O
on	O	O
chest	O	O
x-ray	O	O
,	O	O
and	O	O
mild	O	O
bronchial	O	I-ADR
asthma	O	O
in	O	O
two	O	O
ra	O	O
patients	O	O
and	O	O
by	O	O
pulmonary	O	O
silicosis	O	O
in	O	O
the	O	O
patient	O	O
with	O	O
psa	O	O
may	O	O
account	O	O
for	O	O
a	O	O
predisposition	O	O
to	O	O
the	O	O
development	O	O
of	O	O
mtx	O	O
pneumonitis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
methotrexate-induced	O	O
pneumonitis	I-ADR	I-ADR
in	O	O
patients	O	O
with	O	O
rheumatoid	O	O
arthritis	O	O
and	O	O
psoriatic	O	O
arthritis	O	O
:	O	O
report	O	O
of	O	O
five	O	O
cases	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O
EOS	O	O
BOS	O	O
on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
mtx-induced	O	O
pneumonitis	I-ADR	I-ADR
seems	O	O
to	O	O
be	O	O
very	O	O
rare	O	O
in	O	O
psoriatic	O	O
arthritis	O	O
(	O	O
psa	O	O
)	O	O
.	O	O
EOS	O	O
BOS	O	O
our	O	O
review	O	O
of	O	O
194	O	O
ra	O	O
patients	O	O
and	O	O
38	O	O
psa	O	O
patients	O	O
receiving	O	O
mtx	O	O
has	O	O
identified	O	O
four	O	O
ra	O	O
patients	O	O
and	O	O
one	O	O
psa	O	O
patient	O	O
with	O	O
mtx-induced	O	O
pneumonitis	I-ADR	I-ADR
,	O	O
giving	O	O
a	O	O
prevalence	O	O
of	O	O
2.1	O	O
%	O	O
and	O	O
0.03	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O
EOS	O	O
BOS	O	O
pneumonitis	I-ADR	I-ADR
is	O	O
emerging	O	O
as	O	O
one	O	O
of	O	O
the	O	O
most	O	O
unpredictable	O	O
and	O	O
potentially	O	O
serious	O	O
,	O	O
adverse	O	O
effects	O	O
of	O	O
treatment	O	O
with	O	O
mtx	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
lymphocyte	O	O
alveolitis	O	I-ADR
with	O	O
a	O	O
predominance	O	O
of	O	O
cd4	O	O
+	O	O
t	O	O
cells	O	O
in	O	O
3	O	O
ra	O	O
patients	O	O
and	O	O
cd8	O	O
+	O	O
t	O	O
cells	O	O
with	O	O
a	O	O
concomitant	O	O
increase	O	O
in	O	O
neutrophils	O	O
in	O	O
another	O	O
case	O	O
suggests	O	O
that	O	O
immunologically	O	O
mediated	O	O
reactions	O	O
may	O	O
be	O	O
one	O	O
damage	O	O
mechanism	O	O
in	O	O
mtx-induced	O	O
pneumonitis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
a	O	O
retrospective	O	O
epidemiological	O	O
study	O	O
of	O	O
deaths	O	I-ADR
from	O	O
hepatic	I-ADR	I-ADR
angiosarcoma	I-ADR	I-ADR
(	O	O
has	O	O
)	O	O
in	O	O
the	O	O
u	O	O
.	O	O
s	O	O
.	O	O
showed	O	O
that	O	O
during	O	O
1964	O	O
-	O	O
-	O	O
74	O	O
there	O	O
were	O	O
168	O	O
such	O	O
cases	O	O
,	O	O
of	O	O
which	O	O
37	O	O
(	O	O
22	O	O
%	O	O
)	O	O
were	O	O
associated	O	O
with	O	O
previously	O	O
known	O	O
causes	O	O
(	O	O
vinyl	O	O
chloride	O	O
,	O	O
'	O	O
thorotrast	O	O
'	O	O
,	O	O
and	O	O
inorganic	O	O
arsenic	O	O
)	O	O
and	O	O
4	O	O
(	O	O
3.1	O	O
%	O	O
)	O	O
of	O	O
the	O	O
remaining	O	O
131	O	O
cases	O	O
with	O	O
the	O	O
use	O	O
of	O	O
androgenic-anabolic	O	O
steroids	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
retrospective	O	O
epidemiological	O	O
study	O	O
of	O	O
deaths	O	I-ADR
from	O	O
hepatic	I-ADR	I-ADR
angiosarcoma	I-ADR	I-ADR
(	O	O
has	O	O
)	O	O
in	O	O
the	O	O
u	O	O
.	O	O
s	O	O
.	O	O
showed	O	O
that	O	O
during	O	O
1964	O	O
-	O	O
-	O	O
74	O	O
there	O	O
were	O	O
168	O	O
such	O	O
cases	O	O
,	O	O
of	O	O
which	O	O
37	O	O
(	O	O
22	O	O
%	O	O
)	O	O
were	O	O
associated	O	O
with	O	O
previously	O	O
known	O	O
causes	O	O
(	O	O
vinyl	O	O
chloride	O	O
,	O	O
'	O	O
thorotrast	O	O
'	O	O
,	O	O
and	O	O
inorganic	O	O
arsenic	O	O
)	O	O
and	O	O
4	O	O
(	O	O
3.1	O	O
%	O	O
)	O	O
of	O	O
the	O	O
remaining	O	O
131	O	O
cases	O	O
with	O	O
the	O	O
use	O	O
of	O	O
androgenic-anabolic	O	O
steroids	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
retrospective	O	O
epidemiological	O	O
study	O	O
of	O	O
deaths	O	I-ADR
from	O	O
hepatic	I-ADR	I-ADR
angiosarcoma	I-ADR	I-ADR
(	O	O
has	O	O
)	O	O
in	O	O
the	O	O
u	O	O
.	O	O
s	O	O
.	O	O
showed	O	O
that	O	O
during	O	O
1964	O	O
-	O	O
-	O	O
74	O	O
there	O	O
were	O	O
168	O	O
such	O	O
cases	O	O
,	O	O
of	O	O
which	O	O
37	O	O
(	O	O
22	O	O
%	O	O
)	O	O
were	O	O
associated	O	O
with	O	O
previously	O	O
known	O	O
causes	O	O
(	O	O
vinyl	O	O
chloride	O	O
,	O	O
'	O	O
thorotrast	O	O
'	O	O
,	O	O
and	O	O
inorganic	O	O
arsenic	O	O
)	O	O
and	O	O
4	O	O
(	O	O
3.1	O	O
%	O	O
)	O	O
of	O	O
the	O	O
remaining	O	O
131	O	O
cases	O	O
with	O	O
the	O	O
use	O	O
of	O	O
androgenic-anabolic	O	O
steroids	O	O
.	O	O
EOS	O	O
BOS	O	O
recent	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
under	O	O
experimental	O	O
conditions	O	O
ferrous	O	O
sulfate	O	O
may	O	O
reduce	I-ADR	O
the	I-ADR	O
gastrointestinal	I-ADR	I-ADR
absorption	I-ADR	I-ADR
of	I-ADR	O
orally	I-ADR	O
administered	I-ADR	O
levothyroxine	I-ADR	O
sodium	I-ADR	O
in	O	O
patients	O	O
with	O	O
primary	O	O
hypothyroidism	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
a	O	O
patient	O	O
who	O	O
became	O	O
hypothyroid	I-ADR	I-ADR
while	O	O
taking	O	O
ferrous	O	O
sulfate	O	O
.	O	O
EOS	O	O
BOS	O	O
however	O	O
,	O	O
as	O	O
the	O	O
use	O	O
of	O	O
hepatitis	O	O
b	O	O
vaccination	O	O
is	O	O
growing	O	O
,	O	O
adverse	O	O
side	O	O
effects	O	O
,	O	O
including	O	O
mental	I-ADR	I-ADR
nerve	I-ADR	I-ADR
neuropathy	I-ADR	I-ADR
,	O	O
should	O	O
be	O	O
observed	O	O
with	O	O
an	O	O
increased	O	O
frequency	O	O
.	O	O
EOS	O	O
BOS	O	O
mental	I-ADR	I-ADR
nerve	I-ADR	I-ADR
neuropathy	I-ADR	I-ADR
as	O	O
a	O	O
result	O	O
of	O	O
hepatitis	O	O
b	O	O
vaccination	O	O
.	O	O
EOS	O	O
BOS	O	O
although	O	O
its	O	O
side	O	O
effects	O	O
are	O	O
few	O	O
,	O	O
tamoxifen	O	O
increases	O	O
the	O	O
incidence	O	O
of	O	O
proliferative	I-ADR	I-ADR
lesions	I-ADR	I-ADR
of	I-ADR	O
the	I-ADR	O
endometrium	I-ADR	I-ADR
,	O	O
which	O	O
theoretically	O	O
should	O	O
be	O	O
preventable	O	O
with	O	O
progestational	O	O
agents	O	O
.	O	O
EOS	O	O
BOS	O	O
cases	O	O
:	O	O
two	O	O
postmenopausal	O	O
women	O	O
treated	O	O
with	O	O
tamoxifen	O	O
and	O	O
progestational	O	O
agents	O	O
for	O	O
breast	O	O
carcinoma	O	O
developed	O	O
uterine	I-ADR	I-ADR
enlargement	I-ADR	I-ADR
and	O	O
intermittent	I-ADR	I-ADR
spotting	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
the	O	O
value	O	O
of	O	O
multihormonal	O	O
therapy	O	O
in	O	O
breast	O	O
carcinoma	I-ADR	O
is	O	O
not	O	O
established	O	O
,	O	O
and	O	O
the	O	O
addition	O	O
of	O	O
progestogens	O	O
to	O	O
tamoxifen	O	O
may	O	O
not	O	O
reduce	O	O
of	O	O
developing	O	O
endometrial	I-ADR	I-ADR
lesions	I-ADR	I-ADR
,	O	O
including	O	O
carcinoma	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
bleomycin	O	O
and	O	O
cyclophosphamide	O	O
toxicity	O	I-ADR
simulating	O	O
metastatic	I-ADR	I-ADR
nodules	I-ADR	I-ADR
to	O	O
the	O	O
lungs	O	I-ADR
in	O	O
childhood	O	O
cancer	O	O
.	O	O
EOS	O	O
BOS	O	O
bleomycin	O	O
and	O	O
cyclophosphamide	O	O
toxicity	O	I-ADR
simulating	O	O
metastatic	I-ADR	I-ADR
nodules	I-ADR	I-ADR
to	O	O
the	O	O
lungs	O	I-ADR
in	O	O
childhood	O	O
cancer	O	O
.	O	O
EOS	O	O
BOS	O	O
thoracoscopic	O	O
biopsy	O	O
to	O	O
confirm	O	O
metastasis	O	O
revealed	O	O
instead	O	O
fibrotic	I-ADR	I-ADR
lesions	I-ADR	I-ADR
apparently	O	O
attributable	O	O
to	O	O
bleomycin	O	O
or	O	O
cyclophosphamide	O	O
.	O	O
EOS	O	O
BOS	O	O
thoracoscopic	O	O
biopsy	O	O
to	O	O
confirm	O	O
metastasis	O	O
revealed	O	O
instead	O	O
fibrotic	I-ADR	I-ADR
lesions	I-ADR	I-ADR
apparently	O	O
attributable	O	O
to	O	O
bleomycin	O	O
or	O	O
cyclophosphamide	O	O
.	O	O
EOS	O	O
BOS	O	O
an	O	O
elderly	O	O
man	O	O
with	O	O
procainamide	O	O
hydrochloride-induced	O	O
lupus	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
had	O	O
a	O	O
circulating	O	O
anticoagulant	O	O
against	O	O
factor	O	O
xi	O	O
and	O	O
a	O	O
biologic	O	O
false-positive	O	O
(	O	O
bfp	O	O
)	O	O
test	O	O
result	O	O
for	O	O
syphilis	O	O
.	O	O
EOS	O	O
BOS	O	O
circulating	O	O
anticoagulant	O	O
in	O	O
the	O	O
procainamide-induced	O	O
lupus	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
clinical	O	O
signs	O	O
of	O	O
hypermagnesemia	I-ADR	I-ADR
are	O	O
an	O	O
uncommon	O	O
complication	O	O
following	O	O
oral	O	O
administration	O	O
of	O	O
magnesium	O	O
sulfate	O	O
.	O	O
EOS	O	O
BOS	O	O
overdose	O	O
of	O	O
magnesium	O	O
sulfate	O	O
in	O	O
combination	O	O
with	O	O
renal	O	O
insufficiency	O	I-ADR
,	O	O
hypocalcemia	O	I-ADR
,	O	O
or	O	O
compromise	O	O
of	O	O
intestinal	O	O
integrity	O	O
may	O	O
predispose	O	O
horses	O	O
to	O	O
magnesium	I-ADR	O
toxicosis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
case	O	O
summaries	O	O
:	O	O
in	O	O
each	O	O
case	O	O
,	O	O
the	O	O
patients	O	O
were	O	O
treated	O	O
over	O	O
5	O	O
years	O	O
with	O	O
lovastatin	O	O
and	O	O
developed	O	O
rhabdomyolysis	I-ADR	I-ADR
that	O	O
coincided	O	O
with	O	O
the	O	O
completion	O	O
of	O	O
a	O	O
prescribed	O	O
regimen	O	O
of	O	O
a	O	O
newer	O	O
macrolide	O	O
antibiotic	O	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
the	O	O
risk	O	O
of	O	O
drug-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
due	O	O
to	O	O
the	O	O
potential	O	O
interaction	O	O
between	O	O
lovastatin	O	O
and	O	O
azithromycin	O	O
or	O	O
clarithromycin	O	O
should	O	O
be	O	O
considered	O	O
before	O	O
the	O	O
concomitant	O	O
use	O	O
of	O	O
these	O	O
agents	O	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
the	O	O
risk	O	O
of	O	O
drug-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
due	O	O
to	O	O
the	O	O
potential	O	O
interaction	O	O
between	O	O
lovastatin	O	O
and	O	O
azithromycin	O	O
or	O	O
clarithromycin	O	O
should	O	O
be	O	O
considered	O	O
before	O	O
the	O	O
concomitant	O	O
use	O	O
of	O	O
these	O	O
agents	O	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
the	O	O
risk	O	O
of	O	O
drug-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
due	O	O
to	O	O
the	O	O
potential	O	O
interaction	O	O
between	O	O
lovastatin	O	O
and	O	O
azithromycin	O	O
or	O	O
clarithromycin	O	O
should	O	O
be	O	O
considered	O	O
before	O	O
the	O	O
concomitant	O	O
use	O	O
of	O	O
these	O	O
agents	O	O
.	O	O
EOS	O	O
BOS	O	O
discussion	O	O
:	O	O
rhabdomyolysis	I-ADR	I-ADR
is	O	O
a	O	O
clinical	O	O
syndrome	O	O
resulting	O	O
from	O	O
the	O	O
destruction	O	O
of	O	O
skeletal	O	O
muscle	O	O
that	O	O
may	O	O
progress	O	O
to	O	O
renal	O	O
failure	O	O
several	O	O
drugs	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
rhabdomyolysis	I-ADR	I-ADR
,	O	O
including	O	O
lovastatin	O	O
,	O	O
a	O	O
hydroxymethylglutaryl-coenzyme	O	O
a	O	O
reductase	O	O
inhibitor	O	O
.	O	O
EOS	O	O
BOS	O	O
erythromycin	O	O
is	O	O
a	O	O
macrolide	O	O
antibiotic	O	O
that	O	O
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
lovastatin-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
erythromycin	O	O
is	O	O
a	O	O
macrolide	O	O
antibiotic	O	O
that	O	O
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
lovastatin-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
lovastatin-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
possibly	O	O
associated	O	O
with	O	O
clarithromycin	O	O
and	O	O
azithromycin	O	O
.	O	O
EOS	O	O
BOS	O	O
lovastatin-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
possibly	O	O
associated	O	O
with	O	O
clarithromycin	O	O
and	O	O
azithromycin	O	O
.	O	O
EOS	O	O
BOS	O	O
lovastatin-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
possibly	O	O
associated	O	O
with	O	O
clarithromycin	O	O
and	O	O
azithromycin	O	O
.	O	O
EOS	O	O
BOS	O	O
objective	O	O
:	O	O
to	O	O
describe	O	O
two	O	O
cases	O	O
of	O	O
rhabdomyolysis	I-ADR	I-ADR
in	O	O
patients	O	O
taking	O	O
lovastatin	O	O
that	O	O
were	O	O
precipitated	O	O
by	O	O
the	O	O
use	O	O
of	O	O
the	O	O
newer	O	O
macrolide	O	O
antibiotics	O	O
clarithromycin	O	O
and	O	O
azithromycin	O	O
.	O	O
EOS	O	O
BOS	O	O
objective	O	O
:	O	O
to	O	O
describe	O	O
two	O	O
cases	O	O
of	O	O
rhabdomyolysis	I-ADR	I-ADR
in	O	O
patients	O	O
taking	O	O
lovastatin	O	O
that	O	O
were	O	O
precipitated	O	O
by	O	O
the	O	O
use	O	O
of	O	O
the	O	O
newer	O	O
macrolide	O	O
antibiotics	O	O
clarithromycin	O	O
and	O	O
azithromycin	O	O
.	O	O
EOS	O	O
BOS	O	O
objective	O	O
:	O	O
to	O	O
describe	O	O
two	O	O
cases	O	O
of	O	O
rhabdomyolysis	I-ADR	I-ADR
in	O	O
patients	O	O
taking	O	O
lovastatin	O	O
that	O	O
were	O	O
precipitated	O	O
by	O	O
the	O	O
use	O	O
of	O	O
the	O	O
newer	O	O
macrolide	O	O
antibiotics	O	O
clarithromycin	O	O
and	O	O
azithromycin	O	O
.	O	O
EOS	O	O
BOS	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
these	O	O
cases	O	O
are	O	O
the	O	O
first	O	O
published	O	O
reports	O	O
of	O	O
lovastatin-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
associated	O	O
with	O	O
azithromycin	O	O
and	O	O
clarithromycin	O	O
.	O	O
EOS	O	O
BOS	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
these	O	O
cases	O	O
are	O	O
the	O	O
first	O	O
published	O	O
reports	O	O
of	O	O
lovastatin-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
associated	O	O
with	O	O
azithromycin	O	O
and	O	O
clarithromycin	O	O
.	O	O
EOS	O	O
BOS	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
these	O	O
cases	O	O
are	O	O
the	O	O
first	O	O
published	O	O
reports	O	O
of	O	O
lovastatin-induced	O	O
rhabdomyolysis	I-ADR	I-ADR
associated	O	O
with	O	O
azithromycin	O	O
and	O	O
clarithromycin	O	O
.	O	O
EOS	O	O
BOS	O	O
these	O	O
cases	O	O
were	O	O
considered	O	O
unusual	O	O
in	O	O
light	O	I-ADR
of	O	O
the	O	O
short	O	O
delay	O	O
of	O	O
their	O	O
onset	O	O
after	O	O
initiation	O	O
of	O	O
immunosuppressive	O	O
therapy	O	O
and	O	O
their	O	O
fulminant	O	O
course	O	O
:	O	O
3	O	O
of	O	O
these	O	O
patients	O	O
died	I-ADR	O
of	O	O
pcp	O	O
occurring	O	O
during	O	O
the	O	O
first	O	O
month	O	O
of	O	O
treatment	O	O
with	O	O
prednisone	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
the	O	O
specifics	O	O
of	O	O
12	O	O
cases	O	O
of	O	O
severe	I-ADR	I-ADR
hypertension	I-ADR	I-ADR
after	O	O
the	O	O
intraoperative	O	O
use	O	O
of	O	O
topical	O	O
phenylephrine	O	O
,	O	O
submucosal	O	O
epinephrine	O	O
,	O	O
or	O	O
both	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
the	O	O
specifics	O	O
of	O	O
12	O	O
cases	O	O
of	O	O
severe	I-ADR	I-ADR
hypertension	I-ADR	I-ADR
after	O	O
the	O	O
intraoperative	O	O
use	O	O
of	O	O
topical	O	O
phenylephrine	O	O
,	O	O
submucosal	O	O
epinephrine	O	O
,	O	O
or	O	O
both	O	O
.	O	O
EOS	O	O
BOS	O	O
acute	I-ADR	I-ADR
leukaemia	I-ADR	I-ADR
during	O	O
tamoxifen	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
tamoxifen	O	O
is	O	O
suggested	O	O
to	O	O
be	O	O
carcinogenic	I-ADR	O
both	O	O
through	O	O
direct	O	O
genotoxic	O	O
and	O	O
epigenetic	O	O
mechanisms	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
two	O	O
cases	O	O
that	O	O
developed	O	O
acute	I-ADR	I-ADR
myeloid	I-ADR	I-ADR
leukaemia	I-ADR	I-ADR
(	O	O
aml	I-ADR	I-ADR
)	O	O
during	O	O
tamoxifen	O	O
therapy	O	O
for	O	O
breast	O	O
cancer	O	O
.	O	O
EOS	O	O
BOS	O	O
relapse	I-ADR	O
in	I-ADR	O
the	I-ADR	O
external	I-ADR	O
auditory	I-ADR	O
canal	I-ADR	O
of	I-ADR	O
acute	I-ADR	I-ADR
promyelocytic	I-ADR	I-ADR
leukemia	I-ADR	I-ADR
after	O	O
treatment	O	O
with	O	O
all-trans	O	O
retinoic	O	O
acid	O	O
.	O	O
EOS	O	O
BOS	O	O
this	O	O
case	O	O
suggests	O	O
the	O	O
importance	O	O
of	O	O
careful	O	O
observation	O	O
for	O	O
extramedullary	I-ADR	O
relapse	I-ADR	O
in	O	O
patients	O	O
who	O	O
are	O	O
treated	O	O
with	O	O
atra	O	O
.	O	O
EOS	O	O
BOS	O	O
cutaneous	I-ADR	I-ADR
reactions	I-ADR	I-ADR
to	O	O
propylthiouracil	O	O
and	O	O
methimazole	O	O
occur	O	O
in	O	O
3	O	O
%	O	O
-	O	O
5	O	O
%	O	O
of	O	O
adults	O	O
.	O	O
EOS	O	O
BOS	O	O
cutaneous	I-ADR	I-ADR
reactions	I-ADR	I-ADR
to	O	O
propylthiouracil	O	O
and	O	O
methimazole	O	O
occur	O	O
in	O	O
3	O	O
%	O	O
-	O	O
5	O	O
%	O	O
of	O	O
adults	O	O
.	O	O
EOS	O	O
BOS	O	O
generalized	I-ADR	I-ADR
maculopapular	I-ADR	I-ADR
and	I-ADR	O
papular	I-ADR	I-ADR
purpuric	I-ADR	I-ADR
eruptions	I-ADR	I-ADR
are	O	O
perhaps	O	O
the	O	O
most	O	O
common	O	O
thionamide-induced	O	O
reactions	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
propylthiouracil-induced	O	O
cutaneous	I-ADR	I-ADR
vasculitis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
the	O	O
observation	O	O
of	O	O
cutaneous	I-ADR	I-ADR
vasculitis	I-ADR	I-ADR
during	O	O
administration	O	O
of	O	O
propylthiouracil	O	O
suggested	O	O
that	O	O
clinical	O	O
awareness	O	O
of	O	O
this	O	O
complication	O	O
should	O	O
be	O	O
of	O	O
considerable	O	O
importance	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
2	O	O
-	O	O
year-old	O	O
mentally	O	O
retarded	O	O
boy	O	O
with	O	O
frontal	O	O
lobe	O	O
epilepsy	O	O
presented	O	O
with	O	O
an	O	O
episode	O	O
that	O	O
resembled	O	O
heat	I-ADR	I-ADR
stroke	I-ADR	I-ADR
during	O	O
the	O	O
administration	O	O
of	O	O
zonisamide	O	O
.	O	O
EOS	O	O
BOS	O	O
children	O	O
receiving	O	O
zonisamide	O	O
should	O	O
be	O	O
monitored	O	O
for	O	O
oligohidrosis	I-ADR	O
and	O	O
the	O	O
development	O	O
of	O	O
neurological	I-ADR	I-ADR
symptoms	I-ADR	I-ADR
associated	O	O
with	O	O
an	O	O
elevation	O	I-ADR
of	O	O
body	O	I-ADR
temperature	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
heat	I-ADR	I-ADR
stroke-like	I-ADR	I-ADR
episode	I-ADR	I-ADR
in	O	O
a	O	O
child	O	O
caused	O	O
by	O	O
zonisamide	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
oligohidrosis	I-ADR	I-ADR
caused	O	O
by	O	O
zonisamide	O	O
was	O	O
reversible	O	O
in	O	O
that	O	O
the	O	O
patient	O	O
regained	O	O
the	O	O
ability	O	O
to	O	O
sweat	O	O
within	O	O
2	O	O
weeks	O	O
of	O	O
the	O	O
cessation	O	O
of	O	O
drug	O	O
administration	O	O
.	O	O
EOS	O	O
BOS	O	O
acute	I-ADR	I-ADR
renal	I-ADR	I-ADR
failure	I-ADR	I-ADR
in	O	O
a	O	O
patient	O	O
receiving	O	O
treatment	O	O
with	O	O
suramin	O	O
.	O	O
EOS	O	O
BOS	O	O
acute	O	I-ADR
renal	I-ADR	I-ADR
failure	I-ADR	I-ADR
should	O	O
be	O	O
recognized	O	O
as	O	O
a	O	O
potential	O	O
complication	O	O
of	O	O
suramin	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
other	O	O
potential	O	O
causes	O	O
of	O	O
renal	I-ADR	I-ADR
failure	I-ADR	I-ADR
were	O	O
not	O	O
present	O	O
in	O	O
our	O	O
patient	O	O
and	O	O
his	O	O
renal	O	O
function	O	O
gradually	O	O
recovered	O	O
with	O	O
the	O	O
cessation	O	O
of	O	O
suramin	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
metastatic	O	O
prostate	O	O
cancer	O	O
who	O	O
developed	O	O
nonoliguric	I-ADR	I-ADR
renal	I-ADR	I-ADR
failure	I-ADR	I-ADR
during	O	O
treatment	O	O
with	O	O
suramin	O	O
.	O	O
EOS	O	O
BOS	O	O
clozapine	O	O
induced	O	O
polyserositis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
polyserositis	I-ADR	I-ADR
(	O	O
pericardial	I-ADR	I-ADR
effusion	I-ADR	I-ADR
,	O	O
pleural	I-ADR	I-ADR
effusion	I-ADR	I-ADR
,	O	O
and	O	O
pericarditis	I-ADR	I-ADR
)	O	O
after	O	O
being	O	O
started	O	O
on	O	O
clozapine	O	O
,	O	O
and	O	O
whose	O	O
symptoms	O	O
remitted	O	O
upon	O	O
discontinuation	O	O
of	O	O
clozapine	O	O
.	O	O
EOS	O	O
BOS	O	O
when	O	O
the	O	O
disease	O	O
recurred	O	O
conventional	O	O
amphotericin	O	O
b	O	O
was	O	O
used	O	O
again	O	O
,	O	O
but	O	O
had	O	O
to	O	O
be	O	O
stopped	O	O
because	O	O
of	O	O
severe	I-ADR	I-ADR
side	I-ADR	O
effects	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
thirty-six	O	O
patients	O	O
with	O	O
al	O	O
received	O	O
,	O	O
in	O	O
a	O	O
three-month	O	O
period	O	O
,	O	O
51	O	O
cycles	O	O
of	O	O
combined	O	O
chemotherapy	O	O
which	O	O
included	O	O
,	O	O
in	O	O
all	O	O
of	O	O
them	O	O
,	O	O
cytosine	O	O
arabinoside	O	O
(	O	O
ara-c	O	O
);	O	O
among	O	O
them	O	O
,	O	O
along	O	O
with	O	O
myelosuppression	O	O
,	O	O
five	O	O
experienced	O	O
fever	I-ADR	I-ADR
,	O	O
infectious	I-ADR	I-ADR
complications	I-ADR	I-ADR
,	O	O
gastrointestinal	I-ADR	I-ADR
tract	I-ADR	I-ADR
symptoms	I-ADR	I-ADR
and	O	O
severe	I-ADR	I-ADR
myalgias	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
thirty-six	O	O
patients	O	O
with	O	O
al	O	O
received	O	O
,	O	O
in	O	O
a	O	O
three-month	O	O
period	O	O
,	O	O
51	O	O
cycles	O	O
of	O	O
combined	O	O
chemotherapy	O	O
which	O	O
included	O	O
,	O	O
in	O	O
all	O	O
of	O	O
them	O	O
,	O	O
cytosine	O	O
arabinoside	O	O
(	O	O
ara-c	O	O
);	O	O
among	O	O
them	O	O
,	O	O
along	O	O
with	O	O
myelosuppression	O	O
,	O	O
five	O	O
experienced	O	O
fever	I-ADR	I-ADR
,	O	O
infectious	I-ADR	I-ADR
complications	I-ADR	I-ADR
,	O	O
gastrointestinal	I-ADR	I-ADR
tract	I-ADR	I-ADR
symptoms	I-ADR	I-ADR
and	O	O
severe	I-ADR	I-ADR
myalgias	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
conclusion	O	O
:	O	O
we	O	O
believe	O	O
this	O	O
to	O	O
be	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
rhgh-induced	O	O
hypercalcemia	I-ADR	I-ADR
in	O	O
an	O	O
hiv-infected	O	O
patient	O	O
.	O	O
EOS	O	O
BOS	O	O
hypercalcemia	I-ADR	I-ADR
in	O	O
an	O	O
aids	O	O
patient	O	O
treated	O	O
with	O	O
growth	O	O
hormone	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
hypercalcemia	I-ADR	I-ADR
responded	O	O
to	O	O
discontinuation	O	O
of	O	O
rhgh	O	O
and	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
intravenous	O	O
pamidronate	O	O
disodium	O	O
and	O	O
has	O	O
not	O	O
recurred	O	O
in	O	O
8	O	O
months	O	O
of	O	O
follow-up	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
a	O	O
male	O	O
patient	O	O
with	O	O
advanced	O	O
aids	O	O
who	O	O
developed	O	O
hypercalcemia	I-ADR	I-ADR
2	O	O
weeks	O	O
after	O	O
institution	O	O
of	O	O
rhgh	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
hypersensitivity	I-ADR	I-ADR
reactions	I-ADR	I-ADR
to	O	O
cisplatin	O	O
following	O	O
multiple	O	O
uncomplicated	O	O
courses	O	O
:	O	O
a	O	O
report	O	O
on	O	O
two	O	O
cases	O	O
.	O	O
EOS	O	O
BOS	O	O
two	O	O
patients	O	O
with	O	O
ovarian	O	O
cancer	O	O
who	O	O
had	O	O
received	O	O
multiple	O	O
courses	O	O
of	O	O
cisplatin	O	O
without	O	O
complications	O	O
experienced	O	O
hypersensitivity	I-ADR	I-ADR
reactions	I-ADR	I-ADR
to	O	O
cisplatin	O	O
:	O	O
one	O	O
,	O	O
involving	O	O
intrahepatic	O	O
artery	O	O
infusion	O	O
,	O	O
manifested	O	O
general	I-ADR	I-ADR
erythema	I-ADR	I-ADR
,	O	O
dyspnea	I-ADR	I-ADR
,	O	O
and	O	O
hypotension	I-ADR	I-ADR
;	O	O
the	O	O
other	O	O
,	O	O
involving	O	O
intravenous	O	O
infusion	O	O
,	O	O
manifested	O	O
abdominal	I-ADR	I-ADR
pain	I-ADR	I-ADR
,	O	O
general	I-ADR	I-ADR
erythema	I-ADR	I-ADR
,	O	O
and	O	O
fever	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
an	O	O
unusually	O	O
short	O	O
lived	O	O
and	O	O
asymptomatic	O	O
episode	O	O
of	O	O
severe	O	O
cisplatin-induced	O	O
renal	I-ADR	I-ADR
tubular	I-ADR	I-ADR
salt	I-ADR	O
wasting	I-ADR	O
in	O	O
a	O	O
fit	O	O
41	O	O
-	O	O
year-old	O	O
patient	O	O
with	O	O
malignant	O	O
teratoma	O	O
.	O	O
EOS	O	O
BOS	O	O
clinicians	O	O
should	O	O
include	O	O
phenolphthalein	O	O
in	O	O
their	O	O
list	O	O
of	O	O
possible	O	O
causes	O	O
of	O	O
drug-induced	O	O
ten	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
discussion	O	O
:	O	O
phenolphthalein	O	O
is	O	O
the	O	O
active	O	O
ingredient	O	O
in	O	O
several	O	O
over-the-counter	O	O
laxative	O	O
preparations	O	O
and	O	O
has	O	O
only	O	O
rarely	O	O
been	O	O
reported	O	O
to	O	O
cause	O	O
ten	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
objective	O	O
:	O	O
to	O	O
report	O	O
a	O	O
case	O	O
of	O	O
phenolphthalein-induced	O	O
toxic	I-ADR	I-ADR
epidermal	I-ADR	I-ADR
necrolysis	I-ADR	I-ADR
(	O	O
ten	I-ADR	O
)	O	O
in	O	O
a	O	O
patient	O	O
maintained	O	O
on	O	O
several	O	O
other	O	O
medications	O	O
more	O	O
commonly	O	O
known	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
ten	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
phenolphthalein-induced	O	O
toxic	I-ADR	I-ADR
epidermal	I-ADR	I-ADR
necrolysis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
the	O	O
patient's	O	O
previous	O	O
rash	I-ADR	I-ADR
and	O	O
the	O	O
temporal	O	O
relation	O	O
of	O	O
this	O	O
event	O	O
and	O	O
the	O	O
ingestion	O	O
of	O	O
phenolphthalein	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
similarity	O	O
of	O	O
this	O	O
case	O	O
to	O	O
other	O	O
reports	O	O
,	O	O
point	O	O
to	O	O
phenolphthalein	O	O
as	O	O
the	O	O
cause	O	O
of	O	O
ten	I-ADR	O
in	O	O
this	O	O
patient	O	O
.	O	O
EOS	O	O
BOS	O	O
carbamazepine	I-ADR	O
toxicity	I-ADR	I-ADR
induced	O	O
by	O	O
clarithromycin	O	O
coadministration	O	O
in	O	O
psychiatric	O	O
patients	O	O
.	O	O
EOS	O	O
BOS	O	O
during	O	O
clarithromycin	O	O
coadministration	O	O
,	O	O
four	O	O
out	O	O
of	O	O
the	O	O
seven	O	O
patients	O	O
developed	O	O
moderate-to-severe	O	O
toxic	I-ADR	I-ADR
symptoms	I-ADR	O
of	O	O
carbamazepine	O	O
,	O	O
such	O	O
as	O	O
drowsiness	I-ADR	I-ADR
,	O	O
dizziness	I-ADR	I-ADR
,	O	O
and	O	O
ataxia	I-ADR	I-ADR
,	O	O
which	O	O
resolved	O	O
within	O	O
5	O	O
days	O	O
after	O	O
clarithromycin	O	O
discontinuation	O	O
.	O	O
EOS	O	O
BOS	O	O
during	O	O
clarithromycin	O	O
coadministration	O	O
,	O	O
four	O	O
out	O	O
of	O	O
the	O	O
seven	O	O
patients	O	O
developed	O	O
moderate-to-severe	O	O
toxic	I-ADR	I-ADR
symptoms	I-ADR	O
of	O	O
carbamazepine	O	O
,	O	O
such	O	O
as	O	O
drowsiness	I-ADR	I-ADR
,	O	O
dizziness	I-ADR	I-ADR
,	O	O
and	O	O
ataxia	I-ADR	I-ADR
,	O	O
which	O	O
resolved	O	O
within	O	O
5	O	O
days	O	O
after	O	O
clarithromycin	O	O
discontinuation	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
present	O	O
report	O	O
suggests	O	O
that	O	O
clarithromycin	O	O
coadministration	O	O
induces	O	O
increased	I-ADR	I-ADR
plasma	I-ADR	I-ADR
carbamazepine	I-ADR	O
concentrations	O	O
,	O	O
which	O	O
may	O	O
result	O	O
in	O	O
carbamazepine	I-ADR	O
toxicity	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
present	O	O
report	O	O
suggests	O	O
that	O	O
clarithromycin	O	O
coadministration	O	O
induces	O	O
increased	I-ADR	I-ADR
plasma	I-ADR	I-ADR
carbamazepine	I-ADR	O
concentrations	O	O
,	O	O
which	O	O
may	O	O
result	O	O
in	O	O
carbamazepine	I-ADR	O
toxicity	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
acute	I-ADR	I-ADR
hemorrhagic	I-ADR	I-ADR
gastritis	I-ADR	I-ADR
associated	O	O
with	O	O
acetazolamide	O	O
intoxication	O	I-ADR
in	O	O
a	O	O
patient	O	O
with	O	O
chronic	O	O
renal	O	O
failure	O	O
.	O	O
EOS	O	O
BOS	O	O
as	O	O
far	O	O
as	O	O
we	O	O
know	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
case	O	O
report	O	O
of	O	O
acute	I-ADR	I-ADR
hemorrhagic	I-ADR	I-ADR
gastritis	I-ADR	I-ADR
associated	O	O
with	O	O
az	O	O
intoxication	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
experienced	O	O
a	O	O
case	O	O
of	O	O
chronic	O	O
renal	O	I-ADR
failure	O	I-ADR
in	O	O
a	O	O
patient	O	O
suffering	O	O
from	O	O
acute	I-ADR	O
hemorrhagic	I-ADR	I-ADR
gastritis	I-ADR	I-ADR
associated	O	O
with	O	O
az	O	O
intoxication	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
thus	O	O
concluded	O	O
that	O	O
an	O	O
excessive	O	O
dose	O	O
of	O	O
az	O	O
had	O	O
probably	O	O
destroyed	I-ADR	O
the	I-ADR	O
gastric	I-ADR	O
mucosal	I-ADR	I-ADR
barrier	I-ADR	I-ADR
or	O	O
thrombocytopenia	I-ADR	I-ADR
due	I-ADR	O
to	I-ADR	O
bone	I-ADR	O
marrow	I-ADR	O
disorder	I-ADR	O
and	O	O
thus	O	O
eventually	O	O
led	O	O
to	O	O
the	O	O
development	O	O
of	O	O
hemorrhagic	I-ADR	I-ADR
gastritis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
in	O	O
association	O	O
with	O	O
this	O	O
tocolysis	O	O
,	O	O
urinary	I-ADR	I-ADR
calculus	I-ADR	I-ADR
of	O	O
magnesium	O	I-ADR
ammonium	O	O
phosphate	O	O
occurred	O	O
at	O	O
34	O	O
weeks	O	O
gestation	O	O
.	O	O
EOS	O	O
BOS	O	O
magnesium	O	O
tocolysis	O	O
as	O	O
the	O	O
cause	O	O
of	O	O
urinary	I-ADR	I-ADR
calculus	I-ADR	I-ADR
during	O	O
pregnancy	O	O
.	O	O
EOS	O	O
BOS	O	O
danazol	O	O
induced	O	O
thrombocytopenia	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
on	O	O
the	O	O
next	O	O
day	O	O
,	O	O
after	O	O
a	O	O
total	O	O
dose	O	O
of	O	O
only	O	O
600	O	O
mg	O	O
of	O	O
danazol	O	O
,	O	O
gingival	I-ADR	I-ADR
bleeding	I-ADR	I-ADR
and	O	O
purpura	I-ADR	I-ADR
occurred	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
diagnosed	O	O
this	O	O
case	O	O
as	O	O
danazol	O	O
induced	O	O
thrombocytopenia	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
it	O	O
occasionally	O	O
accompanies	O	O
the	O	O
heparin-associated	O	O
thrombocytopenia	I-ADR	I-ADR
and	O	O
thrombosis	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
skin	I-ADR	I-ADR
necrosis	I-ADR	I-ADR
is	O	O
a	O	O
rare	O	O
complication	O	O
of	O	O
subcutaneous	O	O
heparin	O	O
therapy	O	O
that	O	O
usually	O	O
occurs	O	O
at	O	O
injection	O	O
sites	O	O
.	O	O
EOS	O	O
BOS	O	O
skin	I-ADR	I-ADR
necrosis	I-ADR	I-ADR
secondary	O	O
to	O	O
low-molecular	O	O
weight	O	O
heparin	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
antiphospholipid	O	O
antibody	O	O
syndrome	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
the	O	O
antiphospholipid	O	O
syndrome	O	O
who	O	O
had	O	O
skin	I-ADR	I-ADR
necrosis	I-ADR	I-ADR
develop	O	O
from	O	O
low-molecular	O	O
weight	O	O
heparin	O	O
therapy	O	O
at	O	O
sites	O	O
distant	O	O
from	O	O
injection	O	O
sites	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
case	O	O
of	O	O
contact	I-ADR	O
dermatitis	I-ADR	I-ADR
due	O	O
to	O	O
sodium	O	O
bisulfite	O	O
in	O	O
an	O	O
ophthalmic	O	O
solution	O	O
.	O	O
EOS	O	O
BOS	O	O
therefore	O	O
,	O	O
we	O	O
diagnosed	O	O
her	O	O
eruption	I-ADR	I-ADR
as	O	O
contact	I-ADR	I-ADR
dermatitis	I-ADR	I-ADR
due	O	O
to	O	O
sodium	O	O
bisulfite	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
contact	I-ADR	O
dermatitis	I-ADR	I-ADR
due	O	O
to	O	O
sodium	O	O
bisulfite	O	O
in	O	O
tathion	O	O
eye	O	O
drops	O	O
.	O	O
EOS	O	O
BOS	O	O
acute	I-ADR	I-ADR
pancreatitis	I-ADR	I-ADR
after	O	O
long-term	O	O
5	O	O
-	O	O
aminosalicylic	O	O
acid	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
acute	I-ADR	I-ADR
pancreatitis	I-ADR	I-ADR
is	O	O
a	O	O
known	O	O
,	O	O
although	O	O
rare	O	O
,	O	O
complication	O	O
of	O	O
mesalamine	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
rechallenge	O	O
,	O	O
performed	O	O
in	O	O
both	O	O
patients	O	O
,	O	O
confirmed	O	O
the	O	O
diagnosis	O	O
of	O	O
mesalamine-induced	O	O
pancreatitis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
these	O	O
case	O	O
reports	O	O
provide	O	O
evidence	O	O
that	O	O
5	O	O
-	O	O
aminosalicylic	O	O
acid	O	O
may	O	O
induce	O	O
acute	I-ADR	I-ADR
pancreatitis	I-ADR	I-ADR
after	O	O
long	O	O
term	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
two	O	O
cases	O	O
of	O	O
acute	I-ADR	I-ADR
pancreatitis	I-ADR	I-ADR
that	O	O
occurred	O	O
after	O	O
long	O	O
term	O	O
mesalamine	O	O
therapy	O	O
for	O	O
ulcerative	O	O
colitis	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
35	O	O
-	O	O
year-old	O	O
nephrotic	O	O
man	O	O
developed	O	O
acute	I-ADR	I-ADR
renal	I-ADR	I-ADR
failure	I-ADR	I-ADR
with	O	O
serum	O	I-ADR
creatinine	O	I-ADR
to	O	O
1543	O	O
micromol	O	O
/	O	O
l	O	O
after	O	O
a	O	O
month	O	O
of	O	O
therapy	O	O
with	O	O
enalapril	O	O
.	O	O
EOS	O	O
BOS	O	O
acute	I-ADR	I-ADR
renal	I-ADR	I-ADR
failure	I-ADR	I-ADR
with	O	O
severe	I-ADR	I-ADR
tubulointerstitial	I-ADR	I-ADR
changes	I-ADR	I-ADR
in	O	O
a	O	O
patient	O	O
with	O	O
minimal	O	O
change	O	O
nephrotic	O	O
syndrome	O	O
treated	O	O
with	O	O
enalapril	O	O
.	O	O
EOS	O	O
BOS	O	O
early	O	O
ritonavir-induced	O	O
maculopapular	I-ADR	I-ADR
eruption	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
ritonavir	O	O
should	O	O
be	O	O
added	O	O
to	O	O
the	O	O
list	O	O
of	O	O
drugs	O	O
that	O	O
can	O	O
induce	O	O
adverse	I-ADR	O
cutaneous	I-ADR	I-ADR
reactions	I-ADR	I-ADR
in	O	O
hiv	O	O
patients	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
2	O	O
cases	O	O
of	O	O
maculopapular	I-ADR	I-ADR
eruption	I-ADR	I-ADR
and	O	O
fever	I-ADR	I-ADR
in	O	O
patients	O	O
infected	O	O
with	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
(	O	O
hiv	O	O
)	O	O
on	O	O
the	O	O
2nd	O	O
day	O	O
of	O	O
first	O	O
administration	O	O
of	O	O
ritonavir	O	O
,	O	O
a	O	O
protease	O	O
inhibitor	O	O
.	O	O
EOS	O	O
BOS	O	O
nephropathy	I-ADR	I-ADR
caused	O	O
by	O	O
methicillin	O	O
therapy	O	O
for	O	O
staphylococcal	O	O
septicemia	O	O
.	O	O
EOS	O	O
BOS	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
relating	O	O
to	O	O
methicillin-induced	O	O
nephropathy	I-ADR	I-ADR
suggests	O	O
a	O	O
hypersensitivity	O	I-ADR
origin	O	O
for	O	O
this	O	O
disorder	O	O
,	O	O
but	O	O
immunologic	O	O
and	O	O
ultrastructural	O	O
investigation	O	O
to	O	O
date	O	O
has	O	O
failed	O	O
to	O	O
elucidate	O	O
pathogenesis	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
25	O	O
-	O	O
year-old	O	O
woman	O	O
sought	O	O
medical	O	O
attention	O	O
because	O	O
of	O	O
iliocaval	O	O
manifestations	O	O
of	O	O
retroperitoneal	I-ADR	I-ADR
fibrosis	I-ADR	I-ADR
while	O	O
she	O	O
was	O	O
taking	O	O
methysergide	O	O
.	O	O
EOS	O	O
BOS	O	O
methysergide-induced	O	O
retroperitoneal	I-ADR	I-ADR
fibrosis	I-ADR	I-ADR
:	O	O
successful	O	O
outcome	O	O
and	O	O
two	O	O
new	O	O
laboratory	O	O
features	O	O
.	O	O
EOS	O	O
BOS	O	O
vitiligo	I-ADR	I-ADR
associated	O	O
with	O	O
alpha-interferon	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
chronic	O	O
active	O	O
hepatitis	O	O
c	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
vitiligo	I-ADR	I-ADR
that	O	O
occurred	O	O
during	O	O
the	O	O
second	O	O
month	O	O
of	O	O
interferon	O	O
alpha	O	O
2a	O	O
therapy	O	O
for	O	O
chronic	O	O
active	O	O
hepatitis	O	O
c	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
case	O	O
is	O	O
reported	O	O
of	O	O
an	O	O
elderly	O	O
woman	O	O
who	O	O
developed	O	O
febrile	I-ADR	I-ADR
agranulocytosis	I-ADR	I-ADR
several	O	O
weeks	O	O
after	O	O
commencing	O	O
ticlopidine	O	O
but	O	O
who	O	O
had	O	O
a	O	O
favorable	O	O
outcome	O	O
after	O	O
cessation	O	O
of	O	O
that	O	O
drug	O	O
and	O	O
treatment	O	O
with	O	O
filgastrim	O	O
.	O	O
EOS	O	O
BOS	O	O
agranulocytosis	I-ADR	I-ADR
associated	O	O
with	O	O
ticlopidine	O	O
:	O	O
a	O	O
possible	O	O
benefit	O	O
with	O	O
filgastim	O	O
.	O	O
EOS	O	O
BOS	O	O
ticlopidine	O	O
is	O	O
an	O	O
oral	O	O
antiplatelet	O	O
agent	O	O
frequently	O	O
utilized	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
cerebrovascular	O	O
disease	O	O
and	O	O
is	O	O
rarely	O	O
associated	O	O
with	O	O
severe	I-ADR	I-ADR
bone	I-ADR	I-ADR
marrow	I-ADR	I-ADR
suppression	I-ADR	I-ADR
,	O	O
typically	O	O
aplastic	I-ADR	I-ADR
anemia	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
hemodialysis	O	O
was	O	O
also	O	O
shown	O	O
to	O	O
reverse	O	O
ifosfamide-related	O	O
neurotoxicity	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
ifosfamide-associated	O	O
neurotoxicity	I-ADR	I-ADR
was	O	O
noted	O	O
within	O	O
hours	O	O
of	O	O
drug	O	O
administration	O	O
and	O	O
improved	O	O
rapidly	O	O
following	O	O
hemodialysis	O	O
.	O	O
EOS	O	O
BOS	O	O
purpose	O	O
:	O	O
we	O	O
evaluated	O	O
the	O	O
in	O	O
vitro	O	O
hemodialysis	O	O
ratio	O	O
and	O	O
subsequent	O	O
toxicity	O	I-ADR
and	O	O
pharmacokinetics	O	O
of	O	O
ifosfamide	I-ADR	O
in	O	O
an	O	O
anephric	O	O
patient	O	O
with	O	O
wilms	O	O
'	O	O
tumor	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
toxicity	I-ADR	I-ADR
and	O	O
plasma	O	O
concentrations	O	O
of	O	O
ifosfamide	O	O
,	O	O
chloroacetaldehyde	O	O
,	O	O
and	O	O
4	O	O
-	O	O
hydroxyifosfamide	O	O
were	O	O
then	O	O
determined	O	O
over	O	O
24	O	O
h	O	O
after	O	O
a	O	O
single	O	O
1.6	O	O
g	O	O
/	O	O
m2	O	O
dose	O	O
of	O	O
ifosfamide	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
toxicity	I-ADR	I-ADR
and	O	O
plasma	O	O
concentrations	O	O
of	O	O
ifosfamide	O	O
,	O	O
chloroacetaldehyde	O	O
,	O	O
and	O	O
4	O	O
-	O	O
hydroxyifosfamide	O	O
were	O	O
then	O	O
determined	O	O
over	O	O
24	O	O
h	O	O
after	O	O
a	O	O
single	O	O
1.6	O	O
g	O	O
/	O	O
m2	O	O
dose	O	O
of	O	O
ifosfamide	O	O
.	O	O
EOS	O	O
BOS	O	O
toxicity	I-ADR	I-ADR
,	O	O
pharmacokinetics	O	O
,	O	O
and	O	O
in	O	O
vitro	O	O
hemodialysis	O	O
clearance	O	O
of	O	O
ifosfamide	O	O
and	O	O
metabolites	O	O
in	O	O
an	O	O
anephric	O	O
pediatric	O	O
patient	O	O
with	O	O
wilms	O	O
'	O	O
tumor	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
55	O	O
-	O	O
year-old	O	O
woman	O	O
developed	O	O
symptoms	O	O
suggestive	O	O
of	O	O
hepatitis	I-ADR	I-ADR
12	O	O
weeks	O	O
after	O	O
first	O	O
receiving	O	O
methyldopa	O	O
for	O	O
hypertension	O	O
.	O	O
EOS	O	O
BOS	O	O
methyldopa-induced	O	O
liver	I-ADR	I-ADR
injury	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
such	O	O
a	O	O
rapid	O	O
and	O	O
relentless	O	O
progression	O	O
of	O	O
methyldopa-induced	O	O
liver	I-ADR	I-ADR
injury	I-ADR	I-ADR
is	O	O
undoubtedly	O	O
rare	O	O
,	O	O
but	O	O
it	O	O
may	O	O
be	O	O
prevented	O	O
by	O	O
careful	O	O
supervision	O	O
of	O	O
patients	O	O
who	O	O
exhibit	O	O
liver	O	I-ADR
function	O	O
abnormalities	O	O
early	O	O
in	O	O
the	O	O
course	O	O
of	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
acute	I-ADR	I-ADR
respiratory	I-ADR	I-ADR
depression	I-ADR	I-ADR
as	O	O
a	O	O
complication	O	O
of	O	O
nebulised	O	O
morphine	O	O
.	O	O
EOS	O	O
BOS	O	O
approximately	O	O
15	O	O
min	O	O
after	O	O
the	O	O
first	O	O
administration	O	O
of	O	O
nebulised	O	O
morphine	O	O
the	O	O
patient	O	O
became	O	O
markedly	O	I-ADR
bradypneic	I-ADR	I-ADR
(	O	O
respiratory	O	I-ADR
rate	O	I-ADR
:	O	O
4-5	O	O
bpm	O	O
)	O	O
,	O	O
hypotensive	I-ADR	I-ADR
(	O	O
bp	O	O
70/40	O	O
mmhg	O	O
)	O	O
,	O	O
and	O	O
responded	O	O
only	O	O
partially	O	O
to	O	O
command	O	O
.	O	O
EOS	O	O
BOS	O	O
purpose	O	O
:	O	O
to	O	O
present	O	O
a	O	O
case	O	O
of	O	O
respiratory	I-ADR	I-ADR
depression	I-ADR	I-ADR
following	O	O
the	O	O
administration	O	O
of	O	O
nebulised	O	O
morphine	O	O
.	O	O
EOS	O	O
BOS	O	O
acute	I-ADR	I-ADR
dystonia	I-ADR	I-ADR
with	O	O
thalamic	I-ADR	I-ADR
and	I-ADR	O
brainstem	I-ADR	I-ADR
lesions	I-ADR	I-ADR
after	O	O
initial	O	O
penicillamine	O	O
treatment	O	O
in	O	O
wilson's	O	O
disease	O	O
.	O	O
EOS	O	O
BOS	O	O
from	O	O
these	O	O
data	O	O
,	O	O
acute	I-ADR	I-ADR
generalized	I-ADR	I-ADR
dystonia	I-ADR	I-ADR
with	O	O
brainstem	I-ADR	I-ADR
and	I-ADR	O
thalamic	I-ADR	I-ADR
lesions	I-ADR	I-ADR
may	O	O
occur	O	O
in	O	O
wd	O	O
patients	O	O
after	O	O
an	O	O
initial	O	O
d-penicillamine	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
reported	O	O
3	O	O
patients	O	O
who	O	O
developed	O	O
acute	I-ADR	I-ADR
generalized	I-ADR	I-ADR
dystonia	I-ADR	I-ADR
and	O	O
akinetic	I-ADR	I-ADR
rigid	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
following	O	O
an	O	O
initial	O	O
therapy	O	O
with	O	O
d-penicillamine	O	O
125-500	O	O
mg	O	O
daily	O	O
.	O	O
EOS	O	O
BOS	O	O
ballistic	I-ADR	I-ADR
movements	I-ADR	I-ADR
due	O	O
to	O	O
ischemic	I-ADR	I-ADR
infarcts	I-ADR	I-ADR
after	O	O
intravenous	O	O
heroin	O	O
overdose	O	O
:	O	O
report	O	O
of	O	O
two	O	O
cases	O	O
.	O	O
EOS	O	O
BOS	O	O
patient	O	O
1	O	O
presented	O	O
bilateral	I-ADR	I-ADR
ballism	I-ADR	I-ADR
1	O	O
week	O	O
after	O	O
intravenous	O	O
heroin	O	O
injection	O	O
.	O	O
EOS	O	O
BOS	O	O
stroke	I-ADR	I-ADR
is	O	O
an	O	O
infrequent	O	O
but	O	O
recognized	O	O
complication	O	O
of	O	O
heroin	O	O
addiction	O	O
.	O	O
EOS	O	O
BOS	O	O
two	O	O
heroin	O	O
addicts	O	O
,	O	O
aged	O	O
34	O	O
and	O	O
19	O	O
years	O	O
,	O	O
developed	O	O
ballistic	I-ADR	I-ADR
movements	I-ADR	I-ADR
after	O	O
intravenous	O	O
heroin	O	O
overdose	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
medline	O	O
search	O	O
identified	O	O
all	O	O
the	O	O
reported	O	O
cases	O	O
of	O	O
hypersensitivity	I-ADR	I-ADR
reactions	I-ADR	I-ADR
to	O	O
cyclosporine	O	O
.	O	O
EOS	O	O
BOS	O	O
anaphylaxis	I-ADR	I-ADR
to	O	O
intravenous	O	O
cyclosporine	O	O
and	O	O
tolerance	O	O
to	O	O
oral	O	O
cyclosporine	O	O
:	O	O
case	O	O
report	O	O
and	O	O
review	O	O
.	O	O
EOS	O	O
BOS	O	O
background	O	O
:	O	O
hypersensitivity	I-ADR	I-ADR
reactions	I-ADR	I-ADR
to	O	O
cyclosporine	O	O
are	O	O
rare	O	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
hypersensitivity	I-ADR	I-ADR
reactions	I-ADR	I-ADR
to	O	O
cyclosporine	O	O
are	O	O
due	O	O
to	O	O
cremophor	O	O
el	O	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
hypersensitivity	I-ADR	I-ADR
reactions	I-ADR	I-ADR
to	O	O
cyclosporine	O	O
are	O	O
due	O	O
to	O	O
cremophor	O	O
el	O	O
.	O	O
EOS	O	O
BOS	O	O
fortunately	O	O
,	O	O
a	O	O
hypersensitivity	I-ADR	I-ADR
reaction	I-ADR	I-ADR
to	O	O
one	O	O
formulation	O	O
of	O	O
cyclosporine	O	O
does	O	O
not	O	O
preclude	O	O
use	O	O
of	O	O
a	O	O
different	O	O
formulation	O	O
.	O	O
EOS	O	O
BOS	O	O
methods	O	O
:	O	O
we	O	O
report	O	O
a	O	O
patient	O	O
who	O	O
had	O	O
an	O	O
anaphylactic	I-ADR	I-ADR
reaction	I-ADR	I-ADR
during	O	O
the	O	O
intravenous	O	O
infusion	O	O
of	O	O
cyclosporine	O	O
.	O	O
EOS	O	O
BOS	O	O
objective	O	O
:	O	O
to	O	O
investigate	O	O
the	O	O
mechanisms	O	O
involved	O	O
in	O	O
hypersensitivity	I-ADR	I-ADR
reactions	I-ADR	I-ADR
to	O	O
cyclosporine	O	O
and	O	O
determine	O	O
the	O	O
feasibility	O	O
of	O	O
future	O	O
cyclosporine	O	O
use	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
literature	O	O
search	O	O
revealed	O	O
22	O	O
cases	O	O
of	O	O
hypersensitivity	I-ADR	I-ADR
reaction	I-ADR	I-ADR
to	O	O
cyclosporine	O	O
.	O	O
EOS	O	O
BOS	O	O
prothipendylhydrochloride-induced	O	O
priapism	I-ADR	I-ADR
:	O	O
case	O	O
report	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
present	O	O
the	O	O
first	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
priapism	I-ADR	I-ADR
after	O	O
oral	O	O
intake	O	O
of	O	O
the	O	O
phenothiazine	O	O
prothipendylhydrochloride	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
chemotherapeutics	O	O
,	O	O
including	O	O
vincristine	O	O
,	O	O
actinomycin	O	O
d	O	O
,	O	O
and	O	O
epirubicin	O	O
in	O	O
case	O	O
1	O	O
and	O	O
vincristine	O	O
and	O	O
actinomycin	O	O
d	O	O
in	O	O
case	O	O
2	O	O
,	O	O
were	O	O
given	O	O
before	O	O
the	O	O
hepatotoxicity	I-ADR	I-ADR
developed	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
chemotherapeutics	O	O
,	O	O
including	O	O
vincristine	O	O
,	O	O
actinomycin	O	O
d	O	O
,	O	O
and	O	O
epirubicin	O	O
in	O	O
case	O	O
1	O	O
and	O	O
vincristine	O	O
and	O	O
actinomycin	O	O
d	O	O
in	O	O
case	O	O
2	O	O
,	O	O
were	O	O
given	O	O
before	O	O
the	O	O
hepatotoxicity	I-ADR	I-ADR
developed	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
chemotherapeutics	O	O
,	O	O
including	O	O
vincristine	O	O
,	O	O
actinomycin	O	O
d	O	O
,	O	O
and	O	O
epirubicin	O	O
in	O	O
case	O	O
1	O	O
and	O	O
vincristine	O	O
and	O	O
actinomycin	O	O
d	O	O
in	O	O
case	O	O
2	O	O
,	O	O
were	O	O
given	O	O
before	O	O
the	O	O
hepatotoxicity	I-ADR	I-ADR
developed	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
conclude	O	O
that	O	O
vincristine	O	O
and	O	O
actinomycin	O	O
d	O	O
were	O	O
the	O	O
cause	O	O
of	O	O
this	O	O
rare	O	O
from	O	O
of	O	O
hepatotoxicity	I-ADR	I-ADR
and	O	O
that	O	O
chemotherapy	O	O
for	O	O
the	O	O
underlying	O	O
malignant	O	O
disease	O	O
could	O	O
be	O	O
given	O	O
safely	O	O
after	O	O
clinical	O	O
recovery	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
conclude	O	O
that	O	O
vincristine	O	O
and	O	O
actinomycin	O	O
d	O	O
were	O	O
the	O	O
cause	O	O
of	O	O
this	O	O
rare	O	O
from	O	O
of	O	O
hepatotoxicity	I-ADR	I-ADR
and	O	O
that	O	O
chemotherapy	O	O
for	O	O
the	O	O
underlying	O	O
malignant	O	O
disease	O	O
could	O	O
be	O	O
given	O	O
safely	O	O
after	O	O
clinical	O	O
recovery	O	O
.	O	O
EOS	O	O
BOS	O	O
because	O	O
the	O	O
combination	O	O
of	O	O
bleomycin	O	O
and	O	O
vinca	O	O
alkaloids	O	O
is	O	O
commonly	O	O
used	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
aids-related	O	O
kaposi's	O	O
sarcoma	O	O
,	O	O
clinicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
risk	O	O
of	O	O
provoking	O	O
acral	I-ADR	I-ADR
necrosis	I-ADR	I-ADR
in	O	O
patients	O	O
who	O	O
develop	O	O
raynaud's	I-ADR	O
phenomenon	I-ADR	O
under	O	O
chemotherapy	O	O
.	O	O
EOS	O	O
BOS	O	O
in	O	O
this	O	O
report	O	O
,	O	O
one	O	O
patient	O	O
who	O	O
developed	O	O
gangrene	I-ADR	I-ADR
after	O	O
bleomycin	O	O
and	O	O
vincristine	O	O
/	O	O
vinblastine	O	O
chemotherapy	O	O
for	O	O
aids-related	O	O
kaposi's	O	O
sarcoma	O	O
and	O	O
another	O	O
hiv-infected	O	O
patient	O	O
who	O	O
exhibited	O	O
symptoms	O	O
of	O	O
severe	O	I-ADR
raynaud's	O	I-ADR
phenomenon	O	O
related	O	O
to	O	O
the	O	O
same	O	O
regimen	O	O
are	O	O
presented	O	O
.	O	O
EOS	O	O
BOS	O	O
in	O	O
this	O	O
report	O	O
,	O	O
one	O	O
patient	O	O
who	O	O
developed	O	O
gangrene	I-ADR	I-ADR
after	O	O
bleomycin	O	O
and	O	O
vincristine	O	O
/	O	O
vinblastine	O	O
chemotherapy	O	O
for	O	O
aids-related	O	O
kaposi's	O	O
sarcoma	O	O
and	O	O
another	O	O
hiv-infected	O	O
patient	O	O
who	O	O
exhibited	O	O
symptoms	O	O
of	O	O
severe	I-ADR	I-ADR
raynaud's	I-ADR	I-ADR
phenomenon	I-ADR	O
related	O	O
to	O	O
the	O	O
same	O	O
regimen	O	O
are	O	O
presented	O	O
.	O	O
EOS	O	O
BOS	O	O
in	O	O
this	O	O
report	O	O
,	O	O
one	O	O
patient	O	O
who	O	O
developed	O	O
gangrene	I-ADR	I-ADR
after	O	O
bleomycin	O	O
and	O	O
vincristine	O	O
/	O	O
vinblastine	O	O
chemotherapy	O	O
for	O	O
aids-related	O	O
kaposi's	O	O
sarcoma	O	O
and	O	O
another	O	O
hiv-infected	O	O
patient	O	O
who	O	O
exhibited	O	O
symptoms	O	O
of	O	O
severe	I-ADR	I-ADR
raynaud's	I-ADR	I-ADR
phenomenon	I-ADR	O
related	O	O
to	O	O
the	O	O
same	O	O
regimen	O	O
are	O	O
presented	O	O
.	O	O
EOS	O	O
BOS	O	O
development	O	O
of	O	O
essential	O	O
thrombocythemia	I-ADR	I-ADR
in	O	O
a	O	O
patient	O	O
treated	O	O
with	O	O
interferon	O	O
alfa	O	O
and	O	O
pentostatin	O	O
for	O	O
hairy	O	O
cell	O	O
leukemia	O	O
.	O	O
EOS	O	O
BOS	O	O
development	O	O
of	O	O
essential	O	O
thrombocythemia	I-ADR	I-ADR
in	O	O
a	O	O
patient	O	O
treated	O	O
with	O	O
interferon	O	O
alfa	O	O
and	O	O
pentostatin	O	O
for	O	O
hairy	O	O
cell	O	O
leukemia	O	O
.	O	O
EOS	O	O
BOS	O	O
second	I-ADR	O
cancers	I-ADR	O
including	O	O
various	O	O
types	O	O
of	O	O
hematological	I-ADR	I-ADR
malignancy	I-ADR	I-ADR
have	O	O
been	O	O
reported	O	O
in	O	O
patients	O	O
with	O	O
hairy	O	O
cell	O	O
leukemia	O	O
treated	O	O
with	O	O
chemotherapy	O	O
or	O	O
interferon	O	O
alfa	O	O
.	O	O
EOS	O	O
BOS	O	O
effect	O	O
of	O	O
beta-blockade	O	O
on	O	O
symptomatic	O	O
dexamethasone-induced	O	O
hypertrophic	I-ADR	I-ADR
obstructive	I-ADR	I-ADR
cardiomyopathy	I-ADR	I-ADR
in	O	O
premature	O	O
infants	O	O
:	O	O
three	O	O
case	O	O
reports	O	O
and	O	O
literature	O	O
review	O	O
.	O	O
EOS	O	O
BOS	O	O
one	O	O
patient	O	O
had	O	O
a	O	O
lower	I-ADR	O
average	I-ADR	O
heart	I-ADR	I-ADR
rate	I-ADR	O
and	O	O
two	O	O
patients	O	O
had	O	O
lower	I-ADR	I-ADR
average	I-ADR	I-ADR
mean	I-ADR	O
blood	I-ADR	I-ADR
pressure	I-ADR	I-ADR
values	O	O
during	O	O
propranolol	O	O
treatment	O	O
,	O	O
none	O	O
of	O	O
which	O	O
was	O	O
clinically	O	O
significant	O	O
.	O	O
EOS	O	O
BOS	O	O
study	O	O
design	O	O
:	O	O
case	O	O
reports	O	O
are	O	O
presented	O	O
of	O	O
three	O	O
premature	O	O
infants	O	O
(	O	O
mean	O	O
gestational	O	O
age	O	O
27	O	O
weeks	O	O
)	O	O
cared	O	O
for	O	O
in	O	O
the	O	O
intensive	O	O
care	O	O
nursery	O	O
in	O	O
whom	O	O
clinically	O	O
significant	O	O
septal	I-ADR	I-ADR
hypertrophy	I-ADR	I-ADR
and	O	O
left	I-ADR	I-ADR
ventricular	I-ADR	I-ADR
outflow	I-ADR	I-ADR
tract	I-ADR	I-ADR
obstruction	I-ADR	I-ADR
developed	O	O
during	O	O
dexamethasone	O	O
treatment	O	O
for	O	O
bronchopulmonary	O	O
dysplasia	O	O
.	O	O
EOS	O	O
BOS	O	O
case	O	O
summary	O	O
:	O	O
a	O	O
25	O	O
-	O	O
year-old	O	O
postpartum	O	O
white	O	O
woman	O	O
developed	O	O
multiple	I-ADR	I-ADR
watery	I-ADR	I-ADR
stools	I-ADR	I-ADR
and	O	O
abdominal	I-ADR	I-ADR
cramping	I-ADR	I-ADR
on	O	O
day	O	O
6	O	O
of	O	O
therapy	O	O
with	O	O
clindamycin	O	O
vaginal	O	O
cream	O	O
for	O	O
bacterial	O	O
vaginosis	O	O
.	O	O
EOS	O	O
BOS	O	O
clostridium	I-ADR	O
difficile	I-ADR	O
toxin-induced	I-ADR	O
colitis	I-ADR	I-ADR
after	O	O
use	O	O
of	O	O
clindamycin	O	O
phosphate	O	O
vaginal	O	O
cream	O	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
this	O	O
report	O	O
indicates	O	O
clindamycin	O	O
phosphate	O	O
vaginal	O	O
cream	O	O
as	O	O
the	O	O
most	O	O
probable	O	O
cause	O	O
of	O	O
cdic	I-ADR	O
due	O	O
to	O	O
the	O	O
temporal	O	O
relationship	O	O
between	O	O
the	O	O
occurrence	O	O
of	O	O
diarrhea	I-ADR	I-ADR
and	O	O
clindamycin	O	O
administration	O	O
,	O	O
lack	O	O
of	O	O
concomitant	O	O
medications	O	O
,	O	O
and	O	O
documentation	O	O
of	O	O
c	I-ADR	O
.	I-ADR	O
difficile	I-ADR	O
toxin	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
this	O	O
report	O	O
indicates	O	O
clindamycin	O	O
phosphate	O	O
vaginal	O	O
cream	O	O
as	O	O
the	O	O
most	O	O
probable	O	O
cause	O	O
of	O	O
cdic	I-ADR	O
due	O	O
to	O	O
the	O	O
temporal	O	O
relationship	O	O
between	O	O
the	O	O
occurrence	O	O
of	O	O
diarrhea	I-ADR	I-ADR
and	O	O
clindamycin	O	O
administration	O	O
,	O	O
lack	O	O
of	O	O
concomitant	O	O
medications	O	O
,	O	O
and	O	O
documentation	O	O
of	O	O
c	I-ADR	O
.	I-ADR	O
difficile	I-ADR	O
toxin	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
discussion	O	O
:	O	O
no	O	O
published	O	O
clinical	O	O
studies	O	O
in	O	O
patients	O	O
receiving	O	O
clindamycin	O	O
vaginal	O	O
cream	O	I-ADR
for	O	O
bacterial	O	O
vaginosis	O	O
have	O	O
documented	O	O
c	I-ADR	O
.	I-ADR	O
difficile	I-ADR	I-ADR
toxin	I-ADR	I-ADR
in	I-ADR	O
stool	I-ADR	O
samples	O	O
of	O	O
patients	O	O
with	O	O
diarrhea	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
objective	O	O
:	O	O
to	O	O
report	O	O
a	O	O
case	O	O
of	O	O
toxin-positive	I-ADR	O
clostridium	I-ADR	O
difficile-induced	I-ADR	O
colitis	I-ADR	I-ADR
(	O	O
cdic	O	I-ADR
)	O	O
after	O	O
use	O	O
of	O	O
clindamycin	O	O
phosphate	O	O
vaginal	O	O
cream	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
54	O	O
-	O	O
year-old	O	O
man	O	O
developed	O	O
ten	I-ADR	O
4	O	O
weeks	O	O
after	O	O
beginning	O	O
lamotrigine	O	O
for	O	O
complex	O	O
partial	O	I-ADR
seizures	O	I-ADR
related	O	O
to	O	O
a	O	O
glioblastoma	O	O
multiforme	O	I-ADR
brain	O	I-ADR
tumor	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
administration	O	O
of	O	O
lamotrigine	O	O
,	O	O
especially	O	O
in	O	O
combination	O	O
with	O	O
valproic	O	O
acid	O	O
,	O	O
may	O	O
lead	O	O
to	O	O
the	O	O
development	O	O
of	O	O
ten	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
administration	O	O
of	O	O
lamotrigine	O	O
,	O	O
especially	O	O
in	O	O
combination	O	O
with	O	O
valproic	O	O
acid	O	O
,	O	O
may	O	O
lead	O	O
to	O	O
the	O	O
development	O	O
of	O	O
ten	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
fatal	I-ADR	I-ADR
toxic	I-ADR	I-ADR
epidermal	I-ADR	I-ADR
necrolysis	I-ADR	I-ADR
related	O	O
to	O	O
lamotrigine	O	O
administration	O	O
.	O	O
EOS	O	O
BOS	O	O
it	O	O
was	O	O
hypothesized	O	O
that	O	O
valproic	O	O
acid	O	O
may	O	O
interfere	O	O
with	O	O
glucuronidation	O	O
of	O	O
lamotrigine	O	O
,	O	O
leading	O	O
to	O	O
increased	I-ADR	I-ADR
serum	I-ADR	I-ADR
lamotrigine	I-ADR	O
levels	I-ADR	I-ADR
,	O	O
or	O	O
perhaps	O	O
alter	O	O
the	O	O
drug's	O	I-ADR
metabolism	O	I-ADR
,	O	O
resulting	O	O
in	O	O
accumulation	I-ADR	I-ADR
of	I-ADR	O
a	I-ADR	O
toxic	I-ADR	I-ADR
intermediate	I-ADR	I-ADR
metabolite	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
it	O	O
was	O	O
hypothesized	O	O
that	O	O
valproic	O	O
acid	O	O
may	O	O
interfere	O	O
with	O	O
glucuronidation	O	O
of	O	O
lamotrigine	O	O
,	O	O
leading	O	O
to	O	O
increased	I-ADR	I-ADR
serum	I-ADR	I-ADR
lamotrigine	I-ADR	O
levels	I-ADR	I-ADR
,	O	O
or	O	O
perhaps	O	O
alter	O	O
the	O	O
drug's	O	I-ADR
metabolism	O	I-ADR
,	O	O
resulting	O	O
in	O	O
accumulation	I-ADR	I-ADR
of	I-ADR	O
a	I-ADR	O
toxic	I-ADR	I-ADR
intermediate	I-ADR	I-ADR
metabolite	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
to	O	O
date	O	O
,	O	O
eight	O	O
cases	O	O
of	O	O
ten	I-ADR	O
and	O	O
one	O	O
of	O	O
sjs	I-ADR	I-ADR
related	O	O
to	O	O
lamotrigine	O	O
administration	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
syndrome	I-ADR	I-ADR
of	I-ADR	O
increased	I-ADR	I-ADR
affect	I-ADR	I-ADR
in	O	O
response	O	O
to	O	O
risperidone	O	O
among	O	O
patients	O	O
with	O	O
schizophrenia	O	O
.	O	O
EOS	O	O
BOS	O	O
six	O	O
of	O	O
13	O	O
outpatients	O	O
with	O	O
schizophrenia	O	O
who	O	O
participated	O	O
in	O	O
a	O	O
ten-week	O	O
open	O	O
trial	O	O
of	O	O
risperidone	O	O
had	O	O
an	O	O
initial	O	O
good	O	O
response	O	O
to	O	O
the	O	O
medication	O	O
followed	O	O
by	O	O
development	O	O
of	O	O
intolerable	I-ADR	I-ADR
affect	I-ADR	O
,	O	O
including	O	O
feelings	I-ADR	I-ADR
of	I-ADR	O
agitation	I-ADR	I-ADR
and	O	O
depression	I-ADR	I-ADR
and	O	O
periods	I-ADR	O
of	I-ADR	O
crying	I-ADR	I-ADR
and	O	O
insomnia	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
the	O	O
authors	O	O
suggest	O	O
that	O	O
risperidone	O	O
may	O	O
increase	I-ADR	O
affect	I-ADR	O
in	O	O
patients	O	O
with	O	O
schizophrenia	O	O
and	O	O
that	O	O
some	O	O
patients	O	O
,	O	O
especially	O	O
those	O	O
with	O	O
anxiety	O	O
,	O	O
may	O	O
have	O	O
difficulty	O	O
managing	O	O
the	O	O
increase	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
methanol	O	O
toxicity	O	I-ADR
can	O	O
cause	O	O
severe	I-ADR	I-ADR
central	I-ADR	I-ADR
nervous	I-ADR	I-ADR
system	I-ADR	O
insult	I-ADR	O
in	O	O
which	O	O
a	O	O
characteristic	O	O
pattern	O	O
of	O	O
bilateral	I-ADR	O
putaminal	I-ADR	O
injury	I-ADR	O
is	O	O
noted	O	O
on	O	O
brain	O	O
imaging	O	O
studies	O	O
.	O	O
EOS	O	O
BOS	O	O
putaminal	I-ADR	I-ADR
infarct	I-ADR	I-ADR
in	O	O
methanol	O	O
intoxication	O	O
:	O	O
case	O	O
report	O	O
and	O	O
role	O	O
of	O	O
brain	O	O
imaging	O	O
studies	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
present	O	O
a	O	O
fatal	I-ADR	O
case	O	O
of	O	O
subacute	O	I-ADR
methanol	O	I-ADR
toxicity	O	I-ADR
with	O	O
associated	O	O
diffuse	I-ADR	O
brain	I-ADR	I-ADR
involvement	I-ADR	O
,	O	O
including	O	O
bilateral	I-ADR	I-ADR
putaminal	I-ADR	I-ADR
necrosis	I-ADR	I-ADR
and	O	O
cerebral	I-ADR	I-ADR
edema	I-ADR	I-ADR
with	O	O
ventricular	I-ADR	I-ADR
compression	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
a	O	O
28	O	O
year	O	O
old	O	O
white	O	O
schizophrenic	O	O
male	O	O
has	O	O
been	O	O
under	O	O
risperidone	O	O
monotherapy	O	O
for	O	O
about	O	O
one	O	O
year	O	O
when	O	O
he	O	O
developed	O	O
dyskinetic	I-ADR	I-ADR
movements	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
risperidone-induced	O	O
tardive	I-ADR	I-ADR
dyskinesia	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
this	O	O
report	O	O
presents	O	O
a	O	O
potential	O	O
case	O	O
of	O	O
risperidone-induced	O	O
tardive	I-ADR	I-ADR
dyskinesia	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
increased	I-ADR	I-ADR
ocular	I-ADR	I-ADR
pressure	I-ADR	I-ADR
in	O	O
two	O	O
patients	O	O
with	O	O
narrow	O	O
angle	O	O
glaucoma	O	O
treated	O	O
with	O	O
venlafaxine	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
61	O	O
-	O	O
year-old	O	O
man	O	O
developed	O	O
clinical	I-ADR	O
lupus	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
with	O	O
positive	O	O
antinuclear	O	I-ADR
antibody	O	O
,	O	O
positive	O	O
lupus	I-ADR	I-ADR
erythematosus	I-ADR	I-ADR
(	O	O
le	O	I-ADR
)	O	O
cell	O	O
preparation	O	O
,	O	O
and	O	O
diffuse	I-ADR	I-ADR
proliferative	I-ADR	I-ADR
glomerulonephritis	I-ADR	I-ADR
following	O	O
26	O	O
months	O	O
of	O	O
procainamide	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
glomerulonephritis	I-ADR	I-ADR
in	O	O
procainamide	O	O
induced	O	O
lupus	I-ADR	I-ADR
erythematosus	I-ADR	I-ADR
:	O	O
report	O	O
of	O	O
a	O	O
case	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
a	O	O
76	O	O
-	O	O
year-old	O	O
man	O	O
who	O	O
developed	O	O
an	O	O
acute	I-ADR	I-ADR
blistering	I-ADR	I-ADR
eruption	I-ADR	I-ADR
following	O	O
high-dose	O	O
penicillin	O	O
treatment	O	O
for	O	O
pneumococcal	O	O
septicaemia	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
case	O	O
of	O	O
prolonged	O	I-ADR
suxamethonium	O	O
apnoea	I-ADR	I-ADR
successfully	O	O
terminated	O	O
by	O	O
the	O	O
infusion	O	O
of	O	O
a	O	O
commercial	O	O
preparation	O	O
of	O	O
serumcholinesterase	O	O
is	O	O
reported	O	O
.	O	O
EOS	O	O
BOS	O	O
suxamethonium	O	O
apnoea	I-ADR	I-ADR
terminated	O	O
with	O	O
commercial	O	O
serumcholinesterase	O	O
.	O	O
EOS	O	O
BOS	O	O
cardiac	I-ADR	I-ADR
arrest	I-ADR	I-ADR
associated	O	O
with	O	O
sulprostone	O	O
use	O	O
during	O	O
caesarean	O	O
section	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
postulate	O	O
that	O	O
the	O	O
bolus	O	O
of	O	O
sulprostone	O	O
resulted	O	O
in	O	O
possible	O	O
coronary	I-ADR	I-ADR
spasm	I-ADR	I-ADR
that	O	O
resulted	O	O
in	O	O
cardiac	I-ADR	I-ADR
arrest	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
in	O	O
case	O	O
1	O	O
,	O	O
a	O	O
total	O	O
daily	O	O
dose	O	O
of	O	O
25	O	O
mg	O	O
sertraline	O	O
,	O	O
with	O	O
nondetectable	O	O
sertraline	O	O
and	O	O
desmethylsertraline	O	O
blood	O	I-ADR
levels	O	I-ADR
,	O	O
resulted	O	O
in	O	O
a	O	O
doubling	I-ADR	O
of	I-ADR	O
the	I-ADR	O
lamotrigine	I-ADR	O
blood	I-ADR	I-ADR
level	I-ADR	I-ADR
with	O	O
symptoms	I-ADR	O
of	I-ADR	O
toxicity	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
in	O	O
case	O	O
1	O	O
,	O	O
a	O	O
total	O	O
daily	O	O
dose	O	O
of	O	O
25	O	O
mg	O	O
sertraline	O	O
,	O	O
with	O	O
nondetectable	O	O
sertraline	O	O
and	O	O
desmethylsertraline	O	O
blood	O	I-ADR
levels	O	I-ADR
,	O	O
resulted	O	O
in	O	O
a	O	O
doubling	I-ADR	O
of	I-ADR	O
the	I-ADR	O
lamotrigine	I-ADR	O
blood	I-ADR	I-ADR
level	I-ADR	I-ADR
with	O	O
symptoms	I-ADR	O
of	I-ADR	O
toxicity	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
lamotrigine	I-ADR	O
toxicity	I-ADR	I-ADR
secondary	O	O
to	O	O
sertraline	O	O
.	O	O
EOS	O	O
BOS	O	O
flutamide	I-ADR	O
withdrawal	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
is	O	O
characterized	O	O
by	O	O
a	O	O
decrease	I-ADR	I-ADR
in	I-ADR	O
prostate-specific	I-ADR	I-ADR
antigen	I-ADR	I-ADR
(	O	O
psa	O	I-ADR
)	O	O
after	O	O
flutamide	O	O
withdrawal	O	O
in	O	O
a	O	O
subset	O	O
of	O	O
patients	O	O
with	O	O
progressing	O	O
metastatic	O	O
carcinoma	O	O
of	O	O
the	O	O
prostate	O	O
.	O	O
EOS	O	O
BOS	O	O
flutamide	I-ADR	O
withdrawal	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
is	O	O
characterized	O	O
by	O	O
a	O	O
decrease	I-ADR	I-ADR
in	I-ADR	O
prostate-specific	I-ADR	I-ADR
antigen	I-ADR	I-ADR
(	O	O
psa	O	I-ADR
)	O	O
after	O	O
flutamide	O	O
withdrawal	O	O
in	O	O
a	O	O
subset	O	O
of	O	O
patients	O	O
with	O	O
progressing	O	O
metastatic	O	O
carcinoma	O	O
of	O	O
the	O	O
prostate	O	O
.	O	O
EOS	O	O
BOS	O	O
prolonged	I-ADR	O
prostate-specific	I-ADR	O
antigen	I-ADR	O
response	I-ADR	O
in	O	O
flutamide	O	O
withdrawal	O	O
syndrome	O	O
despite	O	O
disease	O	O
progression	O	O
.	O	O
EOS	O	O
BOS	O	O
this	O	O
case	O	O
illustrates	O	O
the	O	O
potential	O	O
decoupling	I-ADR	O
of	I-ADR	O
psa	I-ADR	I-ADR
response	I-ADR	O
from	O	O
disease	O	O
status	O	O
in	O	O
flutamide	O	O
withdrawal	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
androgen-independent	O	O
prostate	O	O
cancer	O	O
in	O	O
whom	O	O
psa	I-ADR	O
continued	I-ADR	O
to	I-ADR	O
decrease	I-ADR	I-ADR
for	O	O
a	O	O
period	O	O
of	O	O
15	O	O
months	O	O
after	O	O
flutamide	O	O
withdrawal	O	O
.	O	O
EOS	O	O
BOS	O	O
anaphylactic	I-ADR	I-ADR
reaction	I-ADR	I-ADR
to	O	O
oral	O	O
prednisone	O	O
:	O	O
a	O	O
case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
nonatopic	O	O
17	O	O
-	O	O
year-old	O	O
girl	O	O
with	O	O
bronchial	O	O
asthma	O	O
and	O	O
aspirin	O	O
intolerance	O	O
who	O	O
developed	O	O
a	O	O
dramatic	O	I-ADR
anaphylactic	I-ADR	I-ADR
reaction	I-ADR	I-ADR
to	O	O
oral	O	O
prednisone	O	O
.	O	O
EOS	O	O
BOS	O	O
animals	O	O
treated	O	O
with	O	O
hal	O	O
showed	O	O
a	O	O
highly	O	O
significant	I-ADR	O
32	I-ADR	O
%	I-ADR	O
-	I-ADR	O
46	I-ADR	O
%	I-ADR	O
loss	I-ADR	I-ADR
of	I-ADR	O
tyrosine	I-ADR	I-ADR
hydroxylase	I-ADR	I-ADR
(	I-ADR	O
th	I-ADR	O
)	I-ADR	O
immunoreactive	I-ADR	O
neurons	I-ADR	I-ADR
in	O	O
the	O	O
substantia	O	O
nigra	O	O
,	O	O
and	O	O
20	O	O
%	O	O
contraction	O	I-ADR
of	O	O
the	O	O
th	O	O
stained	O	O
dendritic	O	O
arbour	O	O
.	O	O
EOS	O	O
BOS	O	O
methods	O	O
:	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
titrated	O	O
oral	O	O
challenges	O	O
with	O	O
pancreatic	O	I-ADR
enzymes	O	I-ADR
resulted	O	O
in	O	O
definite	O	O
vomiting	I-ADR	I-ADR
within	O	O
1	O	O
to	O	O
1.5	O	O
hours	O	O
after	O	O
challenges	O	O
with	O	O
viokase	O	O
and	O	O
pancrease	O	O
mt	O	O
16	O	O
,	O	O
but	O	O
not	O	O
with	O	O
placebo	O	O
.	O	O
EOS	O	O
BOS	O	O
methods	O	O
:	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
titrated	O	O
oral	O	O
challenges	O	O
with	O	O
pancreatic	O	I-ADR
enzymes	O	I-ADR
resulted	O	O
in	O	O
definite	O	O
vomiting	I-ADR	I-ADR
within	O	O
1	O	O
to	O	O
1.5	O	O
hours	O	O
after	O	O
challenges	O	O
with	O	O
viokase	O	O
and	O	O
pancrease	O	O
mt	O	O
16	O	O
,	O	O
but	O	O
not	O	O
with	O	O
placebo	O	O
.	O	O
EOS	O	O
BOS	O	O
she	O	O
was	O	O
treated	O	O
with	O	O
pancrease	O	O
mt	O	O
16	O	O
,	O	O
but	O	O
had	O	O
consistent	O	O
vomiting	I-ADR	I-ADR
1	O	O
to	O	O
2	O	O
hours	O	O
after	O	O
administration	O	O
of	O	O
enzymes	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
vomiting	I-ADR	I-ADR
occurred	O	O
on	O	O
switching	O	O
to	O	O
different	O	O
pancreatic	O	O
enzymes	O	O
preparations	O	O
,	O	O
ie	O	O
,	O	O
creon	O	O
10	O	O
,	O	O
viokase	O	O
,	O	O
and	O	O
pancrease	O	O
mt	O	O
16	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
vomiting	I-ADR	I-ADR
occurred	O	O
on	O	O
switching	O	O
to	O	O
different	O	O
pancreatic	O	O
enzymes	O	O
preparations	O	O
,	O	O
ie	O	O
,	O	O
creon	O	O
10	O	O
,	O	O
viokase	O	O
,	O	O
and	O	O
pancrease	O	O
mt	O	O
16	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
vomiting	I-ADR	I-ADR
occurred	O	O
on	O	O
switching	O	O
to	O	O
different	O	O
pancreatic	O	O
enzymes	O	O
preparations	O	O
,	O	O
ie	O	O
,	O	O
creon	O	O
10	O	O
,	O	O
viokase	O	O
,	O	O
and	O	O
pancrease	O	O
mt	O	O
16	O	O
.	O	O
EOS	O	O
BOS	O	O
acute	O	O
valproate	O	O
ingestion	O	O
induces	O	O
symptomatic	I-ADR	I-ADR
methemoglobinemia	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
for	O	O
the	O	O
first	O	O
time	O	O
the	O	O
development	O	O
of	O	O
symptomatic	I-ADR	I-ADR
methemoglobinemia	I-ADR	I-ADR
after	O	O
an	O	O
acute	O	O
ingestion	O	O
of	O	O
divalproex	O	O
sodium	O	O
(	O	O
depakote	O	O
)	O	O
,	O	O
resulting	O	O
in	O	O
serum	O	O
concentrations	O	O
10	O	O
times	O	O
greater	O	O
than	O	O
the	O	O
therapeutic	O	O
range	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
for	O	O
the	O	O
first	O	O
time	O	O
the	O	O
development	O	O
of	O	O
symptomatic	I-ADR	I-ADR
methemoglobinemia	I-ADR	I-ADR
after	O	O
an	O	O
acute	O	O
ingestion	O	O
of	O	O
divalproex	O	O
sodium	O	O
(	O	O
depakote	O	O
)	O	O
,	O	O
resulting	O	O
in	O	O
serum	O	O
concentrations	O	O
10	O	O
times	O	O
greater	O	O
than	O	O
the	O	O
therapeutic	O	O
range	O	O
.	O	O
EOS	O	O
BOS	O	O
in	O	O
rare	O	O
cases	O	O
mitomycin	O	O
c	O	O
(	O	O
mmc	O	O
)	O	O
may	O	O
induce	O	O
cancer-associated	O	O
hemolytic	I-ADR	I-ADR
uremic	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
hemolytic	I-ADR	I-ADR
anemia	I-ADR	I-ADR
,	O	O
thrombocytopenia	I-ADR	I-ADR
and	O	O
progressive	I-ADR	I-ADR
renal	I-ADR	I-ADR
failure	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
in	O	O
rare	O	O
cases	O	O
mitomycin	O	O
c	O	O
(	O	O
mmc	O	O
)	O	O
may	O	O
induce	O	O
cancer-associated	O	O
hemolytic	I-ADR	I-ADR
uremic	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
hemolytic	I-ADR	I-ADR
anemia	I-ADR	I-ADR
,	O	O
thrombocytopenia	I-ADR	I-ADR
and	O	O
progressive	I-ADR	I-ADR
renal	I-ADR	I-ADR
failure	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
mitomycin	O	O
c-related	O	O
hemolytic	I-ADR	I-ADR
uremic	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
in	O	O
cancer	O	O
patients	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
mmc-related	O	O
hemolytic	I-ADR	I-ADR
uremic	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
,	O	O
and	O	O
discuss	O	O
the	O	O
etiologic	O	O
parameters	O	O
,	O	O
clinical	O	O
aspects	O	O
,	O	O
prognosis	O	O
and	O	O
treatment	O	O
modalities	O	O
of	O	O
this	O	O
severe	O	O
syndrome	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
cd4	I-ADR	I-ADR
t-lymphocyte	I-ADR	I-ADR
depletion	I-ADR	I-ADR
,	O	O
myelosuppression	I-ADR	I-ADR
,	O	O
and	O	O
subsequent	O	O
severe	I-ADR	I-ADR
infections	I-ADR	I-ADR
are	O	O
the	O	O
major	O	O
side	O	O
effects	O	O
of	O	O
fludarabine	O	O
phosphate	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
severe	I-ADR	I-ADR
respiratory	I-ADR	I-ADR
syncytial	I-ADR	I-ADR
virus	I-ADR	I-ADR
pulmonary	I-ADR	I-ADR
infection	I-ADR	I-ADR
in	O	O
a	O	O
patient	O	O
treated	O	O
with	O	O
fludarabine	O	O
for	O	O
chronic	O	O
lymphocytic	O	O
leukemia	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
here	O	O
on	O	O
a	O	O
heretofore	O	O
undescribed	O	O
respiratory	I-ADR	I-ADR
syncytial	I-ADR	I-ADR
virus	I-ADR	I-ADR
(	I-ADR	O
rsv	I-ADR	I-ADR
)	I-ADR	O
infection	I-ADR	I-ADR
in	O	O
a	O	O
patient	O	O
with	O	O
a	O	O
long-standing	O	O
history	O	O
of	O	O
refractory	O	O
cll	O	O
that	O	O
was	O	O
treated	O	O
with	O	O
fludarabine	O	O
phosphate	O	O
.	O	O
EOS	O	O
BOS	O	O
serotonin	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
induced	O	O
by	O	O
transitioning	O	O
from	O	O
phenelzine	O	O
to	O	O
venlafaxine	O	O
:	O	O
four	O	O
patient	O	O
reports	O	O
.	O	O
EOS	O	O
BOS	O	O
serotonin	I-ADR	I-ADR
syndrome	I-ADR	I-ADR
induced	O	O
by	O	O
transitioning	O	O
from	O	O
phenelzine	O	O
to	O	O
venlafaxine	O	O
:	O	O
four	O	O
patient	O	O
reports	O	O
.	O	O
EOS	O	O
BOS	O	O
although	O	O
this	O	O
g-csf-driven	O	O
leucocytosis	I-ADR	I-ADR
was	O	O
alarming	O	O
it	O	O
did	O	O
not	O	O
appear	O	O
to	O	O
have	O	O
adversely	O	O
affected	O	O
the	O	O
patient's	O	O
prognosis	O	O
.	O	O
EOS	O	O
BOS	O	O
leukaemoid	I-ADR	I-ADR
monocytosis	I-ADR	I-ADR
in	O	O
m4	O	O
aml	O	O
following	O	O
chemotherapy	O	O
and	O	O
g-csf	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
m4	O	O
aml	O	O
treated	O	O
with	O	O
standard	O	O
chemotherapy	O	O
followed	O	O
by	O	O
g-csf	O	O
who	O	O
developed	O	O
marked	O	I-ADR
monocytosis	I-ADR	I-ADR
on	O	O
day	O	O
8	O	O
of	O	O
g-csf	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
case	O	O
2	O	O
demonstrated	O	O
after	O	O
40	O	O
months	O	O
on	O	O
chlorambucil	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
balanced	I-ADR	O
translocation	I-ADR	O
,	O	O
t	O	O
(	O	O
1	O	O
;	O	O
5	O	O
)	O	O
(	O	O
p36	O	O
;	O	O
q31	O	O
)	O	O
in	O	O
90	O	O
%	O	O
of	O	O
the	O	O
cells	O	O
.	O	O
EOS	O	O
BOS	O	O
chromosome	I-ADR	I-ADR
abnormalities	I-ADR	I-ADR
after	O	O
chlorambucil	O	O
therapy	O	O
of	O	O
polycythaemia	O	O
vera	O	O
.	O	O
EOS	O	O
BOS	O	O
administration	O	O
of	O	O
steroid	O	O
and	O	O
decreasing	O	O
the	O	O
dose	O	O
of	O	O
ptu	O	O
produced	O	O
a	O	O
good	O	O
clinical	O	O
response	O	O
and	O	O
the	O	O
anca	I-ADR	I-ADR
disappeared	O	O
.	O	O
EOS	O	O
BOS	O	O
antineutrophil	I-ADR	I-ADR
cytoplasmic	I-ADR	I-ADR
antibody-positive	I-ADR	I-ADR
crescentic	I-ADR	I-ADR
glomerulonephritis	I-ADR	I-ADR
associated	O	O
with	O	O
propylthiouracil	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
teenage	O	O
girl	O	O
with	O	O
crescentic	O	I-ADR
glomerulonephritis	O	I-ADR
had	O	O
antineutrophil	I-ADR	I-ADR
cytoplasmic	I-ADR	I-ADR
antibody	I-ADR	I-ADR
(	O	O
anca	O	I-ADR
)	O	O
detected	O	O
after	O	O
she	O	O
had	O	O
received	O	O
propylthiouracil	O	O
(	O	O
ptu	O	O
)	O	O
for	O	O
hyperthyroidism	O	O
without	O	O
cutaneous	O	O
vasculitis	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
teenage	O	O
girl	O	O
with	O	O
crescentic	O	I-ADR
glomerulonephritis	O	I-ADR
had	O	O
antineutrophil	I-ADR	I-ADR
cytoplasmic	I-ADR	I-ADR
antibody	I-ADR	I-ADR
(	O	O
anca	O	I-ADR
)	O	O
detected	O	O
after	O	O
she	O	O
had	O	O
received	O	O
propylthiouracil	O	O
(	O	O
ptu	O	O
)	O	O
for	O	O
hyperthyroidism	O	O
without	O	O
cutaneous	O	O
vasculitis	O	O
.	O	O
EOS	O	O
BOS	O	O
it	O	O
was	O	O
concluded	O	O
that	O	O
anca	I-ADR	I-ADR
is	O	O
closely	O	O
related	O	O
to	O	O
the	O	O
pathogenesis	O	O
of	O	O
crescentic	O	I-ADR
glomerulonephritis	O	I-ADR
and	O	O
that	O	O
treatment	O	O
with	O	O
ptu	O	O
appeared	O	O
to	O	O
induce	O	O
anca	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
a	O	O
drug	I-ADR	O
interaction	I-ADR	O
between	O	O
zafirlukast	O	O
and	O	O
theophylline	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
drug	I-ADR	O
interaction	I-ADR	O
between	O	O
zafirlukast	O	O
and	O	O
theophylline	O	O
.	O	O
EOS	O	O
BOS	O	O
attempts	O	O
were	O	O
made	O	O
to	O	O
stop	O	O
and	O	O
then	O	O
restart	O	O
the	O	O
theophylline	O	O
therapy	O	O
at	O	O
progressively	O	O
lower	O	O
doses	O	O
;	O	O
however	O	O
,	O	O
with	O	O
each	O	O
attempt	O	O
,	O	O
the	O	O
patient's	O	O
reaction	I-ADR	O
to	I-ADR	O
the	I-ADR	O
drug	I-ADR	O
became	I-ADR	O
more	I-ADR	O
toxic	I-ADR	I-ADR
,	O	O
with	O	O
serum	O	I-ADR
theophylline	O	O
levels	O	I-ADR
ranging	O	O
between	O	O
99.9	O	O
and	O	O
149.9	O	O
micromol	O	O
/	O	O
l	O	O
(	O	O
18	O	O
and	O	O
27	O	O
microg	O	O
/	O	O
ml	O	O
)	O	O
.	O	O
EOS	O	O
BOS	O	O
one	O	O
explanation	O	O
for	O	O
the	O	O
noted	O	O
increase	I-ADR	I-ADR
in	I-ADR	O
the	I-ADR	O
theophylline	I-ADR	O
level	I-ADR	I-ADR
is	O	O
that	O	O
metabolism	O	O
occurs	O	O
mainly	O	O
by	O	O
cytochrome	O	O
p450	O	O
(	O	O
cyp	O	O
1a2	O	O
)	O	O
,	O	O
an	O	O
enzyme	O	O
that	O	O
is	O	O
known	O	O
to	O	O
be	O	O
inhibited	O	O
with	O	O
high	O	O
concentrations	O	O
of	O	O
zafirlukast	O	O
.	O	O
EOS	O	O
BOS	O	O
one	O	O
explanation	O	O
for	O	O
the	O	O
noted	O	O
increase	I-ADR	I-ADR
in	I-ADR	O
the	I-ADR	O
theophylline	I-ADR	O
level	I-ADR	I-ADR
is	O	O
that	O	O
metabolism	O	O
occurs	O	O
mainly	O	O
by	O	O
cytochrome	O	O
p450	O	O
(	O	O
cyp	O	O
1a2	O	O
)	O	O
,	O	O
an	O	O
enzyme	O	O
that	O	O
is	O	O
known	O	O
to	O	O
be	O	O
inhibited	O	O
with	O	O
high	O	O
concentrations	O	O
of	O	O
zafirlukast	O	O
.	O	O
EOS	O	O
BOS	O	O
recently	O	O
,	O	O
her	O	O
serum	O	O
theophylline	I-ADR	O
levels	I-ADR	I-ADR
had	I-ADR	O
increased	I-ADR	I-ADR
to	I-ADR	O
the	I-ADR	O
toxic	I-ADR	I-ADR
range	I-ADR	O
(	O	O
133.2	O	O
micromol	O	O
/	O	O
l	O	O
[	O	O
24	O	O
microg	O	O
/	O	O
ml	O	O
]	O	O
)	O	O
shortly	O	O
after	O	O
the	O	O
addition	O	O
of	O	O
zafirlukast	O	O
(	O	O
accolate	O	O
,	O	O
zeneca	O	O
pharmaceuticals	O	O
,	O	O
wilmington	O	O
,	O	O
del	O	O
)	O	O
to	O	O
her	O	O
regimen	O	O
.	O	O
EOS	O	O
BOS	O	O
recently	O	O
,	O	O
her	O	O
serum	O	O
theophylline	I-ADR	O
levels	I-ADR	I-ADR
had	I-ADR	O
increased	I-ADR	I-ADR
to	I-ADR	O
the	I-ADR	O
toxic	I-ADR	I-ADR
range	I-ADR	O
(	O	O
133.2	O	O
micromol	O	O
/	O	O
l	O	O
[	O	O
24	O	O
microg	O	O
/	O	O
ml	O	O
]	O	O
)	O	O
shortly	O	O
after	O	O
the	O	O
addition	O	O
of	O	O
zafirlukast	O	O
(	O	O
accolate	O	O
,	O	O
zeneca	O	O
pharmaceuticals	O	O
,	O	O
wilmington	O	O
,	O	O
del	O	O
)	O	O
to	O	O
her	O	O
regimen	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
noted	O	O
increase	I-ADR	I-ADR
in	I-ADR	O
the	I-ADR	O
theophylline	I-ADR	O
level	I-ADR	I-ADR
after	O	O
zafirlukast	O	O
administration	O	O
is	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
original	O	O
reports	O	O
by	O	O
the	O	O
manufacturer	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
noted	O	O
increase	I-ADR	I-ADR
in	I-ADR	O
the	I-ADR	O
theophylline	I-ADR	O
level	I-ADR	I-ADR
after	O	O
zafirlukast	O	O
administration	O	O
is	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
original	O	O
reports	O	O
by	O	O
the	O	O
manufacturer	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
present	O	O
the	O	O
first	O	O
case	O	O
(	O	O
to	O	O
our	O	O
knowledge	O	O
)	O	O
of	O	O
a	O	O
potentially	O	O
serious	O	O
drug-drug	I-ADR	O
interaction	I-ADR	O
between	O	O
zafirlukast	O	O
and	O	O
theophylline	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
present	O	O
the	O	O
first	O	O
case	O	O
(	O	O
to	O	O
our	O	O
knowledge	O	O
)	O	O
of	O	O
a	O	O
potentially	O	O
serious	O	O
drug-drug	I-ADR	O
interaction	I-ADR	O
between	O	O
zafirlukast	O	O
and	O	O
theophylline	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
21	O	O
-	O	O
year-old	O	O
patient	O	O
developed	O	O
rhabdomyolysis	I-ADR	I-ADR
during	O	O
his	O	O
nineteenth	O	O
week	O	O
of	O	O
treatment	O	O
with	O	O
clozapine	O	O
for	O	O
drug-resistant	O	O
schizophrenia	O	O
.	O	O
EOS	O	O
BOS	O	O
clozapine	O	O
is	O	O
speculated	O	O
to	O	O
cause	O	O
rhabdomyolysis	I-ADR	I-ADR
in	O	O
patients	O	O
with	O	O
defective	O	O
calcium-activated	O	O
k	O	O
+	O	O
channels	O	O
.	O	O
EOS	O	O
BOS	O	O
rhabdomyolysis	I-ADR	I-ADR
associated	O	O
with	O	O
clozapine	O	O
treatment	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
decreased	O	O
calcium-dependent	O	O
potassium	O	O
permeability	O	O
of	O	O
cell	O	O
membranes	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
children	O	O
and	O	O
adolescents	O	O
with	O	O
chronic	O	O
hematologic	O	O
and	O	O
oncologic	O	O
diseases	O	O
who	O	O
exhibited	O	O
drug-seeking	I-ADR	I-ADR
behavior	I-ADR	I-ADR
or	O	O
anticholinergic	I-ADR	I-ADR
symptoms	I-ADR	I-ADR
with	O	O
the	O	O
use	O	O
of	O	O
diphenhydramine	O	O
.	O	O
EOS	O	O
BOS	O	O
excluding	O	O
other	O	O
causes	O	O
,	O	O
pentasa-associated	O	O
pancytopenia	I-ADR	I-ADR
was	O	O
considered	O	O
.	O	O
EOS	O	O
BOS	O	O
he	O	O
developed	O	O
fever	I-ADR	I-ADR
,	O	O
nausea	I-ADR	I-ADR
,	O	O
diarrhea	I-ADR	I-ADR
,	O	O
and	O	O
malaise	I-ADR	I-ADR
and	O	O
stopped	O	O
taking	O	O
on	O	O
the	O	O
third	O	O
day	O	O
after	O	O
commencing	O	O
pentasa	O	O
.	O	O
EOS	O	O
BOS	O	O
pancytopenia	I-ADR	I-ADR
associated	O	O
with	O	O
5	O	O
-	O	O
aminosalicylic	O	O
acid	O	O
use	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
crohn's	O	O
disease	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
pancytopenia	I-ADR	I-ADR
in	O	O
a	O	O
23	O	O
-	O	O
year-old	O	O
man	O	O
with	O	O
crohn's	O	O
disease	O	O
who	O	O
was	O	O
treated	O	O
with	O	O
5	O	O
-	O	O
aminosalicylic	O	O
acid	O	O
(	O	O
pentasa	O	O
;	O	O
nisshin	O	O
,	O	O
tokyo	O	O
,	O	O
japan	O	O
)	O	O
3.0	O	O
g	O	O
/	O	O
day	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
pancytopenia	I-ADR	I-ADR
in	O	O
a	O	O
23	O	O
-	O	O
year-old	O	O
man	O	O
with	O	O
crohn's	O	O
disease	O	O
who	O	O
was	O	O
treated	O	O
with	O	O
5	O	O
-	O	O
aminosalicylic	O	O
acid	O	O
(	O	O
pentasa	O	O
;	O	O
nisshin	O	O
,	O	O
tokyo	O	O
,	O	O
japan	O	O
)	O	O
3.0	O	O
g	O	O
/	O	O
day	O	O
.	O	O
EOS	O	O
BOS	O	O
1	O	O
.	O	O
changes	I-ADR	O
in	I-ADR	O
the	I-ADR	O
plasma	I-ADR	O
cortisol	I-ADR	O
level	I-ADR	I-ADR
were	O	O
reported	O	O
in	O	O
a	O	O
male	O	O
patient	O	O
with	O	O
panic	O	I-ADR
disorder	O	O
during	O	O
the	O	O
period	O	O
of	O	O
low-dose	O	O
alprazolam	O	O
treatment	O	O
(	O	O
mean	O	O
0.62	O	O
+	O	O
/	O	O
-	O	O
0.15	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
compared	O	O
with	O	O
during	O	O
the	O	O
period	O	O
of	O	O
high-dose	O	O
period	O	O
(	O	O
mean	O	O
1.08	O	O
+	O	O
/	O	O
-	O	O
0.28	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
.	O	O
EOS	O	O
BOS	O	O
3	O	O
.	O	O
thus	O	O
,	O	O
the	O	O
decreased	I-ADR	O
plasma	I-ADR	I-ADR
cortisol	I-ADR	I-ADR
level	I-ADR	O
during	O	O
alprazolam	O	O
treatment	O	O
of	O	O
panic	O	O
disorder	O	O
was	O	O
suggested	O	O
to	O	O
be	O	O
caused	O	O
not	O	O
by	O	O
symptom	O	O
alleviation	O	O
due	O	O
to	O	O
alprazolam	O	O
but	O	O
by	O	O
alprazolam	O	O
administration	O	O
itself	O	O
.	O	O
EOS	O	O
BOS	O	O
decreased	I-ADR	I-ADR
plasma	I-ADR	I-ADR
cortisol	I-ADR	I-ADR
level	I-ADR	I-ADR
during	O	O
alprazolam	O	O
treatment	O	O
of	O	O
panic	O	O
disorder	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
a	O	O
renal	O	O
transplant	O	O
recipient	O	O
maintained	O	O
on	O	O
cyclosporine	O	O
and	O	O
prednisone	O	O
developing	O	O
nocardia	I-ADR	I-ADR
asteroides	I-ADR	I-ADR
brain	I-ADR	I-ADR
abscess	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
a	O	O
renal	O	O
transplant	O	O
recipient	O	O
maintained	O	O
on	O	O
cyclosporine	O	O
and	O	O
prednisone	O	O
developing	O	O
nocardia	I-ADR	I-ADR
asteroides	I-ADR	I-ADR
brain	I-ADR	I-ADR
abscess	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
young	O	O
children	O	O
undergoing	O	O
cisplatin	O	O
chemotherapy	O	O
are	O	O
known	O	O
to	O	O
be	O	O
at	O	O
risk	O	O
for	O	O
progressive	I-ADR	I-ADR
sensorineural	I-ADR	I-ADR
hearing	I-ADR	I-ADR
loss	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
a	O	O
47	O	O
year-old	O	O
woman	O	O
who	O	O
had	O	O
a	O	O
4	O	O
-	O	O
year	O	O
history	O	O
of	O	O
intramuscular	O	O
pentazocine	O	O
injections	O	O
in	O	O
the	O	O
lower	O	O
extremities	O	O
,	O	O
developed	O	O
gradual	I-ADR	I-ADR
stiffness	I-ADR	I-ADR
and	O	O
weakness	I-ADR	I-ADR
of	I-ADR	I-ADR
the	I-ADR	I-ADR
lower	I-ADR	I-ADR
extremities	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
caution	O	O
in	O	O
longterm	O	O
usage	O	O
and	O	O
early	O	O
recognition	O	O
of	O	O
pentazocine	O	O
toxicity	O	O
as	O	O
a	O	O
neuromuscular	I-ADR	O
complication	I-ADR	O
are	O	O
important	O	O
in	O	O
order	O	O
to	O	O
prevent	O	O
irreversible	O	O
drug-induced	O	O
fibrous	I-ADR	I-ADR
myopathy	I-ADR	I-ADR
and	O	O
localized	O	I-ADR
neuropathy	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
pentazocine-induced	O	O
fibrous	I-ADR	I-ADR
myopathy	I-ADR	I-ADR
and	O	O
localized	O	I-ADR
neuropathy	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
in	O	O
two	O	O
of	O	O
these	O	O
cases	O	O
akathisia	I-ADR	I-ADR
resolved	O	O
after	O	O
withdrawal	O	O
of	O	O
olanzapine	O	O
and	O	O
substitution	O	O
by	O	O
a	O	O
classical	O	O
or	O	O
an	O	O
atypical	O	O
neuroleptic	O	O
agent	O	O
,	O	O
respectively	O	O
.	O	O
EOS	O	O
BOS	O	O
like	O	O
other	O	O
atypical	O	O
neuroleptics	O	O
olanzapine	O	O
is	O	O
considered	O	O
to	O	O
show	O	O
a	O	O
reduced	O	O
prevalence	O	O
of	O	O
extrapyramidal	I-ADR	I-ADR
side	I-ADR	I-ADR
effects	I-ADR	I-ADR
when	O	O
compared	O	O
to	O	O
classical	O	O
neuroleptic	O	O
drugs	O	O
.	O	O
EOS	O	O
BOS	O	O
one	O	O
should	O	O
therefore	O	O
be	O	O
aware	O	O
of	O	O
possible	O	O
extrapyramidal	I-ADR	I-ADR
side	I-ADR	O
effects	I-ADR	I-ADR
with	O	O
olanzapine	O	O
that	O	O
are	O	O
reduced	O	O
compared	O	O
to	O	O
classical	O	O
neuroleptic	O	O
drugs	O	O
but	O	O
not	O	O
completely	O	O
eliminated	O	O
.	O	O
EOS	O	O
BOS	O	O
severe	I-ADR	I-ADR
akathisia	I-ADR	I-ADR
during	O	O
olanzapine	O	O
treatment	O	O
of	O	O
acute	O	O
schizophrenia	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
on	O	O
three	O	O
patients	O	O
with	O	O
acute	O	O
schizophrenia	O	O
,	O	O
who	O	O
developed	O	O
severe	I-ADR	I-ADR
akathisia	I-ADR	I-ADR
during	O	O
treatment	O	O
with	O	O
olanzapine	O	O
(	O	O
20-25	O	O
mg	O	O
/	O	O
d	O	O
)	O	O
.	O	O
EOS	O	O
BOS	O	O
seizures	I-ADR	I-ADR
occurred	O	O
in	O	O
two	O	O
patients	O	O
with	O	O
probable	O	O
alzheimer's	O	O
disease	O	O
who	O	O
were	O	O
receiving	O	O
long-term	O	O
treatment	O	O
with	O	O
metrifonate	O	O
,	O	O
an	O	O
irreversible	O	O
acetylcholinesterase	O	O
inhibitor	O	O
.	O	O
EOS	O	O
BOS	O	O
however	O	O
,	O	O
1	O	O
eye	O	O
had	O	O
vitreous	I-ADR	I-ADR
hemorrhage	I-ADR	I-ADR
after	O	O
repeated	O	O
injections	O	O
of	O	O
tpa	O	O
.	O	O
EOS	O	O
BOS	O	O
however	O	O
,	O	O
repeated	O	O
intracameral	O	O
tpa	O	O
injections	O	O
may	O	O
cause	O	O
unwanted	O	O
complications	O	O
such	O	O
as	O	O
vitreous	I-ADR	I-ADR
hemorrhage	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
although	O	O
praziquantel	O	O
administration	O	O
may	O	O
have	O	O
been	O	O
effective	O	O
in	O	O
killing	O	O
the	O	O
parasite	O	O
in	O	O
both	O	O
patients	O	O
,	O	O
we	O	O
are	O	O
concerned	O	O
about	O	O
the	O	O
production	O	O
of	O	O
marked	O	I-ADR
inflammation	I-ADR	I-ADR
as	O	O
a	O	O
result	O	O
of	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
nms	I-ADR	I-ADR
is	O	O
a	O	O
drug-related	O	O
response	O	O
to	O	O
various	O	O
medications	O	O
,	O	O
such	O	O
as	O	O
haloperidol	O	O
,	O	O
which	O	O
the	O	O
patient	O	O
was	O	O
receiving	O	O
.	O	O
EOS	O	O
BOS	O	O
methimazole-induced	O	O
aplastic	I-ADR	I-ADR
anemia	I-ADR	I-ADR
in	O	O
third	O	O
exposure	O	O
:	O	O
successful	O	O
treatment	O	O
with	O	O
recombinant	O	O
human	O	O
granulocyte	O	O
colony-stimulating	O	O
factor	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
present	O	O
a	O	O
case	O	O
of	O	O
a	O	O
58	O	O
-	O	O
year-old	O	O
female	O	O
patient	O	O
with	O	O
graves	O	O
'	O	O
disease	O	O
who	O	O
developed	O	O
aa	I-ADR	O
in	O	O
the	O	O
third	O	O
exposure	O	O
to	O	O
methimazole	O	O
(	O	O
mmi	O	O
)	O	O
.	O	O
EOS	O	O
BOS	O	O
fsgs	I-ADR	I-ADR
induced	O	O
by	O	O
adriamycin	O	O
(	O	O
pharmacia	O	O
&	O	O
upjohn	O	O
,	O	O
columbus	O	O
,	O	O
oh	O	O
)	O	O
has	O	O
been	O	O
observed	O	O
experimentally	O	O
in	O	O
rats	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
case	O	O
demonstrates	O	O
that	O	O
hypersensitivity	I-ADR	I-ADR
reaction	I-ADR	I-ADR
to	O	O
pranlukast	O	O
and	O	O
resultant	O	O
atin	I-ADR	O
is	O	O
possible	O	O
,	O	O
and	O	O
that	O	O
periodic	O	O
urine	O	O
testing	O	O
in	O	O
patients	O	O
receiving	O	O
pranlukast	O	O
should	O	O
be	O	O
considered	O	O
.	O	O
EOS	O	O
BOS	O	O
tubulointerstitial	I-ADR	I-ADR
nephritis	I-ADR	I-ADR
induced	O	O
by	O	O
the	O	O
leukotriene	O	O
receptor	O	O
antagonist	O	O
pranlukast	O	O
.	O	O
EOS	O	O
BOS	O	O
within	O	O
6	O	O
months	O	O
of	O	O
pranlukast	O	O
withdrawal	O	O
,	O	O
anemia	I-ADR	I-ADR
resolved	O	O
and	O	O
urinary	O	I-ADR
sediment	O	I-ADR
and	O	O
renal	O	I-ADR
function	O	I-ADR
normalized	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
65	O	O
-	O	O
year-old	O	O
woman	O	O
with	O	O
angina	O	O
pectoris	O	O
presented	O	O
with	O	O
syncope	I-ADR	I-ADR
after	O	O
sublingual	O	O
ingestion	O	O
of	O	O
isosorbide	O	O
dinitrate	O	O
(	O	O
5	O	O
mg	O	O
)	O	O
.	O	O
EOS	O	O
BOS	O	O
elderly	O	O
patients	O	O
for	O	O
whom	O	O
nitrate	O	O
has	O	O
been	O	O
prescribed	O	O
should	O	O
be	O	O
warned	O	O
of	O	O
the	O	O
occurrence	O	O
of	O	O
hypotension	I-ADR	I-ADR
,	O	O
leading	O	O
to	O	O
unconsciousness	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
in	O	O
a	O	O
postural	O	O
challenge	O	O
test	O	O
after	O	O
administration	O	O
of	O	O
isosorbide	O	O
dinitrate	O	O
(	O	O
5	O	O
mg	O	O
)	O	O
,	O	O
blood	I-ADR	O
pressure	I-ADR	O
decreased	I-ADR	O
from	O	O
120/67	O	O
to	O	O
65/35	O	O
mmhg	O	O
,	O	O
followed	O	O
by	O	O
syncope	I-ADR	I-ADR
with	O	O
a	O	O
sudden	I-ADR	I-ADR
decrease	I-ADR	I-ADR
in	I-ADR	O
pulse	I-ADR	I-ADR
rate	I-ADR	I-ADR
from	O	O
85	O	O
to	O	O
60	O	O
beats	O	O
/	O	O
min	O	O
.	O	O
EOS	O	O
BOS	O	O
syncope	I-ADR	I-ADR
in	O	O
a	O	O
65	O	O
-	O	O
year-old	O	O
woman	O	O
after	O	O
nitrate	O	O
ingestion	O	O
.	O	O
EOS	O	O
BOS	O	O
three	O	O
diabetic	O	O
cases	O	O
of	O	O
acute	I-ADR	I-ADR
dizziness	I-ADR	I-ADR
due	O	O
to	O	O
initial	O	O
administration	O	O
of	O	O
voglibose	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
observed	O	O
3	O	O
diabetic	O	O
patients	O	O
with	O	O
intolerable	I-ADR	O
dizziness	I-ADR	I-ADR
followed	O	O
by	O	O
nausea	I-ADR	I-ADR
and	O	O
vomiting	I-ADR	I-ADR
immediately	O	O
after	O	O
an	O	O
initial	O	O
administration	O	O
of	O	O
the	O	O
alpha-glucosidase	O	O
inhibitor	O	O
,	O	O
voglibose	O	O
.	O	O
EOS	O	O
BOS	O	O
naproxen-associated	O	O
sudden	I-ADR	I-ADR
sensorineural	I-ADR	I-ADR
hearing	I-ADR	I-ADR
loss	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
naproxen	O	O
is	O	O
a	O	O
commonly	O	O
used	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
drug	O	O
(	O	O
nsaid	O	O
)	O	O
whose	O	O
side	O	O
effects	O	O
include	O	O
tinnitus	I-ADR	I-ADR
and	O	O
transient	I-ADR	I-ADR
hearing	I-ADR	I-ADR
loss	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
this	O	O
article	O	O
reports	O	O
the	O	O
case	O	O
of	O	O
an	O	O
otherwise	O	O
healthy	O	O
patient	O	O
who	O	O
experienced	O	O
permanent	O	I-ADR
sensorineural	I-ADR	I-ADR
hearing	I-ADR	I-ADR
loss	I-ADR	I-ADR
after	O	O
a	O	O
brief	O	O
course	O	O
of	O	O
naproxen	O	O
and	O	O
reviews	O	O
the	O	O
literature	O	O
on	O	O
nsaid-related	O	O
permanent	O	O
sensorineural	I-ADR	O
hearing	I-ADR	O
loss	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
dental	I-ADR	O
and	I-ADR	O
gingival	I-ADR	I-ADR
pain	I-ADR	I-ADR
as	O	O
side	O	O
effects	O	O
of	O	O
niacin	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
cause	O	O
of	O	O
these	O	O
previously	O	O
unreported	O	O
side	O	O
effects	O	O
of	O	O
niacin	O	O
therapy	O	O
is	O	O
uncertain	O	O
but	O	O
may	O	O
be	O	O
related	O	O
to	O	O
prostaglandin-mediated	I-ADR	O
vasodilatation	I-ADR	I-ADR
,	O	O
hyperalgesia	I-ADR	I-ADR
of	I-ADR	O
sensory	I-ADR	I-ADR
nerve	I-ADR	I-ADR
receptors	I-ADR	I-ADR
,	O	O
and	O	O
potentiation	I-ADR	I-ADR
of	I-ADR	O
inflammation	I-ADR	I-ADR
in	I-ADR	O
the	I-ADR	O
gingiva	I-ADR	O
with	O	O
referral	O	O
of	O	O
pain	I-ADR	I-ADR
to	I-ADR	O
the	I-ADR	O
teeth	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
two	O	O
65	O	O
-	O	O
year-old	O	O
white	O	O
men	O	O
with	O	O
coronary	O	O
heart	O	O
disease	O	O
,	O	O
given	O	O
niacin	O	O
therapy	O	O
for	O	O
dyslipidemia	O	O
for	O	O
5	O	O
months	O	O
,	O	O
developed	O	O
intense	I-ADR	I-ADR
dental	I-ADR	I-ADR
and	I-ADR	O
gingival	I-ADR	I-ADR
pain	I-ADR	I-ADR
that	O	O
was	O	O
associated	O	O
with	O	O
increases	O	I-ADR
in	O	O
dose	O	O
and	O	O
that	O	O
was	O	O
relieved	O	O
with	O	O
discontinuance	O	O
of	O	O
niacin	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
although	O	O
major	O	O
hazards	O	O
of	O	O
treatment	O	O
of	O	O
hypophosphatemic	O	I-ADR
osteomalacia	O	I-ADR
with	O	O
phosphate	O	O
and	O	O
calcitriol	O	O
are	O	O
secondary	I-ADR	O
hyperparathyroidism	I-ADR	I-ADR
and	O	O
vitamin	I-ADR	O
d	I-ADR	O
intoxication	I-ADR	I-ADR
,	O	O
potassium	I-ADR	I-ADR
loss	I-ADR	I-ADR
also	O	O
should	O	O
be	O	O
kept	O	O
in	O	O
mind	O	O
.	O	O
EOS	O	O
BOS	O	O
although	O	O
major	O	O
hazards	O	O
of	O	O
treatment	O	O
of	O	O
hypophosphatemic	O	I-ADR
osteomalacia	O	I-ADR
with	O	O
phosphate	O	O
and	O	O
calcitriol	O	O
are	O	O
secondary	I-ADR	O
hyperparathyroidism	I-ADR	I-ADR
and	O	O
vitamin	I-ADR	O
d	I-ADR	O
intoxication	I-ADR	I-ADR
,	O	O
potassium	I-ADR	I-ADR
loss	I-ADR	I-ADR
also	O	O
should	O	O
be	O	O
kept	O	O
in	O	O
mind	O	O
.	O	O
EOS	O	O
BOS	O	O
high-dose	O	O
phosphate	O	O
treatment	O	O
leads	O	O
to	O	O
hypokalemia	I-ADR	I-ADR
in	O	O
hypophosphatemic	O	I-ADR
osteomalacia	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
it	O	O
was	O	O
concluded	O	O
that	O	O
potassium	I-ADR	I-ADR
loss	I-ADR	I-ADR
occurred	O	O
by	O	O
a	O	O
non-renal	O	O
(	O	O
intestinal	O	O
)	O	O
route	O	O
in	O	O
phosphate-induced	O	O
hypokalemia	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
progressive	I-ADR	I-ADR
hypokalemia	I-ADR	I-ADR
developed	O	O
during	O	O
phosphate	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
mechanism	O	O
of	O	O
the	O	O
decrease	I-ADR	I-ADR
in	I-ADR	I-ADR
plasma	I-ADR	I-ADR
potassium	I-ADR	I-ADR
induced	O	O
by	O	O
phosphate	O	O
treatment	O	O
was	O	O
investigated	O	O
in	O	O
a	O	O
24	O	O
-	O	O
year-old	O	O
hypertensive	O	O
patient	O	O
with	O	O
hypophosphatemic	O	O
osteomalacia	O	O
,	O	O
who	O	O
was	O	O
the	O	O
youngest	O	O
of	O	O
four	O	O
patients	O	O
,	O	O
belonging	O	O
to	O	O
a	O	O
23	O	O
number	O	O
kindred	O	O
of	O	O
five	O	O
generations	O	O
.	O	O
EOS	O	O
BOS	O	O
transtubular	I-ADR	O
potassium	I-ADR	I-ADR
gradient	I-ADR	I-ADR
(	I-ADR	O
ttkg	I-ADR	I-ADR
)	I-ADR	O
also	I-ADR	O
decreased	I-ADR	I-ADR
and	O	O
an	O	O
inverse	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
ttkg	O	O
and	O	O
doses	O	O
of	O	O
phosphate	O	O
(	O	O
r	O	O
=	O	O
-0.37	O	O
;	O	O
p	O	O
<	O	O
0.02	O	O
;	O	O
n	O	O
=	O	O
38	O	O
)	O	O
.	O	O
EOS	O	O
BOS	O	O
alveolar-interstitial	I-ADR	I-ADR
pneumopathy	I-ADR	I-ADR
after	O	O
gold-salts	O	O
compounds	O	O
administration	O	O
,	O	O
requiring	O	O
mechanical	O	O
ventilation	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
pulmonary	I-ADR	I-ADR
toxicity	I-ADR	I-ADR
of	O	O
gold	O	O
salts	O	O
is	O	O
an	O	O
uncommon	O	O
cause	O	O
of	O	O
life-threatening	O	O
respiratory	I-ADR	I-ADR
failure	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
severe	O	I-ADR
respiratory	I-ADR	I-ADR
failure	I-ADR	I-ADR
due	O	O
to	O	O
gold	O	O
salt	O	O
toxicity	O	I-ADR
in	O	O
a	O	O
patient	O	O
suffering	O	O
from	O	O
rheumatoid	O	O
arthritis	O	O
requiring	O	O
mechanical	O	O
ventilation	O	O
.	O	O
EOS	O	O
BOS	O	O
as	O	O
this	O	O
relapse	O	O
coincided	O	O
with	O	O
development	O	O
of	O	O
a	O	O
strong	O	O
delayed-type	O	I-ADR
hypersensitivity	I-ADR	I-ADR
response	I-ADR	O
to	O	O
tuberculin	O	O
and	O	O
improved	O	O
after	O	O
treatment	O	O
with	O	O
the	O	O
anti-inflammatory	O	O
agent	O	O
oxpentifylline	O	O
,	O	O
it	O	O
was	O	O
probably	O	O
caused	O	O
by	O	O
restoration	O	O
of	O	O
pathogen-specific	O	O
cellular	O	O
immunity	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
patient	O	O
with	O	O
psoriasis	O	O
is	O	O
described	O	O
who	O	O
had	O	O
an	O	O
abnormal	O	O
response	O	O
to	O	O
the	O	O
glucose	O	O
tolerance	O	O
test	O	O
without	O	O
other	O	O
evidence	O	O
of	O	O
diabetes	O	O
and	O	O
then	O	O
developed	O	O
postprandial	I-ADR	I-ADR
hyperglycemia	I-ADR	I-ADR
and	O	O
glycosuria	I-ADR	I-ADR
during	O	O
a	O	O
period	O	O
of	O	O
topical	O	O
administration	O	O
of	O	O
a	O	O
corticosteroid	O	O
cream	O	O
,	O	O
halcinonide	O	O
cream	O	O
0.1	O	O
%	O	O
,	O	O
under	O	O
occlusion	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
second	O	O
patient	O	O
with	O	O
a	O	O
similar	O	O
glucose	O	O
tolerance	O	O
test	O	O
result	O	O
showed	O	O
postprandial	I-ADR	I-ADR
hyperglycemia	I-ADR	I-ADR
when	O	O
treated	O	O
similarly	O	O
with	O	O
betamethasone	O	O
valerate	O	O
cream	O	O
0.1	O	O
%	O	O
.	O	O
EOS	O	O
BOS	O	O
after	O	O
1	O	O
week	O	O
of	O	O
nefazodone	O	O
therapy	O	O
the	O	O
patient	O	O
experienced	O	O
headache	I-ADR	I-ADR
,	O	O
confusion	I-ADR	I-ADR
,	O	O
and	O	O
"	O	O
gray	I-ADR	I-ADR
areas	I-ADR	I-ADR
"	O	O
in	O	O
her	O	O
vision	O	I-ADR
,	O	O
without	O	O
abnormal	O	I-ADR
ophthalmologic	O	I-ADR
findings	O	O
.	O	O
EOS	O	O
BOS	O	O
coadministration	O	O
of	O	O
antidepressant	O	O
agents	O	O
such	O	O
as	O	O
nefazodone	O	O
,	O	O
or	O	O
any	O	O
other	O	O
drug	O	O
that	O	O
inhibits	O	O
the	O	O
cyp	O	O
3a4	O	O
isoenzyme	O	O
subfamily	O	O
,	O	O
should	O	O
be	O	O
anticipated	O	O
to	O	O
interfere	I-ADR	O
with	I-ADR	O
tacrolimus	I-ADR	O
metabolism	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
coadministration	O	O
of	O	O
antidepressant	O	O
agents	O	O
such	O	O
as	O	O
nefazodone	O	O
,	O	O
or	O	O
any	O	O
other	O	O
drug	O	O
that	O	O
inhibits	O	O
the	O	O
cyp	O	O
3a4	O	O
isoenzyme	O	O
subfamily	O	O
,	O	O
should	O	O
be	O	O
anticipated	O	O
to	O	O
interfere	I-ADR	O
with	I-ADR	O
tacrolimus	I-ADR	O
metabolism	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
interaction	I-ADR	O
between	O	O
tacrolimus	O	O
and	O	O
nefazodone	O	O
in	O	O
a	O	O
stable	O	O
renal	O	O
transplant	O	O
recipient	O	O
.	O	O
EOS	O	O
BOS	O	O
interaction	I-ADR	O
between	O	O
tacrolimus	O	O
and	O	O
nefazodone	O	O
in	O	O
a	O	O
stable	O	O
renal	O	O
transplant	O	O
recipient	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
suspect	O	O
that	O	O
nefazodone	O	O
inhibits	I-ADR	O
metabolism	I-ADR	I-ADR
of	I-ADR	O
tacrolimus	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
suspect	O	O
that	O	O
nefazodone	O	O
inhibits	I-ADR	O
metabolism	I-ADR	I-ADR
of	I-ADR	O
tacrolimus	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
the	O	O
case	O	O
of	O	O
intoxication	I-ADR	O
of	O	O
a	O	O
41	O	O
-	O	O
year-old	O	O
female	O	O
patient	O	O
suffering	O	O
from	O	O
major	O	O
depression	O	O
with	O	O
mirtazapine	O	O
complicated	O	O
by	O	O
severe	O	I-ADR
hypothermia	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
conclusion	O	O
:	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
the	O	O
use	O	O
of	O	O
pamidronate	O	O
for	O	O
significant	O	O
hypercalcemia	I-ADR	I-ADR
secondary	O	O
to	O	O
acute	O	I-ADR
vitamin	O	I-ADR
d	O	O
poisoning	O	O
.	O	O
EOS	O	O
BOS	O	O
pamidronate	O	O
therapy	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
hypercalcemia	I-ADR	I-ADR
secondary	O	O
to	O	O
acute	O	I-ADR
vitamin	O	I-ADR
d	O	O
poisoning	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
patient	O	O
was	O	O
initially	O	O
treated	O	O
with	O	O
hydration	O	O
and	O	O
furosemide	O	O
but	O	O
developed	O	O
congestive	I-ADR	I-ADR
heart	I-ADR	I-ADR
failure	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
the	O	O
use	O	O
of	O	O
pamidronate	O	O
for	O	O
acute	O	O
,	O	O
severe	I-ADR	I-ADR
hypercalcemia	I-ADR	I-ADR
secondary	O	O
to	O	O
iatrogenic	O	O
vitamin	O	O
d	O	O
poisoning	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
40	O	O
-	O	O
year-old	O	O
man	O	O
with	O	O
a	O	O
long	O	O
standing	O	O
history	O	O
of	O	O
rheumatoid	O	O
arthritis	O	O
was	O	O
treated	O	O
with	O	O
mtx	O	O
over	O	O
a	O	O
6	O	O
month	O	O
period	O	O
and	O	O
developed	O	O
an	O	O
overwhelming	I-ADR	O
hepatic	I-ADR	I-ADR
necrosis	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
methotrexate-induced	O	O
hepatic	I-ADR	I-ADR
necrosis	I-ADR	I-ADR
requiring	O	O
liver	O	O
transplantation	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
rheumatoid	O	O
arthritis	O	O
.	O	O
EOS	O	O
BOS	O	O
mtx-induced	O	O
hepatic	I-ADR	I-ADR
injury	I-ADR	I-ADR
and	O	O
liver	I-ADR	I-ADR
enzyme	I-ADR	I-ADR
elevations	I-ADR	I-ADR
have	O	O
been	O	O
demonstrated	O	O
after	O	O
treatment	O	O
of	O	O
leukemia	O	O
,	O	O
gestational	O	O
disease	O	O
and	O	O
during	O	O
treatment	O	O
of	O	O
psoriasis	O	O
and	O	O
rheumatoid	O	O
arthritis	O	O
.	O	O
EOS	O	O
BOS	O	O
clinicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
possibility	O	O
that	O	O
vinorelbine	O	O
may	O	O
cause	O	O
siadh	I-ADR	I-ADR
and	O	O
possibly	O	O
hypokalemia	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
because	O	O
of	O	O
its	O	O
structural	O	O
similarity	O	O
to	O	O
the	O	O
other	O	O
vinca	O	O
alkaloids	O	O
,	O	O
vinorelbine	O	O
is	O	O
believed	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
siadh	I-ADR	I-ADR
in	O	O
our	O	O
patient	O	O
.	O	O
EOS	O	O
BOS	O	O
objective	O	O
:	O	O
to	O	O
describe	O	O
onset	O	O
of	O	O
syndrome	I-ADR	I-ADR
of	I-ADR	O
inappropriate	I-ADR	I-ADR
antidiuretic	I-ADR	I-ADR
hormone	I-ADR	I-ADR
(	O	O
siadh	I-ADR	I-ADR
)	O	O
associated	O	O
with	O	O
vinorelbine	O	O
therapy	O	O
for	O	O
advanced	O	O
breast	O	O
cancer	O	O
.	O	O
EOS	O	O
BOS	O	O
syndrome	I-ADR	I-ADR
of	I-ADR	O
inappropriate	I-ADR	I-ADR
antidiuretic	I-ADR	I-ADR
hormone	I-ADR	I-ADR
associated	O	O
with	O	O
vinorelbine	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
pirmenol	O	O
hydrochloride-induced	O	O
qt	I-ADR	I-ADR
prolongation	I-ADR	I-ADR
and	O	O
t	I-ADR	O
wave	I-ADR	I-ADR
inversion	I-ADR	I-ADR
on	O	O
electrocardiogram	O	I-ADR
during	O	O
treatment	O	O
for	O	O
symptomatic	O	O
atrial	O	O
fibrillation	O	O
.	O	O
EOS	O	O
BOS	O	O
thus	O	O
,	O	O
an	O	O
immunological	O	O
mechanism	O	O
might	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
mechanism	O	O
of	O	O
pirmenol-induced	O	O
qt	I-ADR	I-ADR
prolongation	I-ADR	I-ADR
and	O	O
t	I-ADR	O
wave	I-ADR	I-ADR
inversion	I-ADR	I-ADR
on	O	O
the	O	O
electrocardiogram	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
on	O	O
a	O	O
56	O	O
-	O	O
year-old	O	O
female	O	O
who	O	O
exhibited	O	O
drug	O	O
refractory	O	I-ADR
paroxysmal	O	I-ADR
atrial	O	I-ADR
fibrillation	O	I-ADR
,	O	O
in	O	O
which	O	O
marked	O	I-ADR
prolongation	I-ADR	I-ADR
of	I-ADR	O
the	I-ADR	I-ADR
qt	I-ADR	I-ADR
interval	I-ADR	I-ADR
and	O	O
t	I-ADR	O
wave	I-ADR	I-ADR
inversion	I-ADR	I-ADR
on	O	O
electrocardiogram	O	I-ADR
was	O	O
demonstrated	O	O
reproducibly	O	O
shortly	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
oral	O	O
pirmenol	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
disseminated	O	I-ADR
muscular	O	I-ADR
cysticercosis	O	I-ADR
with	O	O
myositis	I-ADR	I-ADR
induced	O	O
by	O	O
praziquantel	O	O
therapy	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
disseminated	O	I-ADR
muscular	O	I-ADR
cysticercosis	O	I-ADR
followed	O	O
by	O	O
myositis	I-ADR	I-ADR
(	O	O
fever	I-ADR	I-ADR
,	O	O
diffuse	I-ADR	I-ADR
myalgia	I-ADR	I-ADR
,	O	O
weakness	I-ADR	I-ADR
of	I-ADR	O
the	I-ADR	I-ADR
lower	I-ADR	I-ADR
limbs	I-ADR	I-ADR
,	O	O
and	O	O
inflammatory	I-ADR	I-ADR
reaction	I-ADR	I-ADR
around	I-ADR	O
dying	I-ADR	I-ADR
cysticerci	I-ADR	I-ADR
)	O	O
induced	O	O
by	O	O
praziquantel	O	O
therapy	O	O
,	O	O
an	O	O
event	O	O
not	O	O
described	O	O
previously	O	O
.	O	O
EOS	O	O
BOS	O	O
massive	I-ADR	I-ADR
subfascial	I-ADR	I-ADR
hematoma	I-ADR	I-ADR
after	O	O
alteplase	O	O
therapy	O	O
for	O	O
acute	O	O
myocardial	O	O
infarction	O	O
.	O	O
EOS	O	O
BOS	O	O
physicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
possible	O	O
association	O	O
between	O	O
the	O	O
use	O	O
of	O	O
alteplase	O	O
and	O	O
the	O	O
development	O	O
of	O	O
subfascial	I-ADR	I-ADR
hemorrhage	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
the	O	O
authors	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
who	O	O
received	O	O
alteplase	O	O
for	O	O
acute	O	O
myocardial	O	I-ADR
infarction	O	I-ADR
and	O	O
developed	O	O
spontaneous	O	I-ADR
subfascial	I-ADR	I-ADR
hematoma	I-ADR	I-ADR
without	O	O
any	O	O
evidence	O	O
of	O	O
direct	O	O
trauma	O	O
.	O	O
EOS	O	O
BOS	O	O
the	O	O
development	O	O
of	O	O
cutaneous	I-ADR	I-ADR
ecchymosis	I-ADR	I-ADR
associated	O	O
with	O	O
a	O	O
sudden	I-ADR	I-ADR
fall	I-ADR	I-ADR
in	I-ADR	O
hemoglobin	I-ADR	O
after	O	O
the	O	O
administration	O	O
of	O	O
alteplase	O	O
should	O	O
strongly	O	O
suggest	O	O
the	O	O
possibility	O	O
of	O	O
diffuse	I-ADR	O
subfascial	I-ADR	O
hematoma	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
a	O	O
fatal	I-ADR	O
case	I-ADR	O
of	I-ADR	O
pancytopenia	I-ADR	I-ADR
due	O	O
to	O	O
levomepromazine	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
fatal	I-ADR	I-ADR
pancytopenia	I-ADR	I-ADR
occurred	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
an	O	O
history	O	O
of	O	O
depression	O	O
with	O	O
hypomanic	O	O
rebounds	O	O
,	O	O
admitted	O	O
for	O	O
a	O	O
manic	O	O
episode	O	O
and	O	O
treated	O	O
with	O	O
levomepromazine	O	O
,	O	O
diazepam	O	O
and	O	O
lithium	O	O
carbonate	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
fatal	I-ADR	I-ADR
pancytopenia	I-ADR	I-ADR
occurred	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
an	O	O
history	O	O
of	O	O
depression	O	O
with	O	O
hypomanic	O	O
rebounds	O	O
,	O	O
admitted	O	O
for	O	O
a	O	O
manic	O	O
episode	O	O
and	O	O
treated	O	O
with	O	O
levomepromazine	O	O
,	O	O
diazepam	O	O
and	O	O
lithium	O	O
carbonate	O	O
.	O	O
EOS	O	O
BOS	O	O
a	O	O
fatal	I-ADR	I-ADR
pancytopenia	I-ADR	I-ADR
occurred	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
an	O	O
history	O	O
of	O	O
depression	O	O
with	O	O
hypomanic	O	O
rebounds	O	O
,	O	O
admitted	O	O
for	O	O
a	O	O
manic	O	O
episode	O	O
and	O	O
treated	O	O
with	O	O
levomepromazine	O	O
,	O	O
diazepam	O	O
and	O	O
lithium	O	O
carbonate	O	O
.	O	O
EOS	O	O
BOS	O	O
amiodarone-induced	O	O
thyrotoxicosis	I-ADR	I-ADR
associated	O	O
with	O	O
thyrotropin	I-ADR	O
receptor	I-ADR	O
antibody	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
among	O	O
12	O	O
thyrotoxic	O	O
patients	O	O
,	O	O
a	O	O
patient	O	O
with	O	O
arrhythmogenic	O	O
right	O	O
ventricular	O	O
dysplasia	O	O
,	O	O
who	O	O
had	O	O
been	O	O
taking	O	O
amiodarone	O	O
for	O	O
4	O	O
years	O	O
,	O	O
developed	O	O
thyrotoxicosis	I-ADR	I-ADR
with	O	O
subacute	O	I-ADR
onset	O	I-ADR
,	O	O
accompanied	O	O
by	O	O
transiently	I-ADR	O
positive	I-ADR	O
thyrotropin	I-ADR	O
(	I-ADR	O
tsh	I-ADR	O
)	I-ADR	O
receptor	I-ADR	O
antibody	I-ADR	O
(	O	O
trab	O	O
)	O	O
,	O	O
or	O	O
thyrotropin-binding	I-ADR	O
inhibiting	I-ADR	O
immunoglobulin	I-ADR	O
(	O	O
tbii	O	O
)	O	O
.	O	O
EOS	O	O
BOS	O	O
since	O	O
amiodarone	O	O
was	O	O
first	O	O
marketed	O	O
in	O	O
1992	O	O
in	O	O
japan	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
amiodarone-induced	O	O
thyrotoxicosis	I-ADR	I-ADR
(	O	O
ait	I-ADR	I-ADR
)	O	O
has	O	O
been	O	O
increasing	O	O
.	O	O
EOS	O	O
BOS	O	O
these	O	O
in	O	O
vitro	O	O
findings	O	O
and	O	O
clinical	O	O
course	O	O
suggest	O	O
that	O	O
trab	I-ADR	O
/	I-ADR	O
tbii	I-ADR	O
without	I-ADR	O
thyroid-stimulating	I-ADR	O
activity	I-ADR	O
may	O	O
develop	O	O
in	O	O
patients	O	O
with	O	O
amiodarone-induced	O	O
destructive	I-ADR	O
thyroiditis	I-ADR	I-ADR
,	O	O
as	O	O
reported	O	O
in	O	O
patients	O	O
with	O	O
destructive	I-ADR	O
thyroiditis	I-ADR	O
,	O	O
such	O	O
as	O	O
subacute	O	I-ADR
and	O	O
silent	O	I-ADR
thyroiditis	O	I-ADR
.	O	O
EOS	O	O
BOS	O	O
conclusion	O	O
:	O	O
lipoid	I-ADR	I-ADR
pneumonia	I-ADR	I-ADR
as	O	O
a	O	O
result	O	O
of	O	O
mineral	O	O
oil	O	O
aspiration	O	O
still	O	O
occurs	O	O
in	O	O
the	O	O
pediatric	O	O
population	O	O
.	O	O
EOS	O	O
BOS	O	O
in	O	O
patients	O	O
with	O	O
swallowing	I-ADR	O
dysfunction	I-ADR	I-ADR
and	O	O
pneumonia	I-ADR	I-ADR
,	O	O
a	O	O
history	O	O
of	O	O
mineral	O	O
oil	O	O
use	O	O
should	O	O
be	O	O
obtained	O	O
and	O	O
a	O	O
diagnosis	O	O
of	O	O
elp	I-ADR	O
should	O	O
be	O	O
considered	O	O
in	O	O
the	O	O
differential	O	O
diagnoses	O	O
if	O	O
mineral	O	O
oil	O	O
use	O	O
has	O	O
occurred	O	O
.	O	O
EOS	O	O
BOS	O	O
lipoid	I-ADR	I-ADR
pneumonia	I-ADR	I-ADR
:	O	O
a	O	O
silent	O	O
complication	O	O
of	O	O
mineral	O	O
oil	O	O
aspiration	O	O
.	O	O
EOS	O	O
BOS	O	O
mineral	O	O
oil	O	O
,	O	O
a	O	O
hydrocarbon	O	O
,	O	O
may	O	O
not	O	O
elicit	O	O
a	O	O
normal	O	I-ADR
protective	O	I-ADR
cough	O	I-ADR
reflex	O	I-ADR
and	O	O
may	O	O
impair	I-ADR	O
mucociliary	I-ADR	I-ADR
transport	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
our	O	O
case	O	O
points	O	O
to	O	O
the	O	O
need	O	O
for	O	O
increased	O	O
awareness	O	O
by	O	O
the	O	O
general	O	O
pediatricians	O	O
of	O	O
the	O	O
potential	I-ADR	O
hazards	I-ADR	O
of	O	O
mineral	O	O
oil	O	O
use	O	O
for	O	O
chronic	O	O
constipation	O	O
.	O	O
EOS	O	O
BOS	O	O
treatment	O	O
of	O	O
elp	I-ADR	O
in	O	O
children	O	O
is	O	O
generally	O	O
supportive	O	O
,	O	O
with	O	O
the	O	O
symptoms	O	I-ADR
and	O	O
roentgenographic	I-ADR	I-ADR
abnormalities	I-ADR	I-ADR
resolving	O	O
within	O	O
months	O	O
after	O	O
stopping	O	O
the	O	O
use	O	O
of	O	O
mineral	O	O
oil	O	O
.	O	O
EOS	O	O
BOS	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
child	O	O
with	O	O
neurodevelopmental	O	O
delay	O	O
with	O	O
chronic	O	O
constipation	O	I-ADR
and	O	O
a	O	O
history	O	O
of	O	O
chronic	O	O
mineral	O	O
oil	O	O
ingestion	O	O
presenting	O	O
as	O	O
asymptomatic	O	O
exogenous	I-ADR	I-ADR
lipoid	I-ADR	I-ADR
pneumonia	I-ADR	I-ADR
(	O	O
elp	I-ADR	I-ADR
)	O	O
.	O	O
EOS	O	O
BOS	O	O
an	O	O
unusual	O	O
cause	O	O
of	O	O
burn	O	I-ADR
injury	O	I-ADR
:	O	O
unsupervised	O	O
use	O	O
of	O	O
drugs	O	O
that	O	O
contain	O	O
psoralens	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
because	O	O
psoralens	O	O
sensitize	O	O
skin	O	I-ADR
to	O	O
ultraviolet	O	O
a	O	O
light	O	O
,	O	O
phototoxic	I-ADR	I-ADR
reactions	I-ADR	I-ADR
are	O	O
the	O	O
most	O	O
frequent	O	O
adverse	O	O
effect	O	O
of	O	O
this	O	O
treatment	O	O
.	O	O
EOS	O	O
BOS	O	O
in	O	O
this	O	O
article	O	O
,	O	O
we	O	O
present	O	O
the	O	O
case	O	O
of	O	O
a	O	O
vitiligo	O	O
patient	O	O
who	O	O
was	O	O
admitted	O	O
to	O	O
our	O	O
facility	O	O
with	O	O
an	O	O
intense	I-ADR	I-ADR
burn	I-ADR	I-ADR
after	O	O
the	O	O
topical	O	O
use	O	O
of	O	O
8	O	O
-	O	O
methoxypsoralen	O	O
solution	O	O
as	O	O
a	O	O
suntanning	O	O
agent	O	O
.	O	O
EOS	O	O
BOS	O	O
sunburn	I-ADR	I-ADR
may	O	O
sometimes	O	O
be	O	O
a	O	O
major	O	O
injury	O	O
in	O	O
psoralen	O	O
users	O	O
because	O	O
high	O	O
doses	O	O
or	O	O
inappropriate	O	O
use	O	O
of	O	O
the	O	O
drug	O	O
may	O	O
render	O	O
the	O	O
skin	I-ADR	O
extremely	I-ADR	O
sensitive	I-ADR	O
.	O	O
EOS	O	O
BOS	O	O
conclusions	O	O
:	O	O
metoclopramide	O	O
may	O	O
cause	O	O
reversible	O	O
nonthrombocytopenic	I-ADR	O
vascular-type	I-ADR	O
palpable	I-ADR	I-ADR
purpura	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
objective	O	O
:	O	O
to	O	O
report	O	O
a	O	O
case	O	O
of	O	O
reversible	O	O
nonthrombocytopenic	I-ADR	O
palpable	I-ADR	I-ADR
purpura	I-ADR	I-ADR
associated	O	O
with	O	O
metoclopramide	O	O
.	O	O
EOS	O	O
BOS	O	O
reversible	O	O
nonthrombocytopenic	I-ADR	O
palpable	I-ADR	I-ADR
purpura	I-ADR	I-ADR
associated	O	O
with	O	O
metoclopramide	O	O
.	O	O
EOS	O	O
BOS	O	O
lithium	O	O
treatment	O	O
was	O	O
terminated	O	O
in	O	O
1975	O	O
because	O	O
of	O	O
lithium	I-ADR	O
intoxication	I-ADR	O
with	O	O
a	O	O
diabetes	I-ADR	I-ADR
insipidus-like	I-ADR	O
syndrome	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
lithium	O	O
treatment	O	O
was	O	O
terminated	O	O
in	O	O
1975	O	O
because	O	O
of	O	O
lithium	I-ADR	O
intoxication	I-ADR	O
with	O	O
a	O	O
diabetes	I-ADR	I-ADR
insipidus-like	I-ADR	O
syndrome	I-ADR	I-ADR
.	O	O
EOS	O	O
BOS	O	O
eosinophilia	I-ADR	I-ADR
caused	O	O
by	O	O
clozapine	O	O
was	O	O
observed	O	O
in	O	O
challenge	O	O
,	O	O
preceded	O	O
by	O	O
a	O	O
faster	O	O
neutrophil	O	O
production	O	O
and	O	O
consecutive	O	O
decrease	O	O
(	O	O
z	O	O
=	O	O
2.27	O	O
,	O	O
p	O	O
=	O	O
0.01	O	O
)	O	O
.	O	O
EOS	O	O
BOS	O	O
eosinophilia	I-ADR	I-ADR
has	O	O
been	O	O
encountered	O	O
from	O	O
0.2	O	O
to	O	O
61.7	O	O
%	O	O
in	O	O
clozapine-treated	O	O
patients	O	O
,	O	O
mostly	O	O
with	O	O
a	O	O
transient	O	O
course	O	O
and	O	O
spontaneous	O	O
remission	O	O
.	O	O
EOS	O	O
BOS	O	O
successful	O	O
challenge	O	O
with	O	O
clozapine	O	O
in	O	O
a	O	O
history	O	O
of	O	O
eosinophilia	I-ADR	I-ADR
.	O	O
EOS	O	O

TEST Approximate Matching Results:
  ADR: Precision 0.8633377135348226 Recall 0.9521739130434783 F1 0.9055823569951758